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Abstract  
Recurrent loss of imprinting at 11p15, paucity of recurrent genetic mutations and 
associated nephrogenic rests (NR; precursor lesions that resemble embryonic kidney 
(EK)) implicate aberrant DNA methylation in tumourigenesis of paediatric Wilms 
tumour (WT) and predict that interrogation of the methylome, rather than the 
genome, is more likely to reveal tumour-specific biomarkers 
To test if aberrant DNA methylation is implicated in tumourigenesis, methylome 
analysis was performed on 36 normal kidney (NK), 22 NR, 36 WT and 4 EK, 
including 20 matched trios and 34 matched NK-WT pairs, using Illumina 450k 
arrays. Findings were validated with bisulfite-sequencing and RNA sequencing. 
This thesis describes the successful identification of changes in methylation that 
distinguish between tissue types. Through analysis of DNA methylation, NR 
formation was associated with gain of methylation at developmental loci related to 
Polycomb target binding sites. Evolution to WT was associated with increase in 
methylation variability in a subset of WTs (group-1), which also showed common 
changes in methylation in comparison to their associated NR, including silencing of 
novel tumour suppressor genes. Group-1 WTs were significantly enriched for 
bilateral cases whereas those in group-2 showed no differences in methylation 
compared to their associated NR.  
Comparison between NK and WT identified three DMRs of genome-wide 
significance (P<5x10
-8
) for use as tumour-specific biomarkers. As proof of principle 
for clinical utility, DMR-2 was successfully used in a case study to monitor tumour 
burden during treatment in cell-free serum DNA.  
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This thesis concludes that methylation levels vary during WT evolution. As group-1 
WT included all bilateral cases, our data suggests that methylation analysis could aid 
treatment planning in bilateral disease and that some WT may be candidates for 
epigenetic-modifier therapy. These findings define the first cell-free epigenetic 
biomarker for WT with potential for clinical utility. 
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Chapter 1: Introduction and background 
1.1 Thesis overview 
The work described in this thesis aims to investigate the hypothesis that 
epigenetic changes (in particular, DNA methylation) underlie:  
 the mechanisms by which embryonic kidney may sometimes fail to fully 
differentiate, leading to persistence of ‘nephrogenic rests’,  
 the transformation of these presumed precursor lesions into fully malignant 
Wilms tumour,  
 the subsequent clinical phenotype of the Wilms tumour, in relation to 
presenting clinical and histological features.  
Chapter 1 provides a broad overview of the molecular biology of Wilms tumour 
(WT) aetiology with particular focus on the process of nephrogenesis (kidney 
development) and how its disruption is associated with persistence of regions of 
incompletely or aberrantly differentiated tissue, termed WT precursors, nephrogenic 
rests (NR). Next, the array of epigenetic modifications and their influence on gene 
expression is discussed in the context of both development and cancer to give an in 
depth understanding of the similarities between both processes that are represented 
in this childhood cancer that results from arrested normal development. Recent 
publications have been included in the introductory background description, that 
although were not considered for generating the thesis hypotheses, incorporate new 
knowledge that substantially supports the contribution of epigenetic changes to WT 
evolution. For example, a recent mouse model of in vivo reprogramming identified 
24 
 
WT-like lesions with altered epigenomic architecture yet no identifiable somatic 
genetic mutations (Ohnishi, Semi et al. 2014). 
 
1.2  Overview of Wilms tumour 
WT is a paediatric kidney cancer with a prevalence of 1 in 10,000 children 
younger than 15 years of age (Breslow, Olshan et al. 1993). WT is an embryonal 
cancer, meaning it shows mimicry of fetal development processes in the 
corresponding organ of origin. Hence it comprises undifferentiated blastema cells, 
immature epithelia and stroma; structures that are seen during normal nephrogenesis 
(Figure 1.1). Embryonal childhood cancers in general were the first models 
described by the Knudson two-hit hypothesis for cancer generation whereby a 
tumour suppressor (TS) gene is silenced by germline loss-of-function mutation or 
deletion of one allele, then the second allele is lost as a somatic event post-natally 
leading to cancer. Mutations in TS genes such as Retinoblastoma 1 (RB1) in 
retinoblastoma and Wilms Tumour 1 (WT1) in WT have been identified in both 
germline and tumour DNA following this hypothesis; however genetic 
predisposition in WT is uncommon (~5% of all cases) and only a minority of such 
cases follow Knudson’s 2-hit model, those involving the WT1 gene.  
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Figure 1.1: Wilms tumour shows mimicry of cell types in normal embryonic kidney. (a) A 
haematoxylin and eosin (H&E) stained 3μm section of an embryonic kidney at 14 weeks showing 
epithelial (E), stromal (S) and blastemal (B) elements. (b) An H&E stained section of a mixed Wilms 
tumour showing E, S and B elements. The epithelia observed in WT is similar to comma-shaped or s-
shaped body or glomeruli in embryonic kidney whereas the blastema mimics condensing metanephric 
mesencyme (MM; discussed later).  
 
Related to its embryonic composition, WTs are associated with disrupted renal 
development. From assessment of post-nephrectomy WT, 40% sporadic tumours and 
~100% bilateral tumours can be associated with NRs which are considered precursor 
lesions to WT (Beckwith, Kiviat et al. 1990) (Figure 1.2). These appear 
morphologically comparable to embryonic kidney (EK) with disrupted architecture, 
however their presence within the post-natal kidney suggests these lesions have 
failed to successfully complete nephrogenesis (Beckwith, Kiviat et al. 1990). There 
are two types of NR; intralobar (ILNR), which are found within the renal medulla, 
and perilobar (PLNR) found towards the periphery of the kidney (Beckwith, Kiviat 
et al. 1990). ILNR are thought to arise at an earlier developmental stage as nephron 
formation begins in the renal medulla then continues outwards towards the periphery 
(Beckwith, Kiviat et al. 1990). NRs are found in approximately 1% of normal 
B 
B S 
S 
E 
E 
a b 
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neonatal kidneys at autopsy (Lonergan, Martinez-Leon et al. 1998) whereas only 1 in 
10,000 children get WT giving a supposed malignant transformation rate of 
approximately 1 in 100. This rate is similar to that found in acute lymphoid leukemia 
(ALL) where the frequency of TEL-AML1 fusion genes in neonatal blood spots is 
100-fold greater than the risk of the corresponding TEL-AML1 positive ALL (Mori, 
Colman et al. 2002). Despite accurate epidemiological characterisation of these 
lesions, the reasons behind tissue retention and the steps leading to transformation 
are unknown. 
Similar to other paediatric malignancies, few genetic mutations have been found in 
WT and the majority of tumours do not carry any of the most common mutations 
(Scott, Murray et al. 2012), although limited genome-wide sequencing studies have 
been published. The most common aberration, that is syndrome-associated and is 
therefore linked to predisposition, occurs at the 11p15 locus. At 11p15, specific loss 
of the maternal allele over the paternal allele resulting in loss of heterozygosity 
(LOH) by duplication of the paternal allele puzzled scientists for years until the 
phenomenon of genomic imprinting at this loci controlling allele-specific expression 
of insulin-like growth factor 2 (IGF2) and imprinted maternally expressed transcript 
(H19) was discovered. As epigenetic alterations, defined as changes to DNA that 
alter gene expression without affecting the DNA coding sequence, are critical in 
development, and since one of the most commonly associated loci with WT (11p15) 
shows epigenetic dysregulation, it can be hypothesised that epigenetic mechanisms 
play a major role in WT tumourgienesis and that interrogation of the methylome, 
rather than the genome, is more likely to reveal tumour-specific biomarkers.   
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Figure 1.2: Schematic of Wilms tumour (WT) growth from its precursor lesion, the nephrogenic 
rest (NR). Normal kidney (NK) development (green arrow) is disrupted in rare cases (orange arrow) 
resulting in a post-natal kidney with perilobar and/or intralobar nephrogenic rests (purple and brown 
respectively). From these, WT can grow (red). 
 
1.3 Epidemiology  
The median age of WT onset is 38 months however age at diagnosis is 
affected by patient sex, the presence of NRs, underlying syndromes and laterality 
(Beckwith, Kiviat et al. 1990; Breslow, Olshan et al. 1993). Males are diagnosed on 
average 6 months earlier than females (Breslow, Olshan et al. 1993). Age at 
diagnosis is also decreased by the presence of ILNRs (16 months) over PLNRs (36 
months) and even further with the presence of both (12 months; see Figure 1.3) 
(Breslow, Olshan et al. 1993).  
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Figure 1.3: Frequency distribution and sub-distributions of age-at-onset by gender for patients 
with unifocal tumours, taken from (Breslow, Beckwith et al. 2006). Solid line = all patients, dotted 
line = NR negative, dashed line = ILNR (+/- PLNR), dashed and dotted line = PLNR only. 
 
There are many syndromes described that predispose to WT (Scott, Stiller et al. 
2006), however, only the two major subgroups of WT predisposition syndromes 
associated with known genetic mechanisms are described here. WAGR syndrome 
(Wilms tumour, aniridia, genitourinary anomalies and mental retardation) and 
Denys-Drash syndrome are associated with genitourinary malformation, WT1 
mutation and ILNRs (Francke, Holmes et al. 1979; Beckwith, Kiviat et al. 1990; 
Pelletier, Bruening et al. 1991). Beckwith-Wiedemann syndrome (BWS) and the 
overlapping hemi-hypertrophy associated WTs are associated with asymmetric 
overgrowth, PLNRs and loss of imprinting at 11p15 affecting expression of genes 
IGF2 and H19 (Beckwith, Kiviat et al. 1990; Reik, Brown et al. 1995). As both WT1 
and the IGF2/H19 locus are located on chromosome 11p, loss of the maternal allele 
may simultaneously cause reduction to homozygosity of a mutant WT1 allele, acting 
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as a tumour suppressor gene and duplication of the paternally expressed IGF2 and 
complete silencing of the maternally expressed H19 genes. Both insults acting 
together have been shown to generate WT an in vivo mouse model (Hu, Gao et al. 
2011). The more recently characterised Perlman syndrome, a rare autosomal 
recessive overgrowth syndrome with increased risk of WT, is associated with 
mutations in the gene DIS3 mitotic control homolog (S. Cerevisiae)-like 2 (DIS3L2) 
with reciprocal upregulation of Let-7 and its targets which promote oncogenesis 
(Chang, Triboulet et al. 2013; Morris, Astuti et al. 2013). 
Familial predisposition to WT has also been associated with loci on 19q (McDonald, 
Douglass et al. 1998) and 17q (Rahman, Arbour et al. 1996) although specific genes 
have not been identified. Besides predisposition syndromes and familial studies, 
comparison of blood from WT patients to controls identified single nucleotide 
polymorphisms (SNPs) at 2p24 and 11q14 that confer susceptibility to WT 
(Turnbull, Perdeaux et al. 2012). 
 
1.4 Pathology and classification  
WTs show a mixed histology with varying proportions of stroma, epithelia 
and blastema. WTs can also be anaplastic, which is a morphological diagnosis 
comprising cells with large or multiple nuclei that are abnormally shaped with 
nucleus size variation at least 3-fold and atypical mitoses. This is a sign of increased 
proliferation and a hallmark of aggressive cancer. There are currently two main 
treatment approaches for WT that differ in their histological classification of WT. 
The Society of Paediatric Oncology (SIOP) protocol used in Europe and some other 
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countries performs pre-operative chemotherapy and then assesses the cellular 
composition according to the tumour response to determine the histological risk 
group and hence the level of post-operative chemotherapy. The Children’s Oncology 
Group (COG) protocol used in the USA performs immediate nephrectomy then 
describes the cellular composition of the untreated tumour. 
Based on histopathological review of a resection, tumours are classified and 
subdivided into (SIOP) low, intermediate and high risk groups or (COG) favourable 
or unfavourable groups (Table 1.1). SIOP tumours are also staged according to 
response to chemotherapy, completeness of tumour excision, whether the renal 
capsule is intact, tumour rupture, presence of tumour beyond excision margins, 
contamination of local vessels or lymph nodes and laterality (Table A1, Appendix 1). 
Currently, no molecular biomarkers aid clinical diagnosis or staging of WT for 
patients treated according to the SIOP protocol however there is new evidence that 
post-chemotherapy blastema volume at nephrectomy may be of valuable prognostic 
significance; this is yet to be fully explored. Conversely, patients treated according to 
the COG protocol are stratified according to loss of heterozygosity (LOH) at 1p and 
16q (Grundy, Telzerow et al. 1994; Grundy, Breslow et al. 2005). 
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SIOP risk 
group 
Histology (post-
chemotherapy) 
COG risk 
group 
Histology (immediate 
nephrectomy) 
Low Completely necrotic Favourable Blastemal predominant  
Intermediate Epithelial type  Stromal predominant 
 Stromal type  Epithelial predominant 
 Mixed type  Mixed histology  
 Regressive type   
 Focal anaplasia   
High Blastema type Unfavourable Diffuse anaplasia 
 Diffuse anaplasia  Focal anaplasia 
Table 1.1 – Wilms tumour histological classification and risk groups according to the SIOP and 
COG protocols. Focal anaplasia refers to distinct focal regions of anaplastic cells whereas diffuse 
anaplasia refers to widespread anaplsia throughout the tumour.  
 
1.5 Clinical management  
WT can be diagnosed clinically from its typical presentation as an 
asymptomatic abdominal mass in an otherwise healthy child and typical imaging 
appearances of an intrarenal tumour. Occasionally, biopsy of the renal mass is used 
for histological confirmation. In the USA, immediate nephrectomy is performed for 
all patients. Although the SIOP protocol specifies pre-operative chemotherapy, 
patients younger than 6 months of age undergo immediate nephrectomy without pre-
operative chemotherapy. In all other cases, a course of pre-operative chemotherapy 
is given of vincristine (V) and dactinomycin (A) for 4 weeks. The length and number 
of drugs given as post-operative chemotherapy is dependent of risk and stage and 
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typically includes V and A for stage I with additional doxorubicin (D) for stages II-
V. Bilateral disease or cases with diffuse anaplasia may be given additional 
cyclophosphamide and etoposide and stage III patients have additional radiotherapy.  
Studies on survivors of paediatric cancers show that around 60% of adolescents 
develop chronic health problems including, for WT, musculoskeletal effects, cardiac 
toxicity, reproductive problems, renal dysfunction and the development of second 
malignant neoplasms (Wright, Green et al. 2009). These are usually due to the 
further drugs and radiotherapy given to higher stage or relapsed patients (Wright, 
Green et al. 2009). 
From 2001-2011 a Society of Paediatric Oncology (SIOP) study allowed for 
consented collection and storage of fresh frozen and formalin fixed paraffin 
embedded (FFPE) tissue. From 2012, this was superseded in the UK by the 
Improving Population Outcomes for Children with Renal Tumours (IMPORT) study 
which also collects serial aliquots of blood serum, blood plasma and urine at 
diagnosis, mid-way during pre-operative chemotherapy, immediately prior to 
nephrectomy, post-surgery prior to post-operative chemotherapy and at end-of-
treatment (Figure 1.4). 
 
Figure 1.4: IMPORT study serial sample collection time-course. Samples are collected at 5 time 
points during treatment indicated by green arrows. 
 
   Pre-operative chemotherapy               Surgery                            Post-operative chemotherapy 
1                         2                         3                    4                                                                              5 
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1.6 Renal development and Wilms tumour 
WT is a developmental cancer, evidenced by its occurrence in early 
childhood, its association with precursor lesions that resemble EK and mixed 
histology of different embryonic cell types. To understand the transformation stages 
involved in Wilms tumourigenesis, it is important to understand the process of 
normal renal development, as the two are closely linked. 
 
1.6.1 Renal development overview  
Nephrogenesis describes the process of embryonic growth and maturation of 
the kidney. This process begins at 22 days and terminates at around 36 weeks 
gestation. During embryogenesis, the intermediate mesoderm (IM) gives rise to the 
metanephros along the anteroposterior axis. Within this structure, IM cells progress 
to form the metanephric mesenchyme (MM), or ‘renal stem cells’. In the meantime, 
from the Wolffian duct, an epithelial structure termed the ureteric bud extends. This 
structure is essential to establish the initiation of nephrogenesis. Upon contact with 
the MM, reciprocal induction occurs, whereby the MM induce the ureteric bud to 
bifurcate and hence form the collecting duct system of the adult kidney whilst the 
ureteric bud simultaneously induces the MM to undergo differentiation (Bard, 
McConnell et al. 1994). Some of these stem cells differentiate into stromal cells that 
predominantly localise to the medulla and some condense into small aggregates that 
go through mesenchymal to epithelial transition (MET) to form comma-shaped then 
S-shaped bodies before forming a nephron (Figure 1.5). The distal end of the 
forming nephron fuses with the bifurcated duct and the proximal end forms a 
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glomerulus and localises with capillaries for ultrafiltration of the blood. Any 
uninduced MM undergo apoptosis (Bard, McConnell et al. 1994; Rivera and Haber 
2005; Schedl 2007). The number of nephrons is species-specific and is acquired in 
utero; no new nephrons will grow postnatally (Merlet-Benichou, Gilbert et al. 1999).  
 
 
Figure 1.5: Reciprocal induction between the ureteric bud and the metanephric mesenchyme 
results in nephron formation. Taken from Burke & Toshe (Burke and Tosh 2005). (A) The ureteric 
bud (yellow) and the metanephric mesenchyme (MM, blue) undergo reciprocal induction upon 
contact. (B) Epithelialisation of the MM, (C) progression into a nephron connecting via the distal end 
to the ureteric bud which forms the collecting duct system. 
 
Several genes, which can be considered markers of renal stem cells, have been 
shown to be specifically expressed in MM cells and are essential for their 
differentiation: PAX2 (Torres, Gomez-Pardo et al. 1995), WT1 (Kreidberg, Sariola et 
al. 1993), EYA1 (Xu, Adams et al. 1999), SIX2 (Brodbeck, Besenbeck et al. 2004), 
HOX11 paralogous group (Wellik, Hawkes et al. 2002), CITED1 (Boyle, Misfeldt et 
al. 2008) and SALL1 (Nishinakamura 2003). 
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1.6.2 Disrupted development: nephrogenic rest formation 
In very rare cases, normal nephrogenesis is disrupted and lesions termed 
nephrogenic rests (NRs) are formed. These morphologically resemble EK with 
immature nephron structures. Apart from the different physical location of PLNRs 
and ILNRs, there are other morphological differences. PLNRs are often numerous 
and diffuse whereas ILNRs are usually observed singularly. Microscopic differences 
include variation in the rest margin; well-defined and smooth in PLNRs (Figure 1.6) 
but irregular and often indistinct in ILNRs (Figure 1.7) and rest composition; PLNRs 
are predominantly blastemal in early lesions but develop epithelial structures or 
sclerosis with age and ILNRs are stromal predominant with the presence of 
occasional blastema and epithelia and often mature fat (Beckwith 1998).  
NRs can follow a variety of fates, not all resulting in transformation to WT. 
Neoplastic NRs are considered as likely WT precursors whereas hyperplastic NRs 
are considered relatively stable despite their generalised growth. NRs can also 
remain dormant or may regress (by apoptosis) resulting in their obsolescence 
(Beckwith, Kiviat et al. 1990). Occasionally, the entire kidney is affected by 
‘nephroblastomatosis’, the presence of diffuse NR. As 60% WT are not visibly 
associated with NR, it can be speculated that the evolving tumour may arise within a 
NR causing infiltration of the NR and loss of its identification in the subsequent 
nephrectomy specimen following tumour excision.  
It is unclear what causes NR retention or persistence and as they are identified only 
from histological examination of formalin fixed paraffin embedded (FFPE) tissue, 
downstream analysis is restricted to methods that support analysis on such tissue. 
Because of this, genomic, transcriptomic and epigenomic data is limited to studies 
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assessing few genes or with small sample sizes and therefore the transformation 
steps required for tumour formation are unknown. Furthermore, although this 
method of detection is used diagnostically, pathologists have to deal with the major 
difficulty of distinguishing between a true NR and chemotherapy-treated WT, both 
of which look morphologically very similar. 
 
 
Figure 1.6: A perilobar nephrogenic rest surrounded by normal kidney (NK).  (a) A 3μm section 
of FFPE nephrectomy sample stained with haematoxylin and eosin (100x). (b) magnification (400x) 
of the highlighted region in (a). A well-defined smooth margin is seen between the PLNR and NK 
tissue. The PLNR tissue shows primitive epithelial structures within sclerotic stroma. In comparison, 
the NK shows tubules with well-defined lumen and mature glomeruli. The large quantity of glomeruli 
within this section of NK implies its location near the periphery of the lobule, where PLNR are 
common. 
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Figure 1.7: Intralobar nephrogenic rest surrounded by normal kidney.  (a) A 3µm section of 
FFPE nephrectomy sample stained with haematoxylin and eosin (100x magnification). (b) The area 
highlighted in (a) at greater magnification (400x) showing the ILNR merging with the NK tissue at its 
border (indistinct rest margin). Within the ILNR blastema and immature epithelial structures with 
relatively large nuclei and scant cytoplasm are observed in a large amount of stroma. Regions that 
have differentiated into fat cells are also seen. The NK shows epithelial cells with large cytoplasm 
forming tubules with well-defined lumen. The reduced density of glomeruli within this section of NK 
implies its location near the central medulla, where ILNR are common.  
 
1.6.3 Supporting molecular data: expression analysis 
Several studies have used array-based methods to study mRNA expression in 
WT and found that expression profiles appear similar to those in EK (Li, Guo et al. 
2002). In particular, of the transcription factors expressed in WT, PAX2, EYA1, 
HBF2 and HOXA11 are all key genes essential for MM proliferation in early renal 
development. Furthermore, expression of SIX1 and SALL2 was found to be high in 
WT and both genes are associated with MET but their expression decreases as cells 
further differentiate (Li, Guo et al. 2002). Taken together, this suggests that the cell-
of-origin is the MM that has committed to MET and arrested development shortly 
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afterwards. This provides an explanation for the triphasic histology observed in WT 
which encompasses all cell-types seen during normal MM differentiation. 
The same study identified genes expressed in WT that are not associated with EK 
including Wnt receptor FZD7, tumour suppressor gene PRAME and imprinted gene 
NNAT (Li, Guo et al. 2002). Further to this, overexpression of imprinted gene IGF2 
and loss of expression of imprinted H19 is reported in ~74% WTs (Scott, Murray et 
al. 2012) suggesting an association between aberrant DNA methylation at imprinted 
loci and Wilms tumourigenesis. This is further supported by observed 
overexpression of imprinted genes DLK1, RTL1, MEG3 and MEST in WT 
(Hubertus, Lacher et al. 2011).  
A recent study with unexpected results gave insight into the properties of tumours 
formed when disruption in renal development occurred. Researchers constructed 
embryonic stem cells (ESCs) where expression of reprogramming factors (Oct3/4, 
Sox2, Klf4 and c-Myc) was inducible by addition of Doxycycline (Dox) (Ohnishi, 
Semi et al. 2014). From these, chimeric mice were generated. Mice treated with Dox 
for a short period of time (4-7 days) developed dysplastic lesions that resolved once 
Dox treatment was removed. Mice treated for longer periods of time (at least 7 days) 
developed tumours that were sustained once treatment was removed, including renal 
tumours that remarkably resembled WT including showing expression of Six2, Eya1 
and Lgr5 (Ohnishi, Semi et al. 2014). These tumours also showed histological 
features of WT (the triphasic morphology) as well as Igf2 overexpression with gain 
of methylation at H19. Importantly, no genetic mutation in Wt1, Wtx, Ctnnb1, Trp53 
or a panel of cancer-related genes (514 in total) was found and no prevalent 
chromosomal alteration, indicating this cancer phenotype could be entirely 
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epigenetic or could be associated with genetic features outside the exonic regions 
sequenced. The authors postulated that in human WT, a reprograming process might 
cause cell-fate conversion into progenitor-like states generating NRs that transform 
to WT. 
 
1.7 Genetic features of Wilms tumour 
The key genes mutated in WT are WT1 (12%), WTX (32%), CTNNB1 (15%), 
TP53 (5%) and FBXW7 (4%) (Williams, Al-Saadi et al. 2010; Scott, Murray et al. 
2012). Most cases of WT1 mutation overlap with CTNNB1 mutation whereas WTX 
mutation is more mutually exclusive (Figure 1.8). These common mutations were 
mostly discovered through association with familial disease or predisposition 
syndromes. As of yet, limited genome-wide mutational analyses have been published 
for WT however preliminary data (through personal communication) indicates 
mutations in SIX2 and MYCN are common in WT. The only published study to 
report the results of genome-wide sequencing in WTs identified common mutations 
in DROSHA (12%) and other mutations in genes of the miRNA processing pathway 
(Torrezan, Ferreira et al. 2014).  
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Figure 1.8: Mutational analysis of WTX, WT1 and CTNNB1 in WT (n=74). Venn diagram 
showing the proportions frequency of mutations in the most commonly mutated genes (WTX; orange, 
WT1; blue and CTNNB1; green) in a total of 74 WT where mutational analysis was carried out (from 
Scott et al (Scott, Murray et al. 2012)). 46 WT were poly-negative for mutation in all three genes. 
 
WT1 encodes a zinc finger DNA binding protein that acts as a transcription factor 
mediating nephrogenesis with many target genes (Moore, McInnes et al. 1999). WT1 
is expressed in the uninduced MM of the developing kidney (Mundlos, Pelletier et 
al. 1993) and is linked to survival and differentiation of the MM (Kreidberg, Sariola 
et al. 1993). WT1 knockout mice fail to form functional MM and fail to grow the 
ureteric bud resulting in embryonic lethality (Kreidberg, Sariola et al. 1993). WT1 
mutation is considered an ‘early’ event in WT as mutations are also seen in 
associated ILNRs (Fukuzawa, Heathcott et al. 2007). 
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CTNNB1 encodes β-catenin, a key protein involved in the Wnt signalling pathway, 
which is critical for epithelialisation post MET (Koesters, Ridder et al. 1999). 
CTNNB1 knockout within renal progenitor cells in mice blocked renal vesicle 
formation and overexpression bypassed the requirement for signalling molecules 
Wnt9b and Wnt4 but also failed to form epithelial structures (Park, Valerius et al. 
2007). In WT, the mutation is activating and therefore overexpression of β-catenin is 
seen which may therefore be associated with the immature nephron structures seen in 
NR and WT tissue. CTNNB1 mutations have been defined as a ‘late’ event in WT 
tumourigenesis as they are present in WT but not NR, although only a small patient 
cohort was studied (Fukuzawa, Heathcott et al. 2007). 
Of 74 WTs where mutational status for WTX, WT1 and CTNNB1 was determined, 
88% tumours with either WT1 or CTNNB1 also had mutation in the other gene 
whereas only 5.8% WTX mutant tumours also had CTNNB1 mutation and 17.6% had 
WT1 mutation (Scott, Murray et al. 2012).  
WTX (Wilms tumour on chromosome X, also known as AMER1)  links both the WT1 
and CTNNB1 genes together as the protein negatively regulates Wnt signalling 
(Major, Camp et al. 2007) and has been associated with WT1 transcriptional control 
(Rivera, Kim et al. 2009). In WT, WTX is mutated or deleted in around 30% tumours 
and has been described as a tumour suppressor gene. WTX is expressed during 
normal development in the MM and WTX knockout mice show defects in tissue 
derived from embryonic mesenchyme (Moisan, Rivera et al. 2011) with 64% of WTX 
null mice having uni- or bilateral kidney agenesis.  
TP53 mutation or loss of copy number occurs in a low proportion of WT, but is 
particularly associated with WT that show anaplasia. These tumours show 
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characteristic copy number profiles with multiple focal areas of gain or loss which 
are generally absent in tumours with wild-type TP53 showing that TP53 loss 
associates with genomic instability; these cases often have a poor prognosis 
(Bardeesy, Falkoff et al. 1994).  
FBXW7 is an E3 ubiquitin ligase that is deleted or mutated in ~4% WT. MycN, a 
target of FBXW7 ubiquitination and degradation, shows copy number gain in a 
subset of WTs (Williams, Al-Saadi et al. 2010), with several others showing 
activating mutation (unpublished personal communication). This suggests a common 
pathway is being targeted. 
A further pathway with common mutations is the miRNA processing pathway with 
mutations in DROSHA, which encodes a protein with an RNaseIII domain for 
cleaving pri-miRNA into pre-mRNA, found in 12% WT (26/222). In total, 81% of 
these mutations cause E1147K mutation in the protein which alters a metal binding 
residue of the RNase IIIb domain. Furthermore, non-recurrent mutations in other 
genes in this pathway (DGCR8, DICER1, XPO5 and TARBP2) were identified, 
indicating the significance of silencing the miRNA processing machinery in Wilms 
tumourigenesis. 
Besides genetic mutations, common chromosomal alterations in WT occur at 16q 
and 1p (loss of heterozygosity), 1q (copy number gain), 17p (copy number loss; 
affecting TP53), 2p (copy number gain; affecting MycN) and 11p15 and 11p13 (loss 
of heterozygosity) (Grundy, Telzerow et al. 1994; Hing, Lu et al. 2001; Williams, 
Al-Saadi et al. 2010). Of these, 1q gain and 1p with 16q loss have shown prognostic 
significance associating with adverse outcome in favourable histology WT in more 
than one study (Hing, Lu et al. 2001; Grundy, Breslow et al. 2005; Messahel, 
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Williams et al. 2009; Gratias, Jennings et al. 2013). Further patient-specific 
chromosomal alterations were studied to discern the relationship between WT and its 
associated NR (Vuononvirta, Sebire et al. 2008). Gain of chr12, chr13 chr18 and loss 
of chr1p were observed in the NRs and termed ‘early’ events which were also seen 
in the associated WT. However in several cases, large scale genomic changes were 
observed in the precursor lesion but not the tumour, which showed different changes. 
This data supports the lesion as a precursor however reinstates that not all NR 
undergo malignant transformation. 
 
1.8 Molecular biomarkers  
There are several characteristic molecular markers of WT that either act as 
outcome-associated markers, markers of the disease or are associated with specific 
aspects of WT pathology or treatment (Table 1.2). 
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Association Biomarker 
Relapse CACNA1E overexpression/amplification, specific to 
favourable histology WT (COG) (Natrajan, Little et al. 2006) 
IGF1R gain/overexpression in blastemal cells (Natrajan, 
Reis-Filho et al. 2006) 
Poor 
prognosis/adverse 
outcome 
1p and 16q loss (Grundy, Telzerow et al. 1994; Grundy, 
Breslow et al. 2005) 
Gain of 1q (Hing, Lu et al. 2001; Natrajan, Williams et al. 
2006; Gratias, Jennings et al. 2013)  
Increased telomere activity (Dome, Bockhold et al. 2005) 
TrkB levels(Eggert, Grotzer et al. 2001) 
WT diagnosis p73 promoter methylation and p73 mRNA expression in 
peripheral blood (increase in WT patients compared to 
controls) (Song, Yue et al. 2013) 
Serum SAA1 and APO C-III levels (Wang, Wang et al. 2012) 
Histology-
associated markers 
Gain of MYCN in unfavourable histology (Williams, Al-Saadi 
et al. 2010; Williams, Al-Saadi et al. 2011) 
miRNA profile expressed in high risk blastema (Watson, 
Bryan et al. 2013) 
TP53 mutation in anaplastic WT (Bardeesy, Falkoff et al. 
1994) 
Reduced retinoic acid pathway activity in high risk tumours 
(Wegert, Bausenwein et al. 2011) 
Table 1.2: Wilms tumour biomarkers  
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1.9 Common pathways  
Combining the known genetic and epigenetic aberrations discovered in WT, 
it is clear that several pathways are commonly targeted in WT aetiology including 
the Wnt signalling pathway, IGF pathway and retinoic acid pathway.  
 
1.9.1 Wnt signalling pathway  
CTNNB1 mutations cause constitutive activation of the Wnt signalling 
pathway which is critical for reciprocal induction of the ureteric bud and MM as well 
as MET (Koesters, Ridder et al. 1999). Upon signalling by Wnt ligands through 
frizzled receptors, β-catenin is stabilised and localises to the nucleus where it forms a 
complex with LEF and TCF transcription factors to switch on expression of target 
genes. In the absence of Wnt signals, β-catenin is phosphorylated at multiple sites by 
CK1A, CK1E and GSK3β which enables recognition, ubiquitylation and hence 
degradation by proteasomes (Huelsken and Behrens 2002). The protein dishevelled 
is responsible for maintaining β-catenin in the presence of WNTs by inhibiting 
GSK3β activity. β-catenin has also been associated with renewal of stem cell 
pluripotency (Reya, Duncan et al. 2003; Sato, Meijer et al. 2004; Sokol 2011). 
Epimutation at 5q31 (hypermethylation of the protocadherin cluster) resulted in loss 
of expression of protocadherin genes and reciprocal increase in Wnt signalling target 
gene expression (Dallosso, Hancock et al. 2009) indicating that other mechanisms 
may increase Wnt signalling in a larger subset of WTs. Despite its relatively 
common mutation rate, there has been little research undertaken into therapeutic 
targeting of the Wnt signalling pathway in WT. However, in one study, using an 
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antibody to Wnt receptor Frizzled-7 (FZD7) induced apoptosis in a primary WT cell 
lines that expressed FZD7 suggesting a subset of WT may respond well to such 
therapies (Pode-Shakked, Harari-Steinberg et al. 2011).  
 
1.9.2 IGF pathway 
IGF2, as mentioned, is implicated in the overgrowth syndrome BWS. In 
normal tissue, this gene is maternally imprinted causing monoallelic expression from 
the paternal allele. Overexpression can result from either loss of this imprinting mark 
or paternal uniparental disomy (pUPD). The mechanisms behind regulation of 
imprinted gene expression will be discussed later in chapter 1.10.3.3. The 
overexpression of IGF2 results in activation of the insulin signalling pathway. 
Binding of insulin, IGF1 or IGF2 to the extracellular portion of the insulin receptor 
(IR), IGF1R or hybrid receptor leads to autophosphorylation of the β-subunit 
tyrosine kinase, followed by the phosphorylation of additional tyrosine residues. 
This leads to recruitment of insulin receptor substrates (IRS)1 to IRS4 and other 
proteins, allowing activation of the PI3K and mitogen activated protein kinase 
(MAPK) signalling pathways which lead to unregulated protein synthesis, cell cycle 
progression and cell growth, and prevention of apoptosis (Gallagher and LeRoith 
2010).  
In terms of targeting this pathway in WT, the IGF1R inhibitor BMS-754807, an 
ATP-competitive small molecule, was tested in vivo using xenograft models of WT 
and demonstrated significant growth delay (Kolb, Gorlick et al. 2011). The anti-
IGF1R monoclonal antibody IMC-A12 was also used to treat the same WT models 
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but showed very limited efficacy (Houghton, Morton et al. 2010). In WT cell lines 
studied in the kidney environment, the use of the IGF1R inhibitor NVP-AEW541 
resulted in growth inhibition associated with down-regulation of PI3K and MAPK 
pathways and down-regulation of cell cycle control genes CCNA2 and CCNB1, with 
drug efficacy dependent on the levels of phosphorylated IGF1R (Bielen, Box et al. 
2012). Targeting this pathway may be improved with combination therapy however 
it seems the cells are not dependent on it for survival so it may not be the best 
therapeutic target. 
 
1.9.3 Retinoic acid pathway 
A study of cDNA in WT identified several genes of the retinoic acid (RA) 
pathway (RARRES2, RARRES3 and CTGF and also RA pathway targets NK4, 
RAMP, and ENPP2) that were downregulated in relapsed tumours (Zirn, Hartmann 
et al. 2006). This was further validated in a second study where RA pathway down 
regulation was seen in high risk WT (Wegert, Bausenwein et al. 2011). Retinoic acid 
(RA) is the biologically active form of vitamin A and binds to the retinoic acid 
receptor (RAR) which binds in the membrane to the retinoic X receptor (RXR) in 
regions called retinoic acid response elements (RAREs). Upon activation of RAR by 
binding RA, the classicial RA pathway induces differentiation, cell cycle arrest and 
eventual apoptosis.  
Treating WT cells with retinoids or all-trans-RA (ATRA) to activate RA signalling 
showed positive effects including reduced proliferation, apoptosis however these 
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were readily  reversible upon drug withdrawal (Zirn, Samans et al. 2005; Wegert, 
Bausenwein et al. 2011). 
 
1.9.4 miRNA processing pathway 
miRNAs are encoded for in human DNA. Expression of mature miRNA 
begins with RNA polymerase proteins transcribing the sequences into pri-miRNA 
which forms a long double-stranded hairpin which is then cleaved by a complex of 
Drosha and DGCR8 (termed Pasha) into a smaller pre-miRNA hairpin which is 
exported from the nucleus. They are then cleaved by Dicer (an RNase) and TRBP 
(with specificity for double stranded RNA) to remove the hairpin loop and leave two 
single stranded miRNAs. The functional strand binds to Argonaute (Ago2) proteins 
into the RNA-induced silencing complex (RISC) where it guides the complex to its 
target mRNA while the non-functional strand is degraded. Targeting of mRNAs by 
this method results in mRNA silencing by mRNA cleavage, translational repression 
or deadenylation.  
Mutations in WTs have been found in genes DROSHA, DGCR8, DICER1, XPO5 (a 
nuclear exporter of pre-miRNA) and TARBP2 (required for RISC formation) 
(Torrezan, Ferreira et al. 2014), (Wu, Sabbaghian et al. 2013). WTs with mutations 
in this pathway showed downregulation of mature miRNAs as expected, and not in 
the primary miRNA transcripts indicating the machinery is failing to generate mature 
mRNA. 
Further showing the importance of miRNA regulation in WT formation is the 
finding that overexpression of Lin28 in renal precursor cells generates proliferative 
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WT-like lesions in mouse kidneys. Lin28 inhibits biogenesis of Let-7 family 
miRNAs, which are key determinants of pluripotency, differentiation and 
transformation (Urbach, Yermalovich et al. 2014). Furthermore, overexpression of 
Lin28 was found in the blastemal elements of human WT in comparison to normal 
kidney (NK) (Urbach, Yermalovich et al. 2014) and activating mutations in DIS3L2, 
which degrades Lin28-mediated uridylated pre-let-7 miRNAs, have been identified 
as predisposing to WT (Chang, Triboulet et al. 2013). Therefore, both LIN28 
overexpression and activation of DIS3L2 result in loss of mature Let-7 miRNAs and 
are associated with causing WT. The full paper describing Lin28 overexpression in 
mouse and human WTs, to which I contributed, can be found in Appendix 2. 
miRNA species play a major role in many human cancers by affecting expression of 
miRNA target genes (Calin and Croce 2006). This occurs by loss, amplification or 
mutation of the miRNA DNA sequence and can be associated with cancer 
predisposition (if germline) or progression (if somatic). In general, a down-
regulation of miRNA is seen in tumour compared to normal tissue (Lu, Getz et al. 
2005). miRNA expression signatures are also a common marker of solid cancers 
(Iorio, Ferracin et al. 2005; Volinia, Calin et al. 2006; Lee, Gusev et al. 2007). In 
WT, as this is a relatively recent discovery, no therapeutic avenues for targeting 
miRNA processing machinery have been explored. 
 
1.10 Overview of epigenetics 
An overview of epigenetics is given at this point due to the significance of 
WT being a developmental tumour as well as the association of specific epimutations 
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with WT, a topic that will be discussed in detail later. Epigenetics describes heritable 
modifications to DNA or chromatin that affect gene expression without changing the 
nucleotide sequence. Every cell type has a unique epigenome that gives cell identity. 
Unlike the genome, the epigenome can be remodelled at any stage; however in 
healthy, terminally differentiated cells it is stable. Epigenetic gene regulatory 
mechanisms can be broadly classified into covalent chromatin modification, DNA 
cytosine methylation and non-coding RNA. 
 
1.10.1 Chromatin remodelling 
Histones are responsible for maintenance of the structure of chromosomal 
DNA. Gene expression can be affected either by expression of histone protein 
variants or by modification of the histone amino acids. Within the histone complex, 
DNA wraps around histone proteins H2a, H2b, H3 and H4. Histone protein H1 binds 
like a clip on the outside of this structure. Each protein has a subfamily of proteins 
with multiple members that can combine together to form a nucleosome. Variants of 
these proteins exist for example H3.3, which is associated with actively transcribed 
genes (Ahmad and Henikoff 2002), H2A.Z which flanks both active and inactive 
gene promoters (Raisner, Hartley et al. 2005) and is involved in the prevention of the 
spread of silent heterochromatin (Meneghini, Wu et al. 2003) and H2A.X which 
binds at DNA double-stranded breaks marking regions undergoing repair (Paull, 
Rogakou et al. 2000). 
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Figure 1.9: Histone 3 tail with the sites of modification highlighted, taken from (Sims and 
Reinberg 2008). Me = methylation; red = repression, green = activation, black = not associated with 
transcription, P = phosphorylation; orange, Ac = acetylation; blue. 
 
Histone tails can be post-translationally modified by acetylation or methylation of 
lysine (K) and arginine (R), phosphorylation of serine (S) and threonine (T), 
ubiquitylation and symoylation of lysine and ribosylation (by example, the N-
terminal tale of histone 3 is shown in Figure 1.9). These modifications alter the 
interaction between histones and DNA. Suppressive modifications increase binding 
affinity and result in DNA being more tightly ‘packed’ into condensed chromatin 
whereas modifications that decrease affinity allow for open DNA structures that can 
be accessed by transcription factors. The study of histone modifications in various 
cell types has generated an overall picture of their regulatory effect on gene 
expression (Table 1.3) (Mikkelsen, Ku et al. 2007; Pan, Tian et al. 2007; Heintzman, 
Hon et al. 2009; Aiden, Rivera et al. 2010; Creyghton, Cheng et al. 2010; Ernst, 
Kheradpour et al. 2011; Martens, Stunnenberg et al. 2011; Rada-Iglesias, Bajpai et 
al. 2011).  
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Locus Histone modification Gene expression 
Active promoter H3K4me3 or H3K27ac On 
Active enhancer H3K4me1 or H3K27ac On 
Actively transcribed genes H3K36me3 On 
Repressed DNA H3K27me3 or H3K9me2/3 Off 
Bivalent domain H3K4me3 or H3K27me3 
Off, but ‘poised’ for 
expression or repression 
Table 1.3: Chromatin modifications and their effect on gene expression. H3 = histone 3, K = 
lysine, me2 = dimethylation, me3 = trimethylation, ac = acetylation. 
 
Overlapping H3K4me3 (Histone 3, Lysine 4 trimethylation) and H3K27me3 mark 
bivalent domains in ESCs (Pan, Tian et al. 2007). These domains show both the 
oppressive and active mark and appear at developmental loci poised for expression 
upon differentiation; these regions have been shown to be specifically disrupted in 
cancer (Pan, Tian et al. 2007; Doi, Park et al. 2009). 
Histone modifications are flexible and enzymes exist to add or remove marks 
depending on cell requirements; for example histone acetylation is controlled by 
histone acetyltransferase (HAT) which adds an acetyl group to histones uncoiling the 
chromatin and facilitating gene transcription and is reversed by histone deacetylase 
(HDAC) which removes acetyl groups from histones coiling the chromatin and 
inhibiting gene transcription. Histone K methylation is also enzymatically reversible 
and is ‘written’ by K methyltransferases (KMTs) and ‘erased’ by K demethylases 
(KDMs). Aberrant modifications may lead to a chromatin conformational change 
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and therefore interfere with transcription of genes, including tumour suppressor 
genes and oncogenes.  
This plasticity is essential during development where histone modifications are 
known to instruct transcriptional networks required for cellular differentiation. In 
particular, histone plasticity and not DNA methylation is essential for TGF-β-
induced epithelial to mesenchymal transition (EMT) where repressive H3K9Me2 
domains were shown to reduce upon EMT while transcription-associated bulk 
H3K36me3 and H3K4me3 domains were increased (McDonald, Wu et al. 2011). 
However, the mechanistic links that drive early-fate decisions as progenitor cells 
differentiate and its disruption that results in tumour formation are still unclear.  
 
1.10.2 miRNA silencing 
As previously described, miRNAs are small noncoding RNAs that regulate 
gene expression by binding to the 3’ untranslated region of messenger RNA 
(mRNA) causing its degradation and preventing protein translation (Bartel 2004). 
Eukaryotes express hundreds of miRNAs that regulate thousands of mRNAs and 
their expression is cell and tissue specific and essential for differentiation. 
 
1.10.3 DNA methylation  
DNA methylation refers to the addition of a methyl group to carbon-5 
position of cytosine residues. This most frequently occurs at CpG residues however 
non-CpG methylation has also been observed, commonly at TACAG motifs, with 
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high levels in pluripotent cells and a decrease upon differentiation with almost no 
non-CpG methylation in fully differentiated cell types (Chen, Feng et al. 2011; 
Ziller, Muller et al. 2011).  
DNA methylation at CpG residues in healthy cells has a multitude of roles including 
silencing of transposable elements, aiding defence against viral DNA and 
determining gene expression, including the expression of imprinted genes so that 
only one allele is expressed in a parent-of-origin specific manner. Aberrant CpG 
methylation can be a marker of a particular disease state or can contribute to a 
disease by altering gene expression as methylation can cause steric hindrance for 
transcription factor binding. 
 
1.10.3.1 Addition and removal of DNA methylation  
DNA methylation is controlled by a family of DNA methyl-transferase 
(DNMT) enzymes including DNMT1, DNMT3A, DNMT3B and DNMT3L. These 
enzymes transfer a methyl group from S-adenosyl-L-methionine (AdoMet) to the C5 
position of cytosine. DNMT1 is a maintenance enzyme that functions to ensure 
replication of methylation marks to daughter cells. It targets newly replicated hemi-
methylated DNA and replicates the methylation pattern to daughter DNA strands. 
DNMT3B is specifically required for methylation of centromeric minor satellite 
repeats (Okano, Bell et al. 1999). DNMT3A has de novo methyl-transferase activity 
during embryogenesis working with its cofactor DNMT3B. Non-CpG methylation in 
embryonic stem cells is also thought to be mediated by DNMT3A (Ramsahoye, 
Biniszkiewicz et al. 2000; Ziller, Müller et al. 2011). Furthermore, DNMT3A 
55 
 
cooperates with DNMT3L during embryogenesis to establish maternal imprints at 
imprinting centres. (Bourc'his, Xu et al. 2001; Chédin, Lieber et al. 2002).  
DNMT3L itself has no de novo DNA methyltransferase activity and binds to DNA 
but not AdoMet however it stimulates de novo activity of other DNA 
methyltransferases by binding them directly via its C-terminal domain (Gowher, 
Liebert et al. 2005). This binding enhances catalytic activity of DNMT3A and 
DNMT3B ~15 fold and increases DNMT3A affinity for AdoMet binding and 
affinity for DNA binding 20-fold. This interaction is transient and DNMT3L acts as 
a substrate exchange factor in this process (Gowher, Liebert et al. 2005). DNMT 
overexpression is associated with DNA hypermethylation and loss of imprinting 
(Biniszkiewicz, Gribnau et al. 2002) in several cancers (Arai, Kanai et al. 2006; Lin, 
Hsu et al. 2007; Roll, Rivenbark et al. 2008).  
Polycomb group proteins are a group of proteins that act to silence genes involved in 
development. Certain Polycomb group proteins, for example EZH2, directly affect 
DNA methylation by recruiting DNMT enzymes to target sites (Vire, Brenner et al. 
2006).  
The reciprocal process, loss of DNA methylation, is mediated by ten-eleven 
translocase enzymes (TET1-3) which target 5-methylcytosine and oxidise it into 5-
hydroxymethylcytosine (Wang, Williamson et al. 2007; Tahiliani, Koh et al. 2009). 
TET enzymes can also perform iterative oxidation generating 5-formylcytosine and 
5-carboxylcytosine (Ito, Shen et al. 2011). Unmodified cytosines are regenerated by 
passive dilution (replication of the DNA strand without copying the modification), 
by direct removal of the oxidised 5-position or by DNA repair-mediated excision by 
the enzyme thymine DNA glygosylase (TDG) (Kohli and Zhang 2013). Mutations in 
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TET genes are frequently found in myeloid cancers. One study found that patient 
bone marrow had significantly lower levels of 5-hydroxymethylcytosine compared 
to healthy controls and the authors suggested that disruption in TET2 activity 
favoured myeloid tumourigenesis (Abdel-Wahab, Mullally et al. 2009; Ko, Huang et 
al. 2010). 
 
1.10.3.2 DNA methylation distribution 
The distribution of CpGs throughout the genome is not uniform and is 
associated with gene expression. CpG islands (CGI) are calculated in silico as 
regions exceeding a set threshold of CG content (>55%) (Takai and Jones 2002) and 
are generally not methylated except for when located within a gene promoter. In 
general, gain of DNA methylation near a gene promoter silences gene expression by 
preventing transcription factor binding. It is now thought that CGI shores (located up 
to 2kb from CGI) hold much more significance in terms of tissue-specific gene 
expression due to their variable nature in both embryonic stem cells, normal tissue 
and in cancer (Doi, Park et al. 2009; Irizarry, Ladd-Acosta et al. 2009; Hansen, Timp 
et al. 2011). Several other features related to the distribution of genomic CpGs have 
recently been described (Table 1.4). In particular, global loss of DNA methylation in 
comparison to healthy tissue is a general property of cancer and is associated with 
loss of genomic stability as loss of tight epigenetic regulation has occurred. 
Conversely, aberrant gain of methylation, which usually occurs at CpG islands, has 
been seen in many cancers and is termed CpG island methylator phenotype, or CIMP 
(reviewed in (Teodoridis, Hardie et al. 2008)). CIMP is defined by methylation of 
multiple CpG islands, often near the promoter regions of tumour suppressor genes. 
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Contiguous regions of DNA that show differential methylation between tissues, cells 
or individuals are referred to as differentially methylated regions (DMRs); the 
methylation status of which may have a direct effect on a particular transcript. A 
small subset of DMRs are imprinting control regions (ICRs) which determine the 
expression of imprinted genes (discussed later). These are set in the germline and 
show allele-specific differential methylation whereas other DMRs are established 
after fertilisation to define gene expression in normal tissues and show biallelic 
methylation patterns that differ between tissues.  
In general, DNA methylation prevents gene expression by preventing transcription 
factor binding, and therefore key tissue-specific transcription factors can be 
identified by studying the genomic regions that are not methylated in comparison to 
other tissues.  
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Feature Significance 
CpG island CpG rich region, generally not methylated, show cancer-specific 
hypermethylation 
CpG shore 2kb from CpG island, inversely correlated with gene expression 
(Doi, Park et al. 2009; Irizarry, Ladd-Acosta et al. 2009) 
CpG shelf 2kb from CpG shore 
Methylation within gene 
promoter region 
In general, inversely correlated with gene expression 
Methylation within gene 
body 
In general, positively correlated with gene expression (Jjingo, 
Conley et al. 2012; Kulis, Heath et al. 2012) 
DNA methylation 
valley 
Large unmethylated fomains where early developmental 
regulatory genes are located. When these specific early 
developmental genes are silenced during cell differentiation, 
H3K27me3 is acquired instead of methylation (Xie, Schultz et al. 
2013). 
DNA methylation 
canyon 
Regions of low methylation protected by DNMT3A that span 
conserved domains frequently containing transcription factors 
and are distinct from CpG islands and shores (Jeong, Sun et al. 
2014).  
Low methylated region 
(LMR) 
Average methylation of 30%; poor CpG dense distal regulatory 
regions that bind transcription factors. This binding is sufficient 
to create LMRs. Cell-type LMRs are occupied by cell-type 
specific TFs. 
Differentially 
methylated region 
(DMR) 
Regions of contiguous methylation that have a different 
methylation status from the comparative tissue. These regions are 
defined by different algorithms depending on the dataset but 
usually contain at least 3 CpGs 
Table 1.4: Features associated with genomic distribution of CpGs 
 
1.10.3.3 Genomic imprinting 
In a subset of genes termed imprinted genes, an epigenetic mark set in the 
germline restricts expression in a parent of origin dependent manner resulting in 
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hemizygous expression. In effect, one copy of an imprinted gene is actively silenced 
by DNA methylation depending on whether it was inherited from a paternal or 
maternal chromosome. Approximately 100 imprinted genes have been identified but 
only a small proportion of these experimentally validated (Morison, Paton et al. 
2001). These imprinted genes, including IGF2 and H19, are more susceptible to 
deregulation as only one copy is active.  
The allele specific DNA methylation is controlled by DMRs which, as previously 
mentioned, are regions of differential methylation that effect transcript expression. A 
small selection of DMRs are imprinting control regions (ICRs) which dictate the 
methylation status of the surrounding DMRs in up to 1Mb of DNA and hence 
regulate the expression of the imprinted genes they control (Weaver, Susiarjo et al. 
2009). Deletion of an ICR causes loss of imprinting (LOI) in adjacent genes 
resulting in biallelic expression (Fitzpatrick, Soloway et al. 2002).  
Imprinting marks must be reset every generation as, for example in a female’s 
oocytes, all paternally inherited chromosomes must be remodelled to be passed to 
her offspring as maternal imprints. For this to occur, all marks are erased within the 
germ cell. In the maternal gamete, methylation is lost passively by loss of DNMT1 
expression whereas in the paternal gamete, methylation remains until fertilisation 
(Smith, Chan et al. 2012). Upon fertilisation, before the two genomes combine, the 
paternal genome is actively demethylated by TET enzymes (Mayer, Niveleau et al. 
2000). Primary imprinting marks at ICRs are then set in the germline (Mann 2001). 
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1.10.3.4 Analysis of DNA methylation and confounders 
DNA methylation is commonly assessed by bisulfite conversion of DNA, 
which causes conversion of all unmethylated cytosine residues to thymine resides 
and leaves all methylated cytosines unchanged (see Figure 1.10). This allows 
distinction between methylated and non-methylated CpGs. After this treatment, 
DNA can be analysed by either array-based or sequencing-based methods.  
 
 
 
 
 
Figure 1.10: Bisulfite conversion of DNA to differentiate methylated from non-methylated 
cytosine residues Bisulfite treatment targets only unmethylated cytosines and deaminates them to 
uracil. Upon one round of PCR, these are substituted for thymine therefore permanently changing the 
unmethylated CpG so that it can be distinguished from a methylated CpGs. 
 
With comparative DNA methylation analyses, there are many confounding factors 
including incomplete bisulfite conversion, batch/chip/bead effects (when using 
microarrays), age and ethnicity of the patient, SNPs and cell type composition. Cell 
composition effects have a marked effect on results, although until recently were 
difficult to account for. As each cell type has a unique epigenome, having different 
proportions of cell types in comparative tissue samples may result in false positive 
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results, or hide true positives. Likewise, in studies that assess methylation markers in 
blood, the many cell types present significantly confound results. This can be limited 
by cell sorting to single populations prior to analysis however this is not always 
possible as a definitive cell-specific marker may be unknown. Alternatively, novel 
computational algorithms have been designed to adjust comparative analyses for cell 
type composition effects. 
One such algorithm was designed by profiling sorted subpopulations of blood and 
discerns the contribution of mixed cell type effects in blood case:control studies 
(Adalsteinsson, Gudnason et al. 2012), however this is the only method that uses 
such a rigourously defined reference (Jaffe and Irizarry 2014). Other current 
methodologies for correcting for cell-type composition include EWASher (Zou, 
Lippert et al. 2014) and RefFreeEWAS (Houseman, Molitor et al. 2014), both of 
which require no reference dataset. The RefFreeEWAS algorithm uses single value 
decomposition to estimate the number of cell types contributing to overall histology, 
then deconvolutes the β-values based on the estimated number of cell types and a 
design matrix specifying analysis covariates, and generates bootstrap-derived CpG-
specific p-values and covariates that correspond to a ‘true’ methylation signal with 
no cell mixture effects. 
Although cell mixture effects can now be taken into account, it is not entirely 
essential for certain study designs as a mixed cell composition, in some cases, is 
indeed a marker of the disease itself.  
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1.11 Biological epigenetics  
As discussed, there are many different aspects of epigenetics, which work in 
unison during cellular differentiation in normal development and in disease. 
 
1.11.1 Epigenetics in development 
Waddington’s theory of gene expression regulation during cellular 
differentiation in development used the analogy of a ball rolling down a hill. In this 
metaphor, the ball at the top of the hill represents the pluripotent stem cell which 
follows decisive pathways regulated by gene expression and hence travels 
downwards (through valleys) to become a fully differentiated cell (see Figure 1.11). 
As cells acquire cell-type specific features during differentiation, they cannot travel 
“up the hill”. This early model, described prior to the understanding of epigenetics, 
has been adapted and refined since then, however today, the same hierarchical 
concept exists. 
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Figure 1.11: Waddington’s hill theory. A pluripotent stem cell has the potential to differentiate into 
any cell in the organism. This cell (depicted as a ball) is shown at the top of a hill. As the ball travels 
down the hill, it runs into a valley. Each valley represents a change in the epigenetic architecture of 
the cell which corresponds to acquiring more differentiated properties, such as lineage specification. 
Once a decision has been made, the ball cannot roll upwards, or across to a different valley, but can 
only travel downwards taking one of many routes towards terminal differentiation. 
 
This hierarchical concept, explained further by the understanding of epigenetics, 
centres around the fact that during development, the genome remains constant while 
the epigenome undergoes programmed remodelling to alter gene expression which is 
essential to define embryo patterning and for organ and cell-type specification. Cells 
acquire cell type-defining permanent epigenetic changes during differentiation, 
which specifies a lineage and then cell type. Consequently cells at an early stage of 
differentiation have a more variable and more easily reshaped epigenome than those 
nearing terminal differentiation, and once a cell fate decision has been made, cells 
cannot reverse the decision to alter, for example, the specified lineage. Upon 
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terminal differentiation, maintenance of the epigenome is essential to maintain 
cellular identity and the epigenome shows little plasticity. 
 
1.11.2 Epigenetics in cancer 
It is commonly observed that loci involved in regulation of normal 
development or differentiation are targeted by aberrant DNA methylation or 
chromatin structure in cancer compared to normal cells. As previously mentioned, 
during development the epigenome shows a great deal of plasticity, particularly at 
early stages. Cancer cells show the same properties either by proliferation of less 
well differentiated cells or by mutation of epigenetic regulators. Having the ability to 
alter the epigenome, gives a cell the ability to adapt to the local microenvironment 
and further insults (e.g. chemotherapy). Mutations in epigenetic regulators have 
recently been identified with the sequencing of many human cancers (van Haaften, 
Dalgliesh et al. 2009; Dalgliesh, Furge et al. 2010). In fact, mutations in a given 
epigenetic regulator can be activating or inactivating (Ernst, Chase et al. 2010; 
Nikoloski, Langemeijer et al. 2010; Sneeringer, Scott et al. 2010), suggesting tumour 
promoting or tumour suppressor functions for the same gene product depending on 
cellular context. Re-acquisition of epigenetic plasticity gives cancer cells self-
renewal and proliferation capacity, similar to normal progenitor populations. Indeed, 
epigenetic events have been considered as the earliest events in tumourigenesis 
whereby Cancer has been described as originating from a pool of progenitor cells 
with unstable epigenomes that later acquire gene-specific genetic or epigenetic 
initiating mutations that result in tumour formation (Feinberg, Ohlsson et al. 2006). 
These tumours then acquire epigenetic and genetic plasticity as a later event which is 
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proposed to lead to tumour heterogeneity (Feinberg and Tycko 2004; Gerlinger, 
Rowan et al. 2012). 
Despite the advantages of its plasticity during cellular differentiation, aberrations in 
the epigenome (epimutations) can impact on gene expression analogous to genetic 
mutations and can therefore confer undesirable effects. Differential gene expression 
has been attributed to epimutation in several cancer predisposition and congenital 
predisposition syndromes by overexpression of oncogenes or silencing of tumour 
suppressor genes. In cancer, aberrant hypomethylation causes expression of 
oncogenes, for example WNT5B in prostate cancer (Wang, Williamson et al. 2007), 
R-RAS in gastric cancer (Nishigaki, Aoyagi et al. 2005) and MAGE1 in melanoma 
(Janssen, van de Locht et al. 1999)  as well as global genomic instability in cancer 
whereas aberrant hypermethylation silences tumour suppressor genes for example 
RB1 in retinoblastoma (Sakai, Toguchida et al. 1991), p16 in melanoma (Gonzalez-
Zulueta, Bender et al. 1995), SLC5A8 in lung cancer (Park, Kim et al. 2013), P16 in 
breast cancer (Lee, Ko et al. 2012) and RASSF2 in cervical cancer (Guerrero-Setas, 
Perez-Janices et al. 2013). Hypermethylated tumour suppressor genes represent one 
of the most consistent hallmarks of human cancers (Merlo, Herman et al. 1995; 
Esteller, Corn et al. 2001; Esteller 2002).  
Previous work has shown that bivalent domains are often targets of aberrant 
hypermethylation in cancer due to the vulnerability gained by going through 
transient chromatin-induced silencing during development (Ohm, McGarvey et al. 
2007; Widschwendter, Fiegl et al. 2007). It is thought that the transient silencing is 
“locked in” by recruitment of DNA methyl transferases by the Polycomb proteins in 
cancer which deposit irreversible DNA methylation, which is the mechanism used in 
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normal development to silence these loci during cellular differentiation (Schlesinger, 
Straussman et al. 2007).  
As well as common changes in methylation occurring at specific regions, an increase 
in stochastic variation in DNA methylation has been associated with tumourigenesis 
(Hansen, Timp et al. 2011). This variability occurs within common regions in 
different cancers; sites that can distinguish each respective normal tissue (Hansen, 
Timp et al. 2011) and is associated with giving cancer cells selective advantage 
through cellular Darwinian selection mechanisms (Issa 2011). In other words, cancer 
cells that display a mixture of epigenetic signatures are more likely to contain cells 
that have different properties such as chemotherapy resistance or metastatic or 
invasive potential, than a single clonal population. Supporting this hypothesis of 
methylation variability increase giving a selective advantage, an increase in 
methylation variability has been observed in colon adenocarcinoma precursor lesions 
and was seen to increase during tumourigenesis (Timp and Feinberg 2013). 
However, a more recent study in cervical cancer found that the peak of variability 
occurred just prior to malignant transformation as, at this stage, there is an absence 
of a dominant subclone typically seen in cancer (Teschendorff, Liu et al. 2014). Both 
studies agree that methylation variability is however cancer-associated. Taking this 
concept further, two studies were able to show that early changes in DNA 
methylation could be predictive of cancer generation. The first showed that DNA 
methylation signatures were more variable when taken from women who later 
developed cervical neoplasia in comparison to those that remained disease-free 
(Teschendorff, Jones et al. 2012), and the second found that white blood cell DNA 
methylation levels at an intragenic ATM locus could predict breast cancer risk 
(Brennan, Garcia-Closas et al. 2012).  
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Finally, the significance of the tight regulation of imprinted genes by DNA 
methylation is shown by the abundance of LOI seen in cancer, including LOI at 
IGF/H19 in WT and colorectal cancer (Sakatani, Kaneda et al. 2005), PEG1/MEST 
in lung cancer (Nakanishi, Suda et al. 2004), CDKN1 in pancreatic cancer (Sato, 
Matsubayashi et al. 2005), DIRAS3 in breast cancer (Yu, Xu et al. 1999), and TP73 
in gastric cancer (Kang, Park et al. 2000). Problems with the establishment of 
coherent imprinted marks during development can cause germline syndromes such 
as BWS which increases susceptibility to WT (Reik, Brown et al. 1995).  
 
1.11.3 Epigenetic cancer biomarkers: circulating cell-free DNA 
As previously stated, epigenetic modifications can be markers of a particular 
disease state without necessarily contributing biologically to disease onset or 
maintenance. In particular, methylated DNA can act as a marker of a cancer which 
can be measured in the blood as tumours release DNA upon cell death. In other 
cancers, methylated circulating cell-free DNA has been extracted from blood serum 
or plasma and used to quantify tumour burden and response to chemotherapy (Mori, 
O’Day et al. 2005; Hauser, Kogej et al. 2013; Hauser, Zahalka et al. 2013; 
Ponomaryova, Rykova et al. 2013; Tian, Yip et al. 2013; Balgkouranidou, 
Chimonidou et al. 2014). 
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1.11.4 Epigenetics in Wilms tumour 
Analysis of several components of the epigenome has been undertaken in 
WT including analysis of global chromatin modification, miRNA analysis and 
targeted DNA methylation analysis. These studies revealed epigenomic architecture 
associated with renal development and with cancer giving novel insight into WT 
biology. 
 
1.11.4.1 Chromatin 
Recently, chromatin immunoprecipitation was performed on three WT, EK 
and normal kidney (NK) tissues using antibodies against H3K4me3 (marking 
transcriptional initiation when present at promoters), H3K36me3 (marking active 
genes) and H3K27me3 (marking silent promoters) (Aiden, Rivera et al. 2010). The 
DNA captured from these chromatin selections was sequenced to identify active and 
suppressive loci and compared to gene expression in WTs and chromatin maps in 
ESCs. 
Both ESCs and WTs showed similar patterns of H3K4me3, specifically at 
developmental loci where both cell types showed broad regions of H3K4me3 that, in 
ESCs, mark key master transcription factors such as OCT4 and SOX2. One of these 
large domains overlapped with transcription factor SIX2, which is essential for renal 
progenitor maintenance, and has been shown to be overexpressed in both the MM 
and WTs. In total, 114 genes showed broad H3K4me3 domains present in WT but 
not NK that encompassed many genes essential for renal development, suggesting 
WTs are governed by a set of transcription factors essential for normal development. 
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The same genes also showed enrichment for H3K36me3 indicating positive 
expression. 
Comparison of narrow H3K4me3 peaks, which mark active promoters, identified a 
set of genes enriched for epigenetic regulators that were positively expressed in 
ESCs and WT but not expressed in NK (Figure 1.12). As terminally differentiated 
NK cells will not need to remodel their epigenome, but ESCs need to for cellular 
differentiation, this evidence suggests that WTs have the potential to actively modify 
their epigenome for further differentiation, hence why a variety of cell types is 
observed in WTs.  
 
 
Figure 1.12: Epigenome remodellers are active in WT and ESCs but not normal kidney, taken 
from (Aiden, Rivera et al. 2010). Peaks identified by chromatin immunoprecipitation using an 
antibody for H3K4me3 and H3K27me3 are shown in green and red respectively. Three epigenetic 
regulators are shown, HDAC4, CBX2 and JARID2. In both WT and ESCs, H3K4me3 peaks can be 
seen but not H3K27me3 suggesting that these genes are positively expressed in both tissues. Normal 
kidneys did not show H3K4me3 peaks at these genes (not shown). 
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Next, analysis of combined H3K4me3 and H3K27me3, or ‘bivalent domains’ in 
WTs identified a subset of genes with low expression in WTs that were also bivalent 
and not expressed in ESCs but were active in normal kidney. In ESCs, bivalent 
domains mark developmental loci that are considered essential for normal 
development and are resolved during cellular differentiation by losing either 
chromatin mark therefore causing the underlying gene to become either expressed or 
repressed. Unsurprisingly, a subset of these genes are strongly expressed in mouse 
kidney epithelial structures indicating that cells are prevented from expressing key 
epithelial genes and therefore differentiating properly. As other domains that are 
bivalent in ESCs showed H3K27me3 and no expression in WTs, the authors suggest 
that WTs show partial lineage commitment and concluded that developmental arrest 
occurs in undifferentiated MM as genes required for differentiation (FOXD1 and 
LHX1 which are involved in stromal and epithelial differentiation respectively) are 
both among the subset of genes with bivalent chromatin that are not expressed. 
 
1.11.4.2 miRNA 
Apart from the evidence described in chapter 1.9.4, the expression of 
miRNAs has been analysed in WT resulting in several associations between aberrant 
expression of global or specific RNAs, their processors or regulators and WT. These 
include detection of a miRNA signature in the blood of WT patients that 
distinguishes it from healthy control blood and may be used to diagnose WT 
(Schmitt, Backes et al. 2012), a miRNA signature in WT blastema that differentiates 
intermediate and high risk WTs and could therefore be used to predict response to 
chemotherapy (Watson, Bryan et al. 2013), expression of both transcription factor 
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E2F3 and Oncomir-1 (an oncogenic cluster of miRNAs on chr13 regulated by E2F3) 
which were increased in WT compared to normal tissue with increase correlating 
with high stage and metastatic disease (Kort, Farber et al. 2008).  
 
1.11.4.3 DNA methylation 
DNA methylation profiling in WT has shown both specific and global 
methylation changes. Epimutations specific to WT are listed in Table 1.5, however 
the most well-characterised of these, likely due to its syndromic association (Reik, 
Brown et al. 1995), is abnormal methylation at 11p15 either due to loss of imprinting 
(LOI) by gain of methylation at the imprinting control region (H19-ICR) or by 
paternal uniparental disomy, observed in ~70% WT (Scott, Murray et al. 2012). 
Interestingly, mosaic gain of methylation at H19 and reciprocal overexpression of 
IGF2 has been observed within the adjacent ‘normal’ kidney tissue of WT patients 
and is commonly found in PLNR (Ohlsson, Cui et al. 1999; Vuononvirta, Sebire et 
al. 2008).  
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Aberration Finding within Wilms tumour 
CASP8 hypermethylation Frequency of 19% and associated with 
RASSF1A methylation (Harada, Toyooka et al. 
2002) 
GLIPR1/RTVP hypomethylation Frequency of 87.5%, results in overexpression 
(Chilukamarri, Hancock et al. 2007) 
Global hypomethylation Results in genome instability in tumour cells 
(Ehrlich, Hopkins et al. 2003; Ludgate, Le Mee 
et al. 2012). 
HACE1 hypermethylation Frequency of 73% (Zhang, Anglesio et al. 
2007) 
Hypermethylation of a CTCF binding site 
downstream of WT1  
Correlated with high WT1 expression 
(Zitzmann, Mayr et al. 2014) 
Hypermethylation of protocadherin 
cluster at 5q31 
Results in expression loss of these proteins at 
the cell surface (Dallosso, Hancock et al. 2009) 
LOI  11p15 Frequency of 69%, results in overexpression of 
IGF2 and down-regulation of  H19 (Haruta, 
Arai et al. 2008; Gadd, Huff et al. 2012; Scott, 
Murray et al. 2012) 
P16 hypermethylation Frequency of 23% (Arcellana-Panlilio, Egeler 
et al. 2000) 
RASSF1 hypermethylation Frequency of 54% (Wagner, Cooper et al. 2002) 
WT1-antisense transcript 
hypomethylation 
Results in biallelic expression (Malik, Salpekar 
et al. 2000) 
Table 1.5: Epimutations in Wilms tumour, taken from Charlton et al (Submitted to Oncotarget) 
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Figure 1.13: H19 imprinting control region. At the maternal locus (top) CTCF binds to the 
imprinting control region (ICR; blue) which prevents enhancer proteins binding which therefore 
cannot express IGF2. At this locus, H19 is actively expressed. Conversely, at the paternal allele 
(bottom), the ICR is methylated causing loss of H19 expression however enhancer proteins can now 
bind and IGF2 expression occurs. 
 
The H19-ICR controls expression levels of IGF2 and H19, and contains 
differentially methylated domains that show parent-of-origin dependent methylation, 
resulting in hemizygous expression of both genes in healthy tissue (Steenman, 
Rainier et al. 1994; Li, Franklin et al. 1998; Honda, Arai et al. 2008). The H19-ICR 
contains binding sites for CTCF (CCCTC-binding factor, zinc finger protein) and, 
upon binding, protects the maternal allele from de novo methylation (Fedoriw, Stein 
et al. 2004). Conversely, at the paternal allele, methylation prevents CTCF from 
binding and IGF2 is actively transcribed (see Figure 1.13). In WT, both alleles are 
methylated by the two mechanisms previously stated which results in biallelic IGF2 
expression.  
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Besides the site-specific methylation changes in WT, global methylation events are 
also reported; large blocks of hypomethylation were observed in WT which 
corroborates the finding of genome-wide centromeric satellite DNA 
hypomethylation (Ehrlich, Hopkins et al. 2003; Ludgate, Le Mee et al. 2012).  
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1.12 Hypotheses to be tested 
Using a well-characterised sample set from UK patients registered in two 
contiguous clinical trials in childhood WT that used the same diagnostic and 
treatment approach, the following experimental aims were proposed: 
i) To determine genome-wide methylation profiles for normal kidney, 
nephrogenic rest and Wilms tumour 
ii) To identify epigenetic changes associated with the persistence of NR in 
post-natal kidney as well as evolution of WT from its presumed precursor 
in normal embryonic kidney  
iii) To identify epigenetic markers that will be useful in distinguishing NR 
from WT – a particularly challenging differential diagnosis for 
histopathology, especially in the context of chemotherapy-treated WT 
iv) To identify changes in methylation associated with progression towards 
malignancy rather than mixed cell populations by performing both non-
corrected and corrected analyses 
Additional aims were subsequently added, once the initial work had established 
that methylation changes could be used to distinguish tissue types: 
v) To identify tumour-specific sites of methylation that can be detected in 
blood serum for use as a biomarker 
vi) To confirm that the blood methylation biomarkers are discriminative in 
an independent cohort and have clinical utility 
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Chapter 2: Materials and Methods 
2.1 General laboratory equipment 
A table of general laboratory equipment used in this project can be found in 
Appendix 3: Table A2. 
 
2.2 Nephrectomy tissue samples 
2.2.1 Source of samples and processing 
All nephrectomy tissue (Wilms tumour (WT), nephrogenic rest (NR) and 
normal kidney (NK)) was derived from samples collected through either the Society 
of Paediatric Oncology (SIOP) 2001 study, the Improving Outcomes for Children 
with Renal Tumours (IMPORT) 2012 study both with signed parental consent or 
from overseas or occasional patients treated at Great Ormond Street Hospital 
(GOSH), not enrolled on either trial but with appropriate consent for biological 
studies. Sample collection was carried out with ethical approval granted by the NHS 
London Bridge Research Ethics Committee (ref: 12/LO/0101).  Each centre 
contributing to these clinical trials collected tissue for research purposes which was 
either frozen fresh in liquid nitrogen or fixed in formalin overnight before being 
embedded in paraffin the next day. Formalin fixed paraffin embedded (FFPE) blocks 
can be stored long-term at room temperature while fresh frozen tissue was stored in 
cryogenic tubes in liquid nitrogen or at -80ºC, according to local policies across the 
CCLG principal treatment centre network. 
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2.2.2 Haematoxylin and eosin staining of tumour sections 
To investigate the composition of an FFPE block, 3μm sections were cut 
using a microtome and mounted onto a slide by heating to 60ºC in an incubator. 
These sections were then stained with haematoxylin and eosin using a Leica 
Autostainer XL (protocol in Table 2.1).  
 
Step Reagent Time  
1 Xylene 2 min 
2 Xylene 2 min 
3 Abs alcohol 1 min 
4 Abs alcohol 1 min 
5 Abs alcohol 1 min 
6 Tap water 2 min  
7 Harris haematoxylin (Leica, Ref 3801560E) 6 min 30 sec 
8 Tap water 2 min 
9 1% acid alcohol 30 sec 
10 Tap water 1 min 
11 1% eosin (Leica, Ref. 3801590E) 4 min 30 sec 
12 Tap water 1 min 
13 Abs alcohol 45 sec 
14 Abs alcohol 30 sec 
15 Xylene 30 sec 
16 Xylene 1 min 
17 Mount with DPX (VWR Ref. 360294H)  
Table 2.1: Protocol for haematoxylin and eosin staining of FFPE sections using the Leica 
Autostainer XL 
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2.2.3 Pathological review and case selection 
For both the SIOP trial and the IMPORT study, centralised pathological 
review for clinical quality assurance of the overall risk group was carried out by 
Professor Gordan Vujanic in Cardiff. He received the stained sections and analysed 
cell composition under the microscope to determine the predominant cell type (if 
present), the extent of post-chemotherapy changes, the presence of NRs and whether 
anaplasia or further differentiation was present. From these reports, cases were 
selected that indicated the presence of NRs and the block numbers recorded. 
Following this, as GOSH the designated biological study coordination hub for both 
studies and therefore the collection point for research tissue, the list of blocks with 
potential NRs was cross-referenced with those in storage and the available blocks 
(including many collected nationally with a higher number of GOSH cases) could 
easily be retrieved and fresh sections cut and stained for local pathology review. 
Local pathology assessment was next carried out by three independent paediatric 
pathologists (Professor Neil Sebire, Dr. Sergey Popov and Dr. William Misfud) who 
assessed the H&E sections under a microscope and marked out regions of NK, NR 
and WT (see Figure 2.1).  
 
Figure 2.1: Haematoxylin and eosin stained 3µm sections of FFPE tissue mounted on glass slides 
with NRs circled by a paediatric pathologist. 
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Cases selected for DNA extraction had large areas of each tissue type identifiable 
with minimal necrosis or chemotherapy induced changes. From review of cases with 
pathology reports indicating the presence of NRs, we found many did not have 
suitable (large enough) NRs, several had very compressed kidney which was 
therefore considered “not normal” and many had only necrotic tumour tissue.  
Therefore, a total of 145 samples were deemed suitable for DNA extraction. 
 
2.3 DNA extraction from clinical tumour samples 
2.3.1 Preparation of samples for DNA extraction 
After cases were marked for DNA extraction, a decision was made whether 
to cut multiple sections or to perform a core puncture into the tissue. This decision 
was based on the surrounding tissue composition, for example if a section showed 
the presence of both NR and NK, it was not possible to tell whether the full tissue 
block (up to 7mm in depth) was NR all the way to the base or whether contaminating 
NK was underneath. Conversely, in a block taken from the periphery of the lesion 
that showed a section composed entirely of NK, we could be confident that the 
whole piece was NK and therefore a core piece was taken. 
For core punctures, a 2μm diameter puncture was taken and the piece finely chopped 
using a scalpel. For tissue requiring multiple sections, up to 30 5μm sections were 
cut (depending on area of target region) and the target region was scraped from the 
slides using a scalpel. In both cases, tissue was put into an Eppendorf. 
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2.3.2 Optimisation of protocol for DNA extraction 
Prior to extraction of DNA from patient tissue, an FFPE block composed 
entirely of NK tissue was used to identify the method that yielded maximum DNA. 
Three Qiagen protocols were compared: DNeasy, QIAamp DNA mini kit and the 
QIAamp FFPE kit. The DNeasy kit had the most basic protocol while the QIAamp 
DNA mini kit added a PBS wash and incubation at 70ºC with buffer AL while the 
QIAamp FFPE kit added an extra incubation at 90ºC prior to buffer AL. All 
combinations of the DNeasy protocol with either one, two or all three additional 
steps were performed on duplicate tissue pieces and the final DNA yield was 
compared. The greatest yield was seen when both the 70ºC and 90ºC heating steps 
were included irrespective of the additional PBS wash, therefore the DNeasy 
protocol was adapted including these steps (see chapter 2.3.3 for protocol). 
 
2.3.3 DNA extraction from FFPE 
The final optimised protocol was as follows: 1ml xylene was added to the 
tissue samples which were vortexed for 15 seconds and centrifuged for 5 minutes. 
Then, the supernatant removed and two further washes in 100% ethanol were carried 
out before excess ethanol was evaporated on a 37˚C heat block. 180µl ATL buffer 
(DNA Mini Kit, Qiagen) with 20µl proteinase K was added for overnight digestion 
at 56˚C and following this, samples were heated to 90˚C for 1 hour. Samples were 
then incubated at 70˚C for 10 minutes with 200µl AL buffer (DNA Mini Kit, 
Qiagen) before 200µl 100% ethanol was added. DNA purification was carried out 
using Qiagen columns (Qiagen DNA Mini Kit). First, the mixture was added to a 
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column and spun at 8,000 rpm for 1 minute. Then, 500μl Buffer AW1 was added and 
samples were centrifuged at 8,000 rpm for 1 minute before the procedure was 
repeated with Buffer AW2. A full-speed centrifugation step for 2 minutes ensured 
the membranes were dry, and then the columns were transferred to new collection 
tubes for incubation with 70μl water for 5 minutes to elute the DNA followed by a 
final spin at full speed for 1 minute. The eluate containing the DNA was transferred 
to a clean Eppendorf and stored at -20ºC. 
 
2.3.4 Quality control of samples 
Concentration of DNA was calculated using a NanoDrop spectrophotometer 
(Thermo Scientific) which also calculates the purity of the sample by giving the 
260/230 ratio. A more stringent calculation of only viable double stranded DNA was 
obtained using the Qubit 2.0 Fluorometer (Life Technologies) according to 
manufacturer’s instructions. 
 
2.4 Blood serum samples 
2.4.1 Source of samples 
Blood was collected on the IMPORT study at 5 time points: (1) at diagnosis, 
(2) mid-way during the course of pre-operative chemotherapy, (3) pre-surgery after 
finishing the course of chemotherapy, (4) post-surgery prior to starting post-surgery 
chemotherapy and (5) at end of treatment all covered by the appropriate consent 
given for participation in the study. Blood serum samples from age-matched controls 
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without cancer were obtained from Great Ormond Street Hospital Department of 
Chemical Pathology with appropriate signed parental consent for research use. 
 
2.4.2 Initial handling and processing 
Blood was collected into a serum tube and left to clot for at least 30 minutes 
in the respective centre that the patient was treated. Each centre then centrifuged the 
tube for 1 minute at 1000rpm at room temperature before the clear serum at the top 
of the tube was removed and decanted into a 1.5 ml Eppendorf before being frozen 
and stored at -80ºC. 
 
2.4.3 Extraction of circulating free DNA from serum 
The QIAamp circulating nucleic acid kit (Qiagen) was used to extract DNA 
from blood serum which was carried out according to manufacturer’s instructions as 
follows. All serum samples were left to thaw on ice then brought up to 2ml by 
adding sterile phosphate-buffered saline (PBS). To begin, 200μl Proteinase K was 
added to the serum sample in a 50ml tube. To this, 1.6ml Buffer ACL was added and 
the mixture was vortexed prior to incubation at 60ºC for 30 minutes. Next, 3.6ml 
Buffer ACB was added and samples were incubated on ice for 5 minutes. To filter 
the samples, a QIAamp mini column was attached to a vacuum pump and the 
solution containing serum was filtered through. The filter was washed with 600μl 
Buffer ACW1, 750μl of ACW2 and 750μl 100% ethanol before the column was 
removed from the vacuum pump and centrifuged at full speed for 3 minutes. The 
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filter membrane was then dried completely by incubation at 56ºC for 10 minutes. 
Finally, 20μl Buffer AVE was added to the centre of the column filter membrane 
followed by a 3 minute incubation and a 1 minute centrifugation to elute the DNA.  
 
2.4.4 Quality control of cfDNA 
As concentrations of DNA extracted from blood serum were so low, the 
Qubit reading showed undeterminable levels of DNA. Therefore, a PCR was 
performed using primers for DMR2 to confirm the presence of DNA along-side a 
control genomic DNA sample that always amplified (Figure 2.2).  
 
 
Figure 2.2: 2% agarose gel image from PCR amplification of DMR 2 from cfDNA extracted 
from blood serum. The gel was labelled with ethidium bromide. +C = positive control: genomic 
DNA that always amplifies, -C = negative control: water, P = cell-free DNA from a patient (child), 
AC = cell-free DNA from an adult. 
 P1    P2   AC1  AC2  +C  -C 
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2.5 Embryonic kidney samples 
2.5.1 Source of samples 
Human embryonic kidneys were provided by the Joint MRC (grant 
#G0700089)/Wellcome Trust (grant #GR082557) Human Developmental Biology 
Resource (www.hdbr.org) at the UCL Institute of Child Health through collaboration 
with Professor Paul Winyard. Ethical approval was covered by the HDBR HTA 
tissue bank licence and ethical approval. Details of approval terms can be found at 
www.hdbr.org.  
 
2.5.2 DNA extraction from embryonic kidney 
DNA was extracted by a colleague from four human embryonic kidneys 
(from gestational age 8 weeks and 12 weeks) using the AllPrep DNA/RNA Micro 
Kit (Invitrogen cat #80284) according to manufacturer’s instructions.  
 
2.6 Bisulfite conversion of extracted DNA 
2.6.1 Bisulfite conversion treatment 
DNA was bisulfite converted using the EZ DNA methylation kit (Zymo 
Research).  For this procedure, 5μl M-dilution buffer was added to 45μl of DNA 
diluted in distilled water. These samples were incubated at 37ºC for 15 minutes 
before 100μl CT conversion reagent was added and samples were mixed by pipetting 
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up and down. Samples were then incubated for 16 hours at 50ºC with a 30 second 
heating step to 95ºC after each hour. Samples were then incubated on ice for 10 
minutes before mixing with 400μl M-binding buffer and passing samples through a 
Zymo-spin column by centrifugation. Columns were then washed with 100μl wash 
buffer, then 200μl M-desulphonation buffer was added and samples were incubated 
at 15-20 minutes at room temperature. Following this, two 200μl washes with M-
wash buffer were performed before DNA was eluted with 10μl M-Elution buffer.  
 
2.6.2 Quantitative PCR to check for conversion success 
To confirm bisulfite conversion, a quantitative PCR (qPCR) reaction was 
performed which selectively amplifies a post-conversion site within the gene MLH1 
(with many unmethylated cytosine residues that will be converted to thymine) with 
primers specific for bisulfite-converted DNA and a pre-conversion site within the 
gene GAPDH with primers specific for normal DNA (primers listed in Table 2.2, 
PCR conditions in Table 2.3).  
qPCRs were performed using MESA blue qPCR Master Mix Plus (cat# RT-SY2X-
03+WOUB 600rs) using the 7900KT Fast Real-Time PCR System (Applied 
Biosystems) with detection for SYBR green. The Applied Biosystems SDS 
programme Version 2.2.2 calculated the respective Ct values for every sample. In 
most cases, the GAPDH loci amplified after a large number of cycles as the DNA 
was bisulfite-converted and therefore the primers were no longer complementary. 
Conversely, fully converted DNA amplified the MLH1 site in very few cycles. The 
86 
 
ΔCt was calculated as the difference between MLH1 and GAPDH Ct values for 
every sample, and the % conversion for each sample was calculated by: 
% unconversion = 100/(1 + (2^ΔCt)) 
Only samples with >98% conversion were included.  
Primer Sequence 
MLH1 F (5’>3’) GGAGTGAAGGAGGTTACGGGTAAGT 
MLH1 R (5’>3’) AAAAACGATAAAACCCTATACCTAATCTATC 
GAPDH F (5’>3’) CGCCCCCGGTTTCTATAAAT 
GAPDH R (5’>3’) CAAAAGAAGATGCGGCTGAC 
Table 2.2: Primers used for qPCR validation of bisulfite conversion 
Step Temp Time 
1 50ºC 2 min 
2 95ºC 10 min 
3 95ºC 15 sec 
4 60ºC 1 min (cycle steps 3 & 4 40 times) 
5 95ºC 15 sec 
6 60ºC 30 sec 
7 95ºC 15 sec 
Table 2.3: PCR conditions used for qPCR validation of bisulfite conversion 
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2.7 Methylation profiling with 450k microarrays 
2.7.1 Ligation reaction 
The quality of DNA extracted from FFPE tissue is poor due to the fixing and 
extraction method which causes fragmentation of the DNA to a range of 300-600bp. 
This is problematic for the Illumina Infinium assay as a downstream whole-genome 
amplification procedure requires templates to be >1kb in length. Therefore, 
following an optimised FFPE protocol (Thirlwell, Eymard et al. 2010) 1-2µg DNA 
(depending on available yield) was treated using the REPLIg FFPE kit (Qiagen) 
which induces random ligation of DNA. Once ligated, the DNA strands are 
lengthened and suitable for whole-genome amplification. 
This protocol involved adding 8μl FFPE buffer, 1μl ligation enzyme and 1μl FFPE 
enzyme to each sample of bisulfite-converted DNA and incubating at 24ºC for 30 
minutes, 95ºC for 5 minutes and then cooling down to 4ºC. 
 
2.7.2 450k beadchip arrays 
These ligated samples were analysed by an in-house service provider (UCL 
Genomics) who ran the DNA on the Illumina 450k HumanMethylation BeadChips 
using HumanMethylation450 DNA Analysis BeadChip Kits (Cat# WG-314-1001, 
Illumina) according to manufacturer’s recommendations. Raw data were extracted 
from Illumia Genome Studio without any processing. 
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2.8 450k data analysis 
2.8.1 Data pre-processing  
For every CpG, a methylated and non-methylated measurement is taken, with 
the intensity of the scanned signal correlating with the quantity of methylated or non-
methylated DNA present in the sample respectively. The raw IDAT files hold this 
intensity information and were extracted from the Illumina HiScan machine. These 
files also contain a detection p-value for every probe, which indicates how well the 
signal intensity has been interpreted (with small p-values indicating high significance 
and good performance). All data analyses were performed using R (Version 3.0.2). 
Raw .idat files were loaded into R using the Bioconductor package ChAMP (Version 
1.2.7) (http://www.bioconductor.org/packages/release/bioc/html/ChAMP.html). The 
algorithm  
> champ.load(directory_of_raw_IDAT_files, p=0.01)  
performed a pre-processing step removing probes with high detection p-values. The 
level of significance used as a cut-off can be altered however for this study it was 
consistently 0.01. The output of this algorithm was loaded methylated and 
unmethylated intensity values (an ‘RGset’ or ‘MethylSet’) with the total number of 
probes filtered for good detection p-values. 
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2.8.2 Data normalisation 
After pre-processing, the data needed to be normalised as there are two 
probes types on the array. Type I probes originated from the 450k predecessor, the 
27K array, and use two probes in the same colour channel to measure methylated 
and unmethylated intensities whereas type II probes were designed differently and 
use one probe and two different colour channels to make the same measurements. 
Due to these two different methods of signal detection, there are slightly different 
signals generated which need to be corrected for to avoid probe type-specific false 
positives. Therefore, intra-array normalisation was essential and was performed 
using either the Dasen method implemented through the Bioconductor wateRmelon 
package (Version 1.4.0) 
(http://www.bioconductor.org/packages/release/bioc/html/wateRmelon.html):  
> Dasen(MethylSet)  
or the SWAN algorithm implemented through Bioconductor package Minfi (Version 
1.10.2) (http://www.bioconductor.org/packages/devel/bioc/html/minfi.html). 
> preprocessSWAN(RGSet)  
Both methods can use an ‘RGset’ or a ‘MethylSet’ as an input which is a measure of 
the raw methylated and unmethylated intensities for each CpG for each sample and 
both perform quantile normalisation, i.e. they adjust intensity signals to give both 
probe distributions identical statistical properties. Quantile normalisation shifts the 
type II probes to fit the type I probe distribution (Figure 2.3). The additional benefit 
of using Dasen is that between-array normalisation is also performed. The 
background difference between type I and type II probes for both methylated and 
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unmethylated intensities is adjusted to prior to quantile normalisation so that chips 
run at different time points are comparable. From the adjusted methylated and 
unmethylated signal intensities, a matrix of β-values was computed by the equation: 
β = methylated probe intensity / methylated probe intensity + unmethylated probe 
intensity 
The resulting data_matrix for downstream analysis had β-values for all samples with 
.idat files included in the pre-processing step and all CpGs included after the pre-
processing step. 
 
Figure 2.3: Quantile normalisation of 450 probes, taken from the Bioconductor Minfi Users 
Guide. The panel titled “raw” shows the distribution of the non-normalised probes. The panel labelled 
“SWAN” shows the probe densities after normalisation. The method of quantile normalisation fits the 
type II probe distribution onto the type I probes so that they both acquire identical statistical 
properties. 
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2.8.3 Cell type composition correction 
Recently, a lot of attention has been given to the generation of algorithms to 
account for the mixed cell type composition effects that arise when comparing two 
tissue types. In this study, the algorithm RefFreeEWAS was used (Houseman, 
Molitor et al. 2014).  
This method began with the command  
> EstDimRMT(data_matrix)  
which uses random matrix theory to estimate the significant components of variation 
(d) within the pre-processed and normalised data_matrix. In this model, d = the 
number of cell types present. As this approach uses vast amounts of computational 
memory, the command was run with 10 randomly selected smaller subsets of the full 
dataset (of 20 samples by 100,000 CpGs). In each instance, d was estimated as 3, 
which biologically makes sense as three predominant cell types were present: 
stroma, epithelia and blastema. There was also a very small number of blood cells, 
cells with rhabdomyoblastic features and fat cells; however these were very rare and 
should not confound the overall analysis.  
Next, the command  
> RefFreeEWASModel(data_matrix, unadjusted_linear_model, d)  
was run. This command takes the pre-processed and normalised data_matrix of β-
values together with a defined linear model (designed using the Bioconductor 
package Limma, see chapter 2.8.4 below) and the estimate for d, and performs the 
linear modelling while deconvoluting the DNA methylation arising as mixtures of 
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cell types. This algorithm returns mixture-adjusted covariate values according to the 
defined linear model, i.e. if a linear model comparing NK to matched NR in five 
patients was designed, the output would be the difference in β-value between NK 
and NR for each patient at every CpG. These covariates would be adjusted for cell 
type composition effects. Although the most substantial changes in methylation can 
be identified, the significance of these needs to be interpreted which is done using 
the algorithm: 
> BootRefFreeEwasModel(output, n) 
Where ‘output’ is the whole model generated by the RefFreeEWASModel algorithm 
(which includes many other variables) and n = the number of bootstraps to run. 
Bootstrapping is a method of generating p-values without generating more data. The 
algorithm defines a new dataset (d_new_1) by taking a smaller sample subset of the 
original data (with all CpGs included) in a random order and then computes the 
covariate values for these samples according to the specified linear model. This 
process is repeated up to d_new_n and the covariates are then compared to generate 
standard deviations and corresponding p-values for every CpG. In this study, n was 
set to 100. Ideal studies would run n>500 however with the computation systems 
available, n=100 still gives reliable p-values for good interpretation. 
 
2.8.4 Linear modelling 
Linear modelling was performed using the Bioconductor package Limma 
(Version 3.20.8) 
(http://www.bioconductor.org/packages/release/bioc/html/limma.html). This package 
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involves generating a design matrix specifying the number of samples and the 
comparisons to make, i.e. a model to compare levels of methylation within one 
patient between histology types (such as NK vs NR). The design matrix can also 
factor in multiple group analyses, for example an ANOVA analysis. Both of these 
formats were used in this study. Wherever a matched design was used, SNPs and sex 
chromosomes could be included as the matched design avoids patient-specific 
genomic events from confounding the analysis. In grouped comparisons, these CpGs 
were excluded. 
Once the design matrix had been specified, the linear model was fitted to the data 
followed by a Bayesian framework fit which moderates standard errors across genes. 
Finally, the topTable command generated an output table of the full list of CpGs 
with covariates, p-values and p-values adjusted for multiple sampling (by a user-
specified method). In this study, the Benjamini-Hochberg model (Benjamini and 
Hochberg 1995) was used. 
 
2.8.5 TREAT 
 The TREAT algorithm (McCarthy and Smyth 2009) allows users to identify 
changes in methylation that are both mathematically and biologically significant. 
The TREAT function is applied to a linear model prior to the Basesian model and 
adjusts p-values based on the detected Δβ (covariates) giving more weight to those 
with a small Δβ (which would be not interesting biologically) but increased weight 
to those with a large Δβ (i.e. the p-value is decreased). The end result is a list of all 
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CpGs sorted by a p-value with the CpGs that show the largest and most significant 
differences in methylation ranked top. 
 
2.8.6 DMR finder 
The algorithm used to identify differentially methylated regions in this study: 
> champ.lasso  
was implemented through the Bioconductor package ChAMP. This algorithm takes 
all the background CpGs and calculates the distance to the nearest neighbouring 
CpG. According to the Illumina annotation, the probes are defined by whether they 
are located in a CpG island, shore, shelf or other and then by location in a 3’UTR, 
5’UTR, TSS200, TSS1500, gene body, IGR or 1st exon (where TSS = transcription 
start site), giving 28 unique categories. The distance to the nearest neighbouring 
probe for every CpG was identified using the Illumina MAPINFO annotation to 
calculate the average CpG density for probes within each category (Figure 2.4). This 
data demonstrates the unusual distribution of probes on the array with large between-
probe distances seen at intergenic regions and small distances seen at TSS200 
regions. The data for each category was plotted linearly and the minimum lasso size 
was set to 10bp. From reading off the  quantile required to reach a minimum lasso 
size of 10bp, this quantile was applied to every category to get a distinct lasso size 
for each feature that best fits the distribution of probes on the array (Figure 2.5). 
Using this information, the category-specific lasso was sent out centred on each 
probe and only those probes with adjusted p-value <0.01 were called significant. 
DMRs were then defined if the lasso connected three or more significant probes. 
95 
 
Any non-significant probes within the lasso region were also included in the DMR 
and those DMRs within 1kb of each other were encompassed into one region. 
 
Figure 2.4: The distance to the nearest neighbouring probes for all CpGs on the 450k array 
separated into categories. The number of CpGs included in each category (N) is shown with the 
distribution of the nearest probe. The IGR_none category shows the greatest range of distributions 
while the 3’UTR_none category shows the greatest mean distance. Probes within the 1st exon and 
TSS200 regions are generally located very close together. 
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Figure 2.5: Defining category-specific lasso radii for 450k probes. A horizontal line is seen at 
10bp, which intersects the TSS200_island category which shows the greatest CpG density. The 
quantile required for this to be set as a minimum parameter is ~0.48, which is then applied to all 
categories and a readout of the lasso radius is taken from the y-axis.  
 
2.8.7 Defining the most variable data points 
For several analyses, the top most variable data points were inputted. These 
were identified using the “varFilter” command from R package genefilter 
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(http://www.bioconductor.org/packages/release/bioc/html/genefilter.html) which 
requires an input of a data matrix of β-values (with columns as samples and rows as 
CpGs) with a user-specified method of discerning those variable positions. The 
parameters chosen were: based on interquartile range, select the top 1% most 
variable data points. 
 
2.8.8 Multidimensional scaling 
Multidimensional scaling (MDS) plots were generated using Minfi command 
“mdsPlot” in R. The input requires a data matrix of β-values and the number of 
positions used to generate the plot, i.e. if number of positions = 1000, the top most 
variable 1000 CpGs were used to perform the multidimensional scaling. The 
algorithm then calculates the distance between samples to generate a distance matrix 
in two dimensions and then represents this as a scatterplot (with the first dimension 
on the x-axis and the second on the y-axis) so that those samples that are more 
similar are closer together. 
 
2.8.9 Hierarchical clustering 
To perform hierarchical clustering, the open source package Heatmap.3 
(Version 3.1.1) (http://www.inside-r.org/packages/cran/GMD/docs/heatmap.3) was 
used. This script uses a matrix of β-values and evaluates the Euclidian average 
distance between samples before generating a hierarchical cluster. The script allows 
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for an input table of colours to generate a user-specified sample-associated colour 
grid at the top of the cluster. 
 
2.8.10 Overlapping regions 
BedTools Version 2.18 (http://bedtools.readthedocs.org/en/latest/) was 
installed and the intersectBed command was used via the command line to compare 
two bed files. The output was a list of all regions that directly overlapped. 
 
2.8.11 Support Vector Machine algorithm 
A support vector machine algorithm was applied using R CRAN package 
e1071 (http://cran.r-project.org/web/packages/e1071/index.html). This algorithm 
used a training set with two groups (NK and WT) specified to identify a group-
specific methylation pattern. Next, the algorithm compared this known pattern to a 
test set and outputted a sample-specific evaluation of whether the sample more 
closely resembled NK or WT. 
 
2.9 Pathway analysis 
Pathway analysis on significant CpGs, (either MVPs or DMRs) was 
performed using Genomic Regions Enrichment of Annotations Tool (GREAT) 
Version 2.0.2 (http://bejerano.stanford.edu/great/public/html/). This freely available 
software takes input Bed files of target sites (i.e. MVPs) as well as a background file 
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of all CpGs that could have been considered significant. This software outputs a 
series of informative tables (listed in Table 2.4) by combining annotations for over 
20 ontologies (McLean, Bristor et al. 2010). 
Ontology   
GO molecular function MSigDB pathway 
GO biological process MGI Expression: detected 
GO cellular component MSigDB Pertubation 
Mouse phenotype Transcription factor targets 
Human phenotype MSigDB predicted promoter motifs 
Disease ontology MSigDB miRNA motifs 
MSigDB Cancer Neighbourhood miRNA targets 
Placenta disorders InterPro 
Panther pathway TreeFam 
Pathway commons HGNC gene families 
BioCyc pathway  
Table 2.4: Output of software GREAT 
 
2.10 Comparison to publically available datasets 
 As genomic data must now be uploaded with submission of a related paper, 
there is a large repository of 450k methylation datasets online. These can be accessed 
through Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) or The 
Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/). Multiple downloads 
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of target regions across many samples can be done using the Marmal-aid package 
(http://marmal-aid.org/).  
In this study, data from four embryonic kidneys (GSM868048, GSM868049, 
GSM848050 and GSM868051), six embryonic stem cell lines (GSM867936, 
GSM867937, GSM867938, GSM867939, GSM867940 and GSM867942) and six 
induced pluripotent stem cell lines (GSM867968, GSM867969, GSM867970, 
GSM867972, GSM867973 and GSM867980) were extracted from GEO (GEO series 
GSE31848). Analysis using these data is described in chapter 4. 
Marmal-aid Version 1.2.1 was used to extract publically available methylation data 
either annotated as disease = ‘Healthy’ and tissue = ‘blood’ (n = 411) or disease = 
‘Cancer’ (n = 5,238) for comparative analyses discussed in chapter 6. 
 
2.11 DNA sequencing using Illumina Miseq 
2.11.1 Primer design 
MethPrimer (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi) 
was used to design primers specific for bisulfite converted DNA. All primers were 
checked using an ePCR tool to confirm amplification of a single product only 
(http://bisearch.enzim.hu/) and ordered from Sigma Aldrich (Table 2.5). 
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Region Forward primer Reverse primer Tm 
DMR1.1 
bisulfite-
converted 
TTTTTATTTTTATAAATAGTAA
GGATTG 
AAAAACTTCAAACAACTATTCAACC 51 
DMR1.2 
bislufite 
converted 
GTTAAAATTTTGGGTTAAGGA
GAT 
AAAATAAAAATTCAAAAAATAACC
C 
51 
DMR2.1 
bisulfite-
converted 
GGTTTTTGAGGAATTGGATTT TCCCAAACTCTTTCTACAATCATAC 51 
DMR2.2 
bisulfite-
converted 
ATTGTAGAAAGAGTTTGGGAG
AT 
TTCTAAAAACCATCTTAAAAAAAA 51 
HISTH1A 
bisulfite-
converted 
ACACTCTTTCCCTACACGACG
CTCTTCCGATCTGGGAGGTAT
TGTTTTAGATATGGTG 
GAGATCGGTCTCGGCATTCCTGCTG
AACCGCTCTTCCGATCCTAAAAACC
CCCAACTACCTTCTA 
59 
HOXD12 
bisulfite-
converted 
ACACTCTTTCCCTACACGACG
CTCTTCCGATCTTTTGAAGAA
TTTGTAGGTAAAGTTT 
GAGATCGGTCTCGGCATTCCTGCTG
AACCGCTCTTCCGATCCCTCAAATT
AAAAAAATAAAAAAAATCTAA 
56 
ZFP42 
bisulfite-
converted 
ACACTCTTTCCCTACACGACG
CTCTTCCGATCTAAAGGGTAA
ATGTGATTATA 
GAGATCGGTCTCGGCATTCCTGCTG
AACCGCTCTTCCGATCTAATCAAAC
TACAACCACCCA 
57 
PRKCZ 
bisulfite-
converted 
 
ACACTCTTTCCCTACACGACG
CTCTTCCGATCTTAGGGGTTG
TTTTTGTGATTT 
 
GAGATCGGTCTCGGCATTCCTGCTG
AACCGCTCTTCCGATCTAAAAATTC
TACCCACTTCC 
58 
AGAP1 
bisulfite-
converted 
 
ACACTCTTTCCCTACACGACG
CTCTTCCGATCTGTTAGTTTTT
TTTTTGGTTAGGG 
 
GAGATCGGTCTCGGCATTCCTGCTG
AACCGCTCTTCCGATCCCTCCTATA
ACCTCTTTATTAAAA 
60 
Table 2.5: List of primers used. DMR1 and DMR2 primers (described in chapter 6) were split into 
two regions to cover the entire region. 
 
Once received, primers were briefly centrifuged at 13,200 rpm to ensure the primer 
pellet was in the base of the tube. For all primers ordered from Sigma Aldrich, a 
varying volume of nuclease-free water was added, as per the accompanying primer 
information sheet, to make a stock concentration of 100 μM. This was then further 
diluted 1:10 to generate 10μM concentrations as required for the PCR reactions. 
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2.11.2 Library preparation 
2.11.2.1 Library preparation: PCRs 
Library preparation began with PCR amplification using region-specific 
primers. For bisulfite-converted DNA, 10ng genomic DNA was diluted in PCR-
grade water to make a total of 25μl. To this, 1μl of forward primer and 1μl reverse 
primer were added with 25 μl 2X KAPA HiFi HotStart Uracil+ ReadyMix (Kapa 
Biosystems). PCR involved initial denaturation at 95ºC for 5 minutes followed by 35 
cycles of (98ºC for 20 seconds, specific annealing temp for 15 seconds, 72ºC for 60 
seconds) before a final extension step at 72ºC for 1 minute. 
 
2.11.2.2 Library preparation: clean-up 
Next, samples were cleaned up using AMPure XP magnetic beads (Beckman 
Coulter). To the PCR sample, 45μl beads were added, mixed by pipetting and 
incubated at room temperature for 5 minutes. Samples were then put on a magnetic 
stand and left for 2 minutes. During this time a pellet formed on the magnet which 
included the target DNA. The supernatant was removed and the beads were washed 
twice with 200μl 100% ethanol to remove the PCR contaminants. Samples were air 
dried to remove residual ethanol and then were removed from the magnetic stand. 
20μl elution buffer was then added and the beads were resuspended by pipetting. 
After incubation at room temperature for 2 minutes, 45μl binding buffer was added 
and samples were incubated for a further 5 minutes at room temperature. The beads 
were subsequently pelleted on the magnetic stand and the supernatant was removed. 
Samples were washed twice with 200μl 100% ethanol then air dried before 
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resuspension in 25μl elution buffer. The beads were pelleted on the magnet one last 
time before the eluate containing the DNA was transferred to a fresh tube. 
 
2.11.2.3 Library preparation: Quantification 
After the clean-up procedure, samples were quantified using the Quant-it 
Picogreen dsDNA assay kit (Life Technologies, cat#P11496). To begin, 1μl 
Picogreen dye was diluted in 199μl TE buffer. Serial dilutions of a known 
concentration of DNA were made up in a plate along-side test concentrations of 8μl 
of H2O with 2μl DNA. To every control and test sample, 90μl Picrogreen mix was 
added. The plate was immediately read on a qPCR machine with detectors for SYBR 
and VIC. A linear regression was then performed using the control samples to 
determine the final concentrations for all test samples. With these concentrations, 
PCR products for each patient were pooled into one plate and samples were 
quantified using a 2100 Bioanalyser (Agilent) to check the range of PCR products 
and the absence of contamination.  
 
2.11.2.4 Library preparation: Final processing 
Next, a PCR was performed to add patient-specific tags to each product. 
Another clean up with beads (as above) was performed prior to a final quantification 
with a bioanalyser chip and a final pooling step of all samples. This pool was then 
run on the Illumina Miseq by UCL Genomics. 
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2.12 Miseq data analysis  
2.12.1 Data alignment 
Raw fast-q files were extracted from the Illumina sequencer. These were then 
processed from the command line using Perl scripts. Data was first mapped using 
Bismark Version 0.9.0 
(http://www.bioinformatics.babraham.ac.uk/projects/bismark/), which uses Bowtie2 
Version 2.2.2 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml) and a 
reference genome (hg19) to perform the alignments. The reference genome gets 
converted to a ‘bisulfite-converted’ genome so that the sequences reads can be 
aligned. ‘Methylation extractor’ was then run using Bismark which extracts a 
methylation call for every C analysed and generates a BedGraph file which is used 
for visualisation in Integrative Genomics Viewer (IGV; 
http://www.broadinstitute.org/igv/home). 
Finally, SAMTools (http://samtools.sourceforge.net/) was used to sort and index the 
Bam files so that regions of interest could be assessed in IGV (i.e. the number of C 
and T reads for every CpG of interest were quantified). 
 
2.12.2 Interpretation of reads 
For every CpG of interest, the number of reads that remained C (i.e. were 
originally methylated) and those that had been converted to T during bisulfite 
treatment (i.e. were originally not methylated) were quantified. The proportion of 
methylated reads was calculated as the number of ‘C’ reads divided by the total 
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number of reads for each CpG. This gave a value between 0 and 1 which was 
comparable to the methylation β-values derived from the 450k array which also used 
the same scale. 
Comparison between platforms involved generating a scatterplot with a linear line of 
best fit and then deriving the R
2
 value as a measure of correlation. 
 
2.12.3 Getting base-specific allele counts 
To generate allele counts for the entire sequence of a specific region (instead 
of selecting target CpGs), the ANGSD package 
(http://popgen.dk/wiki/index.php/ANGSD) was used. This package reads in bed files 
and exports a text file of the entire sequence and the number of reads that were A, C, 
G or T.  
 
2.13 Genome-wide hydroxymethylation quantification 
Quantification of hydroxymethylation (H-Me) was carried out using the 
Global DNA Hydroxymethylation ELISA Kit (Cell Biolabs, Inc, STA-381) 
following manufacturer’s instructions. Samples were initially incubated in the DNA 
High-Binding plate overnight at 4˚C to improve DNA binding. All samples were 
assayed in duplicate. 
Optical density (OD) at 450nm was recorded including 6 H-Me DNA standards 
which were used to determine a standard curve following manufacturer’s instructions 
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with formula y = 0.0186x – 0.0371 (R2 = 0.9351). From the standard curve, H-Me 
quantification was carried out on unknown samples using their OD reading at 
450nm. 
 
2.14 RNA-sequencing 
2.14.1 RNA extraction 
RNA was extracted from 12 samples (4 trios of NK, NR and WT) by cutting 
multiple 5μm sections of FFPE tissue and scraping the target region using a scalpel. 
Tissue was put into an Eppendorf then the RNeasy FFPE kit (Qiagen) was followed 
according to manufacturer’s instructions as follows.  
1ml xylene was added to the Eppendorf which was vortexed for 10 seconds before 
centrifugation for two minutes. The supernatant was then removed and 1ml 100% 
ethanol was added. The Eppendorf was then vortexed and centrifuged for two 
minutes. The supernatant was again removed before the eppendorfs were left to dry 
so that residual ethanol could evaporate. Next, 150μl buffer PKD was added and the 
samples were vortexed and centrifuged for 1 minute, then 10μl proteinase K was 
added and samples were mixed by pipetting up and down. Samples were then 
incubated for 15 minutes at 56ºC then at 80ºC for 15 minutes. Next, samples were 
incubated on ice for 3 minutes then centrifuged for 15 minutes at 13,500 rpm. The 
supernatant was transferred to a new tube leaving behind tissue debris and 16μl 
DNase Booster Buffer was added with 10μl DNase I stock solution. The tube was 
mixed by inverting and incubated at room temperature for 15 minutes. Next, 320μl 
Buffer RBC was added and the lysate was mixed thoroughly. Then 720μl 100% 
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ethanol was added which was mixed well and transferred (in two stages) to an 
RNAeasy MinElute spin column and centrifuged at 10,000 rpm for 15 seconds. The 
flow through was discarded and 500μl Buffer RPE was added and passed through by 
centrifugation at 10,000 rpm for 15 seconds. Next, the column was placed into a new 
collection tube and spun at full speed for 5 minutes with the lid open to fully dry the 
membrane. Finally, the columns were put into a clean 1.5ml Eppendorf and 17μl 
RNase-free water was added directly to the membrane to release the DNA. After 
centrifugation at full speed for 1 minute, the eluate containing the RNA was stored. 
 
2.14.2 RNA library preparation and analysis 
Library preparation, sequencing, alignment and analysis were performed by UCL 
Genomics. Library preparation for the 12 samples was performed using the TruSeq 
RNA access kit (Illumina) and run on the Illumina NextSeq 500. Reads were aligned 
using TopHat2 (Kim, Pertea et al. 2013) and counted using HTseq 
(https://pypi.python.org/pypi/HTSeq) in Python. Two samples were excluded from 
the analysis due to poor read coverage and aberrant clustering in unsupervised 
analysis. The Bioconductor package DESeq 
(http://bioconductor.org/packages/release/bioc/html/DESeq.html) was used in R to 
make group-wise comparisons between NK and NR, then NR and WT, run with 
default parameters. 
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Chapter 3: Genome-wide methylation analysis of normal 
kidney, nephrogenic rest and Wilms tumour 
3.1 Introduction 
To gain an overview of how DNA methylation differs between tissues, DNA 
methylation analysis was performed on normal kidney (NK), nephrogenic rest (NR) 
and Wilms tumour (WT). Chapter three describes how this data was obtained and the 
pre-processing and normalisation methods used that will be referred to again in later 
chapters. Unsupervised analysis of DNA methylation in these tissues was performed 
and will be discussed and finally, an analysis of the composition of the tissues 
included in this study was carried out to understand the importance of cell type 
composition contributing to overall methylation signal. 
 
3.2: Generation and quality control of methylation data 
In total, 120 samples (40 matched trios of normal kidney (NK), nephrogenic 
rest (NR) and Wilms tumour (WT)) were run on the Illumina 450k array, which 
interrogates ~480,000 CpG sites genome-wide at single base pair resolution. Clinical 
details of the patients included in this study can be found in Table 3.1. Although a 
large number of samples were originally included, several sampling problems, 
identified only after the arrays had been run, as well as samples failing the 450k 
quality checks resulted in a final dataset including 36 NK, 22 NR and 36 WT.  
109 
 
Quality control was carried out using R Bioconductor package Minfi with all 
algorithms run using standard parameters. Algorithms within this package take the 
raw data (.idat files that are output from the Illumina BeadScan software) and 
generate density plots and density bean plots so that the distribution of β-values 
between samples can be compared. By studying these plots, it was easy to identify 
samples with poor profiles that failed the array procedure (Figure 3.1). Overall, 5 
samples failed and were removed. 
After the arrays were run, the sections from which DNA was extracted were re-
analysed and, after discussion between three paediatric pathologists, it was decided 
that 13 NR samples were to be excluded from the study even though they had 
produced good quality, usable data. Reasons for exclusion were extremely stringent 
and included that the area removed was contaminated with either NK or WT or that 
the pathologists could not be certain, from such a small piece of tissue, that the 
section was definitely NR and not WT showing post-chemotherapy changes. On top 
of this, five samples were extracted from tissue showing vast chemotherapy induced 
changes or large areas of necrosis, and therefore were also removed from the study. 
Finally, after checking the centrally reviewed histopathology reports (reviewed by 
Professor Gordan Vujanic in Cardiff), it was found that one patient’s final review 
diagnosis was diffuse nephroblastomatosis that is morphologically very similar to 
WT but is a distinct entity; therefore this trio was also removed. A summary of the 
samples excluded from the study (of the 40 trios originally included) with the 
reasons for exclusion can be found in Table 3.2.  
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Patient 
number 
Sex 
Age at 
diagnosis 
Kidney 
Bilateral 
disease 
Nephrogenic 
rest type 
Overall tumour 
histology 
Tumour 
stage 
0 M unknown L Bilateral PLNR mixed 5 
119 F 39 R Bilateral PLNR stromal 2 
152 F 33 R Bilateral PLNR mixed 3 
209 U 58 U Unilateral PLNR mixed 2 
230 F 12 L Unilateral PLNR mixed 1 
250 M 10 R Unilateral PLNR mixed 1 
253 M 41 R Unilateral PLNR mixed 3 
257 M 21 U Unilateral PLNR regressive 4 
264 M 44 R Unilateral ILNR regressive 4 
266 M 10 L Bilateral ILNR mixed 1 
272 M 47 R Unilateral PLNR blastemal 3 
297 F 29 R Unilateral PLNR mixed 3 
314 M 10 L Unilateral PLNR epithelial 1 
323 F 11 L Unilateral PLNR epithelial 1 
324 M 10 R Unilateral PLNR nephroblastomatosis NA 
332 M 44 L Unilateral ILNR mixed 2 
335 F 71 R Unilateral PLNR regressive 3 
340 F 10 R Unilateral PLNR blastemal 2 
350 M 42 L Bilateral PLNR regressive 1 
350 M 42 R Bilateral PLNR anaplastic 1 
381 F 54 R Unilateral PLNR regressive 3 
403 F 23 R Unilateral PLNR mixed 1 
404 F 66 L Unilateral PLNR regressive 2 
407 F 38 L Unilateral PLNR regressive 3 
450 F 29 L Bilateral PLNR diffuse anaplasia 1 
460 F 16 R Bilateral ILNR epithelial 1 
464 M 62 R Unilateral PLNR mixed 1 
467 M 47 L Unilateral PLNR regressive 4 
480 M 20 L Unilateral ILNR stromal 1 
483 F 28 R Unilateral PLNR mixed 3 
517 F 21 R Bilateral ILNR stromal 2 
580 M 39 L Unilateral PLNR stromal 1 
593 M 49 R Unilateral PLNR necrotic 4 
609 F 42 L Bilateral PLNR regressive 3 
651 F 31 L Unilateral PLNR regressive 3 
693 F 12 R Bilateral ILNR stromal 3 
722 F 144 L Bilateral ILNR blastemal 3 
754 F 20 L Bilateral ILNR mixed 1 
754 F 20 R Bilateral ILNR regressive NA 
798 F 49 R Unilateral PLNR blastemal 2 
 
Table 3.1: Clinical and pathological information on the patients included in this study   
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Figure 3.1: 450k quality control: β-value density plots. Both images were plotted using 
Bioconductor package Minfi. (a) Density plots of 8 trios coloured by patient shows that two samples 
have an aberrant distribution with extreme peaks at ~β=0.5. These do not fit the usual bimodal 
distribution which shows peaks at around β=0.1 and β=0.9. (b) Density bean plots show the same data 
in a different view allowing the exact samples that failed to be identified. In this case, 517RK (brown) 
and 340RT (blue) show abnormal density profiles and were excluded from further analysis.  
a 
 
 
 
 
 
 
 
b 
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Patient ID and 
side of tumour 
NK NR WT 
  0L  
 
 
 
Matched trio 
119R  Bad NR  
 
Matched pair 
152R  
 
 
 
Good sample 
209R  Fail Fail 
 
Not included 
230L  
 
 
  250R  Bad NR  
  253R  Bad NR  
  257U  Bad NR  
  264R  Bad NR  
  266L  Bad NR  
  272R    
  297R    
  314L    
  323R  Bad NR  
  324R NB NB NB 
  332L  Bad NR  
  335R  
 
 
  340R  Fail Fail 
  350L    
  350R    
  381R  Bad NR  
  403R    
  404L Bad section  Bad section 
  407L 
 
Bad NR  
  450L Bad section Bad section  
  460R    
  464R    
  467L    
  480L  Bad NR  
  483R  Bad NR  
  517R Fail   
  580L    
  593R  Bad section  
  609L    
  651L    
  693R    
  722L  Bad NR  
  754L    
  754R    
  798R    
  Total number of 
usable samples 
36 22 36 
  
      Fail Failed 450k array QC 
  Bad NR Nephrogenic rest considered not "true" after second analysis 
NB Nephroblastomatosis with no evidence of Wilms tumour 
Bad section Chemotherapy induced change or necrosis  
    
Patient number (sample ID) followed by L=left and R=right indicating the origin of the 
nephrectomy specimen, U=unknown 
Table 3.2: Description of the cohort of samples run on the 450k array 
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3.3 Initial data pre-processing and normalisation 
To begin with, raw data for the 36 NK, 22 NR and 36 WT were loaded into R 
using the Bioconductor package ChAMP (Morris, Butcher et al. 2013) and with the 
same package, probes that showed poor detection (with detection p-value >0.01) in 
any sample were removed. Next, data was normalised using Bioconductor 
wateRmelon algorithm Dasen (Pidsley, CC et al. 2013), which corrected for the two 
probe types included on the 450k array. For comparative analysis of methylation 
values, as non-matched samples were included, the dataset was stringently curated to 
remove “confounding” CpGs that have a SNP either at the target C or G (according 
to the database of SNPs v131; http://www.ncbi.nlm.nih.gov/projects/SNP/), those 
that are located on the sex chromosomes and those that bind repetitive regions or to 
more than one loci, as defined by in silico analyses (Price, Cotton et al. 2013), 
which, for this dataset, left β-values (ranging from 0=unmethylated to 1=methylated) 
for 327,628 CpGs and 94 samples. 
 
3.4 Validation of the 450K platform 
To validate the methylation levels derived from the 450k array platform, as 
the starting material was FFPE and therefore very degraded, bisulfite sequencing was 
performed. A total of five regions covering 18 CpGs were selected (Table 3.3; 
columns 1-4), chosen to cover a wide range of 450k β-values ranging from 0.05 to 
0.94 including intermediate methylation levels. DNA from four trios (12 samples) 
was bisulfite-converted and sequenced using the Illumina MiSeq. Raw fast-q files 
were aligned using custom Perl scripts and visualised using Integrative Genomics 
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Viewer (https://www.broadinstitute.org/igv/home). A text file giving the number of 
C and T reads for every loci was also generated for easy comparison. 
The number of sequencing reads per bisulfite-converted PCR ranged from 9 to 
57,335 (average = 13,649, median = 5,615), showing that the sequencing worked 
well. To enable comparison between 450k β-values and the sequencing data, the 
number of reads with a “C” residue at the target CpG site was calculated then this 
value was divided by the total number of reads for that CpG. As bisulfite treatment 
converts any unmethylated CpG residues to TpGs, the proportion of CpGs directly 
related to the level of methylation of a given site. For example if 2,000 reads were 
generated in total, and 40 were C while 1,960 were T, the level of methylation 
corresponds to 40/2,000 = 0.02. This put the sequencing data on the same scale as 
the 450k β-value which is measured from 0 to 1, as a sample with 2,000/2,000 C 
reads generated a methylation score of 1. Table 3.3 shows the difference in 
respective β-value for each sample at each site. After studying the number of reads 
per sample in more detail, along with the corresponding Δβ between platforms, the 
data was filtered to remove sites with <100 reads. After this, the β-values generated 
by each platform correlated well (R = 0.8365; Figure 3.2) with a median difference 
in β-value of 0.09, (min = 0.0001, max = 0.70) and the 450k methylation data was 
therefore considered reliable and analysed further. 
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Figure 3.2: validation of array β-values by bisulfite sequencing. The β-values discerned by the 
450k array (x-axis) compared to level of methylation detected using bisulfite-sequencing (y-axis) 
show good correlation (Pearson correlation coefficient = 0.8365).  
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3.5 Unsupervised analysis of methylation data 
Next, the 94 normalised samples were subjected to a variation filter in R, using 
Bioconductor package genefilter 
(http://www.bioconductor.org/packages/release/bioc/html/genefilter.html), which 
pulls out a defined number of CpGs (f) that show the most variability across 
samples. Arbitrarily, f=3,277 was set to capture the 1% most variable CpGs across 
the dataset and multidimensional scaling (MDS: Figure 3.3) and unsupervised 
hierarchical clustering using heatmap.3 (http://www.inside-
r.org/packages/cran/GMD/docs/heatmap.3; Figure 3.4) were performed to assess the 
relationship between samples. 
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Figure 3.3: Multidimensional scaling of the top 1% most variable positions across the full 
dataset. Multidimensional scaling of the top 1% most variable positions in normal kidney (NK; 
green), nephrogenic rest (NR; red) and Wilms tumour (WT; blue) 
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Figure 3.4: Hierarchical clustering of the top 1% most variable positions across the full dataset. 
Unsupervised consensus clustering and heatmap of the top 1% most variable positions across the full 
dataset (36 NK, 22 NR and 36 WT) as determined based on interquartile range where blue = low 
levels of methylation and red = high levels of methylation. Three clusters were formed which 
predominantly separated tissue types.  
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MDS generally separated samples into distinct groups although a wider distribution 
of samples was seen in both NR and WT groups in comparison to NK. This may be 
associated in an increase in epigenetic plasticity seen in samples as they progress 
towards malignancy or may be due to the increase in cell types seen which adds 
variability.  
Hierarchical clustering revealed clear separation of samples into tissue-related 
groups, confirming the significant association between tissue type and methylation. 
Of the two clusters formed, cluster 1 included 26 WTs and 1 NR. The original 
section from which this NR tissue was taken is no longer available, however was 
previously confirmed by three pathologists as being composed of definite NR tissue.  
The second cluster separated all normal kidneys into one cluster with 4 NRs and 2 
WTs, then the remaining 16 NRs and WTs into another. One NR clustered very 
closely with NKs (0LR). The FFPE section from this case was re-analysed to 
confirm the presence of NR (Figure 3.5A). Although each sample contained 
differing proportions of cell types (an issue that will be addressed later), this 
preliminary evidence suggests that these three tissue types – NK, NR; the benign 
proliferating tissue and WT; the fully malignant tissue – have distinct patterns of 
DNA methylation.  
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Figure 3.5: Review of nephrogenic rest FFPE sections. Two NR samples are shown to X10 
magnification: (a) The NR that clustered with normal kidney and (b) a NR with similar composition 
that clustered with the other NRs. Both images show regions of stroma (S) and immature epithelial 
structures (E) without the presence of blastema. There is no contaminating NK present in (a), 
indicating that the epigenome, not cellular composition, is responsible for aberrant clustering. 
 
3.6 Unsupervised analysis of 20 matched trios and embryonic kidney 
shows that EK is most similar to NK 
After demonstrating that DNA methylation can distinguish tissue types, the 
20 matched trios were separated to perform comparative analyses. As embryonic  
a 
b 
S 
E 
S 
E 
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kidney (EK) is the predicted cell-of-origin of both NR and WT, and both show 
morphological features that closely resemble EK, DNA methylation data from four 
embryonic kidney (EK) samples were included (samples were extracted and run by a 
colleague who supplied the raw .idat files).  
Each time the number of samples changes, a new pre-processing step must be 
performed as the number of probes that fail the detection p-value is dependent on the 
samples present. Furthermore, normalisation had to be repeated to include the EK 
samples. The same procedure as above was used: data was imported using ChAMP 
then normalised using Dasen, which uses a between-array normalisation based on the 
control probe intensities on the array. This is necessary to prevent confounding 
artefacts as the EKs were run in a separate batch. After pre-processing, normalisation 
and removal of “confounding” CpGs, a data matrix of 330,731 CpGs was obtained 
for 64 samples. MDS (Figure 3.6) and hierarchical clustering (Figure 3.7) were 
performed with f=3,307. 
MDS again separated samples into tissue-related groups and, of interest, clustered 
EK samples together far away from NK, EK and WT. Several WT and NR samples 
seemed to tend towards the EK samples in terms of separation along the Y-axis 
indicating that some samples showed features more similar to EK than others.  
Hierarchical clustering separated samples into two predominant clusters (Figure 3.7). 
Cluster 1 was WT-predominant (14 WTs and 1 NR), cluster 2a contained 
predominantly “healthy” tissues (4 EK, 20 NK and 3 NR) and cluster 2b the majority 
of the NRs (16 NRs and 6 WT).  
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These unsupervised analyses show that EK is more similar to NK than to either NR 
or WT and that the majority of NRs are more similar to NK than WT. It was of 
interest that EK and WT did not cluster together, which may be due to the lower 
levels of blastemal elements in EK, or that WT is epigenetically not very similar to 
EK. Furthermore, one has to remember that these are just the most variable CpGs 
and not representative of genome-wide similarities or differences. This clustering 
also showed samples that seemed to be outliers, including 3 NRs in the NK cluster 
and 1 NR in the WT cluster. Re-analysis of FFPE sections showed no remarkable 
features with all 4 of these NRs containing 12-60% stroma and the rest epithelia with 
no blastema or chemotherapy induced changes present. It can be hypothesised that 
the 3 NRs that cluster with NK show more differentiated epithelia, not visible by 
histopathological review, but present epigenetically. Likewise, the NR that clustered 
with the WTs may show neoplastic features not visible by histopathologial review, 
but present in the epigenome. 
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Figure 3.6: Multidimensional scaling of the top 1% most variable CpGs between trios of NK, 
NR, WT (n=20) and EK (n=4). Multidimensional scaling of the top 1% most variable positions in 
embryonic kidney (EK; pink), normal kidney (NK; green), nephrogenic rest (NR; red) and Wilms 
tumour (WT; blue). It can be predicted that the component separating samples on the X-axis is 
tumourigenicity as normal samples are on the left (NK and EK), then the cancer precursor lesions are 
in the centre with WT samples on the far right. Alternatively, the component separating samples on 
the Y-axis may be blastema, as both NK and NR lack blastema while WTs and EK do have blastema 
cells.  
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Figure 3.7: Hierarchical clustering of the top 1% most variable CpGs across trios of NK, NR, 
WT (n=20) and EK (n=4). Unsupervised consensus clustering of the top 1% most variable positions 
across the full dataset as determined based on interquartile range. Three clusters were formed which 
predominantly separated tissue types. Each sample is labelled by the cluster they fell into (cluster 1; 
grey, cluster 2a; cyan, cluster 2b; purple), by the patient from which the tissue originated (there are 20 
matched trios), and by the histology (EK; pink, NK; green, NR; red and WT; blue). Samples are not 
clustered by patient but by histology as cluster 1 is WT-predominant, 2a is NK and EK-predominant 
and 2b is NR-predominant. 
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3.7 Analysis of tissue composition 
Although clear separation of tissues was seen by unsupervised analysis of 
DNA methylation, when performing comparative methylation analysis, it is 
important to consider that the composition of the tissue will contribute to the overall 
methylation signal. Each cell type has a cell-type specific methylation pattern, which 
regulates the expression of cell-specific genes. The overall methylation signal 
obtained will consist of the cell-specific methylation signatures in the relative 
proportions of the cells present. In terms of WT, the methylation signal, although 
generated from mixed cell proportions, is a biomarker for the tissue, which is 
inherently heterogeneous. 
To understand the contribution that the mixed cell types may have on methylation in 
this dataset, each microdissected section for the 20 matched trios was analysed to 
identify the proportion of stroma, epithelia and blastema cells present (Figure 3.8). 
Although not included in the figure, NK sections, which are far more homogenous, 
were also studied and contained roughly 5% stroma and 95% epithelia in every case. 
This analysis showed that very few NR samples had regions of blastema (6/20) 
whereas many more WTs did (11/20). WTs also tended to show more necrosis and 
chemotherapy-induced changes. The fact that WTs have more blastema may 
confound between-tissue analyses as CpGs associated with blastema cells will 
contribute to the overall methylation signal in many more WT samples than NR 
samples. Furthermore, as NKs have no blastema, analyses comparing to this tissue 
will also be confounded by blastema-specific CpG methylation. The same 
confounding would be seen by comparing samples with high levels of epithelia (for 
example) against samples with low levels, such as NK comparison to WT.  
127 
 
Consequently, comparative analyses between tissues will identify true biomarkers of 
tissue composition, which will be described in chapter 4, but analysis with correction 
for cell type composition will allow identification of underlying changes in 
methylation associated with progression towards malignancy instead of cell type. 
These will be identified and discussed in chapter 5.  
 
 
Figure 3.8: Cellular composition of each microdissected tissue section. Each of the 20 NRs (left) 
and WTs (right) were analysed for the proportions of each cell type within the section that was 
microdissected. Here, blastema is shown in navy, stroma in green, epithelia in pink and necrotic or 
chemotherapy-induced changes in yellow. 
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3.8 Summary and conclusions 
To summarise, this chapter has described the generation of methylation β-
values, the quality control, pre-processing and normalisation steps required prior to 
data analysis as well as unsupervised analysis of NK, NR, WT and EK samples. The 
stringency of sample selection was discussed which is essential for biological 
interpretation of methylation data. 
These preliminary analyses showed that DNA methylation can distinguish between 
NK, EK, NR and WT tissues. The β-values derived by the 450k platform were 
validated by bisulfite sequencing showing good concordance. MDS of the 1% most 
variable CpGs in the dataset showed an increase in methylation variability between 
NR and WT samples compared to NK samples and hierarchical clustering showed 
that EKs were more similar to NK than to NR or WT.  This was surprising but may 
be explained by the origin of the tissue. The EKs included in this analysis were 
derived from aborted specimens of whole kidney which, although they contain 
embryonic blastema and immature epitheial structures, also contain differentiated 
tubules, nephrons and glomeruli. Therefore, the methylation profile derived from the 
whole sample may be more similar to NK due to the signal from the mature kidney 
elements over the immature.  
Finally, analysis of sample-specific cell type compositions showed that NRs and 
WTs varied greatly between samples. This cell type composition heterogeneity will 
be a recurring theme throughout this thesis, particularly addressed in chapter 5.  
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Chapter 4: Comparative analysis of DNA methylation in 
Wilms tumours, nephrogenic rest and normal kidney  
4.1 Introduction 
As shown in chapter three, DNA methylation status clearly distinguished 
between tissue types (NK, NR and WT). To understand the biological significance of 
between-tissue differences in DNA methylation, the 20 matched trios were subjected 
to several supervised analyses to identify CpGs that differ in methylation between 
WT and NR (transformation-associated) and between NR and NK (developmental 
arrest-associated). The biological significance of these changes was interpreted using 
bioinformatics pathway analysis tools and validated using RNA-sequencing. 
 
4.2 Sample variability 
To begin with, pre-processing and normalisation steps were carried out as 
described in chapter 3.2 using SWAN normalisation instead of Dasen, for the 20 
matched trios. This dataset encompassed 453,385 CpGs and 60 samples. As 
observed in chapter 3, and within this dataset of only 20 trios, multidimensional 
scaling of the top 1% most variable data points (of a dataset with the SNPs and sex 
chromosomes removed to avoid confounding) showed wide dispersion of NR and 
WT samples in comparison to NK (Figure 4.1). To quantify this degree of 
variability, a Bartlett test was performed in R which quantified probe-specific 
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variances between NK and NR and then NK and WT. In each comparison, those 
probes that showed significant non-equal variance (N; p<0.01) were predominantly 
due to increased variance in the NR and WT groups compared to NK (NNK>NR 
=9,334; NNR>NK =94,546 and NNK>WT =14,933; NWT>NK =158,189; see Figure 4.2).  
An increase in methylation variability as normal tissues progress towards cancer 
from a premalignant stage has been previously observed in adult colon 
adenocarcinoma (Timp and Feinberg 2013). The study associated gain of 
methylation variability with cancer cell heterogeneity however in adenocarcinoma, 
the cell-of-origin to cancer progression via the pre-malignant precursor stage is 
linear whereas in WTs, NK does not represent the cell-of-origin and a much wider 
variety of cell types are seen at both the precursor and tumour stages. This large 
difference in the histological composition between NRs and WTs compared to NK 
which is generally very uniform with ~5% stroma and ~95% epithelia results in 
major cell type composition effects that will largely affect the overall level of 
variability. Therefore, although this increase observed is likely true and associated 
with a more hypervariable epigenome in the NR and WT, the extreme increase in 
methylation variability is also contributed to by tissue composition effects. This 
large confounding factor will be addressed in chapter 5 which described analyses 
performed with correction for cell mixture effects. 
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Figure 4.1: Nephrogenic rest and Wilms tumour groups show greater between-sample 
variability than normal kidney. Multidimensional scaling of the top 1% most variable positions 
(selected using a variance filter based on interquartile range) showed greater dispersion of points 
within both the NR and WT datasets compared to NK suggesting a greater degree of between-sample 
variability. 
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Figure 4.2: Probe-wise variance between groups shows NR and WT are much more variable 
than NK. The x-axis shows the log2 ratio of variance which is a measure of the probe-specific 
difference in variance between NK and either (a) NR or (b) WT. The density of probes with each 
level of variance is shown by the blue bars. If both sets of probes showed equal variance, the null 
distribution would be observed (shown in red), however in both figures, a shift of the observed data 
(blue bars) is seen indicating that the probe-specific level of variance is not equal for both the NR and 
WT groups in comparison to NK. In both cases, the NK group was substantially skewed toward 
decreased variability (a shift to negative x-axis values) compared with NR groups (skew = -87.89, p < 
a 
 
 
 
 
 
 
 
 
 
b 
WT vs NK 
NR vs NK 
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2.2x10
-16
, D'Agostino skewness test) and WT groups (skew = -160.10, p < 2.2x10
-16
, D'Agostino 
skewness test). 
 
4.3 Supervised analysis identifies two Wilms tumour groups 
To identify those CpGs that most significantly distinguish each tissue type, 
the full data matrix of 453,385 CpGs and 60 samples was subjected to ANOVA 
using the Bioconductor package Limma (Smyth 2005). In total, 7,921 CpGs with 
genome-wide significance (P<5x10
-8
) were identified and were clustered using 
heatmap.3 (Figure 4.3) which revealed two predominant clusters: cluster 1 (13 WT, 
1 NR) and cluster 2 which further separated into cluster 2a (20 NK, 1 NR) and 
cluster 2b (7 WT, 18 NR). These results were similar to the results of unsupervised 
clustering seen in chapter 3 indicating the strong association DNA methylation has 
with tissue identity.  
All NK samples clustered into the same group (cluster 2a) however, the WT samples 
fell into two distinct groups. WTs in cluster 1 were distinctly separated from their 
NRs whereas WTs in cluster 2b were clustered with their respective NR. Due to this 
difference, the WTs were termed group-1 and group-2 WTs respectively. To 
understand the reason behind why these WTs may be behaving in this way, 
biological and clinical information was studied in more detail. There seemed to be no 
association between the separation of WTs and proportions of any cell type, sex, 
tumour stage, overall histology or course of pre-operative chemotherapy (data not 
shown). However, all patients with bilateral disease were found in group-1. By 
performing a chi-square test, the relationship between grouping and bilateral disease 
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was found to be significant (p=0.032). As a consequence of this finding, the MDS 
plot was re-evaluated and clearly showed that group-2 WTs appear closer to the NR 
samples than group-1 WTs (Figure 4.4). As this MDS plot showed a wider 
dispersion of group-1 WTs, a Bartlett test was performed to compare levels of probe-
specific variance between group-1 and group-2 WTs. This test showed that group-1 
WTs had 2.4 times as many probes with a significance increase in variance 
compared to group-2 WTs (31,638 compared to 13,124; p<0.01) suggesting that 
group-1 WTs have a more hyper-variable epigenome. 
To validate the finding that group-2 tumours appear epigenetically similar to their 
associated NR while group-1 WTs appear distinct, groups 1 (n=13) and 2 (n=7) were 
separated and linear modelling was performed within each group to compare 
matched NR-WT pairs. This analysis was carried out using Bioconductor package 
Limma and identified 22,344 significant CpGs that were differentially methylated 
between group-1 WT and NR pairs (FDR<0.01). Strikingly, no significant sites of 
differential methylation were identified in the comparison of group-2 WT and NR 
pairs. This evidence confirmed that group-1 WTs were epigenetically distinct from 
their NR, whereas group-2 WTs were not. 
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Figure 4.3: ANOVA analysis identifies two Wilms tumour groups. Consensus clustering of the 
significant CpGs (n=7,921; P<5x10
-8
) from ANOVA analysis of 20 trios of normal kidney (green), 
nephrogenic rest (blue) and Wilms tumour (pink). Here, three clusters can be seen which show the 
presence of two distinct WT groups. Cluster 1 (grey) comprises group-1 WT (n=13) which includes 
all bilateral WT (dark pink) and 4 unilateral cases (light pink). Group-1 WT cluster separately from 
their associated NR. The second cluster further separates into two, with cluster 2a (purple) containing 
all NK samples and cluster 2b containing group-2 WT (n=7) which are all unilateral and cluster 
together with their associated NR. 
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Figure 4.4: Unsupervised analysis shows two Wilms tumour groups. Re-evaluation of tumour 
separation by multidimensional scaling of the top 1% most variable positions showed separation of 
the two Wilms tumour groups 1 (orange) and 2 (red). Group-2 are more intermixed with the NR 
samples whereas group-1 are located further away and wide dispersion of samples is seen. 
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4.4 WTs silence genes involved in cell adhesion and regulation or 
transcription 
As group-1 WTs appeared to show changes in methylation that render them 
distinct from their NRs, these significant CpGs were focussed on in more detail. To 
begin with, a novel algorithm was applied that groups significant CpGs into discrete 
clusters depending on the local CpG enrichment. The algorithm, champ.lasso, 
implemented through the Bioconductor ChAMP package (Morris, Butcher et al. 
2013), identified 625 differentially methylated regions (DMRs) in total. The 
parameters used for DMR definition in this algorithm can be found in chapter 2.8.6, 
but briefly; a DMR consisted of at least three significant CpGs (FDR<0.01) in close 
proximity (which is assessed by CpG location as some are closely packed while 
others are widely separated). 
Of these DMRs, 460 (73.6%) were hypomethylated and 165 (26.4%) were 
hypermethylated in WT with respect to NR, termed hypo- or hyper-WT-DMRs. As 
previously mentioned, global hypomethylation is a common feature of cancer 
suggesting that during the transformation step from NR to WT, the WTs acquire 
general cancer properties as evidenced by the higher proportion of hypo-WT-DMRs 
over hyper. The hypo-WT-DMRs were enriched in gene bodies and not associated 
with CpG islands, shores or shelves (summary in Table 4.1), suggesting a positive 
correlation between methylation and gene expression for these DMRs (Jones 2012). 
In comparison, the hyper-WT-DMRs were much smaller and were often located at 
gene transcription start sites or within CpG island shores which indicates an inverse 
relationship with regulation of gene expression (Doi, Park et al. 2009; Irizarry, Ladd-
Acosta et al. 2009) (Table 4.1).  
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To infer biological significance from these DMRs, the location of the DMR CpGs 
were entered in bed format into Genomic Regions Enrichment of Annotations Tool 
(GREAT) version 2.0.2 (http://bejerano.stanford.edu/great/public/html/) which 
associates genomic positions with gene regulatory domains. The significant (p<0.01) 
gene ontology biological processes were studied to identify common processes with 
more than 2-fold enrichment. This analysis showed that hypo-WT-DMRs fell into 
regulatory regions affecting genes involved in developmental processes including 
metanephric nephron development and nephron development involving genes such 
as GDNF, IRX2, PDGFB, POU3F3 and SOX8 and in processes involved in stem cell 
maintenance, development and differentiation (Table 4.2). The same analysis for 
hyper-WT-DMRs found enrichment for genes involved in cell adhesion and 
regulation of transcription (Table 4.3). 
These data suggests that genes involved in renal development and stem cell 
maintenance are repressed in group-1 WTs compared to NRs, suggesting that NRs 
are in a more primitive state than WTs. Hypermethylation (and reciprocal silencing) 
of genes involved in cell adhesion would allow cells to overcome the local 
microenrironment and proliferate as a tumour. 
As a proof of concept that RNA extracted from these FFPE samples could give 
quality interpretable sequencing data, RNA sequencing was performed on four trios. 
Although a much larger study is required to rigorously test differential expression 
between tissue types, promising results was seen. After alignment and unsupervised 
analysis, one pair of matched NR and WT samples failed the QC and was excluded. 
The remaining NK was included in group-wise comparisons, which were performed 
using the Bioconductor DESeq package in R 
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(http://bioconductor.org/packages/release/bioc/html/DESeq.html). The RNA 
sequencing data showed 75 genes with significant differential expression between 
NR and WT (FDR<0.05) which were analysed with Panther 
(http://www.pantherdb.org/) to identify common pathways. Even within this small 
list of genes, the over-enriched gene sets identified through interrogation of hyper-
WT-DMRs were validated nicely as six genes involved in cell adhesion or cell 
signalling (CD200, GPR108, TSPAN2 and ADAMTS8 decreased in expression while 
MDK and NCAM1 increased in WT compared to NR) and three genes involved in 
regulation of transcription (NFKB1, MYSM1, PREPL decreased in expression) were 
found to be significantly differentially expressed validating the relationship between 
differential DNA methylation and gene expression. One of these genes, NCAM1 has 
previously been associated with being a marker for cancer-propagating WT cells, 
supporting the association with the transformation step between NR and WT tissues 
(Pode-Shakked, Shukrun et al. 2013).  
Regarding the hypo-WT-DMRs, where enrichment for stem cell processes was 
observed, the genes differentially methylated in particular, GDNF, IRX2, PDGFB, 
POU3F3 and SOX8 showed no significant difference in expression across samples. 
Reasons for non-concordance could be due to the very small number of samples 
included in the validation set. Likewise, no genes involved in renal development 
were found to be significantly differentially expressed. In this small sample set, the 
relationship between DNA hypomethylation and gene expression still requires 
further validation. 
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Hyper-methylated 
DMRs 
Hypo-methylated 
DMRs 
Median size (bp) 527 1555.5 
Mean size (bp) 1130.4 1749.8 
Range (bp) 108-5,118 110-6,780 
Total (bp) 186,507 804,907 
   % enrichment: CpG island 0.8 -22.3 
% enrichment: CpG shore 5.5 -0.5 
% enrichment: CpG shelf -2.7 2.2 
% enrichment: 'other' -3.6 20.6 
   % enrichment: gene body -3.5 14.6 
% enrichment: TSS200 1.6 -5.6 
% enrichment: TSS1500 -3.5 -10.4 
% enrichment: 3’ UTR -2.7 -1.3 
% enrichment: 5’ UTR -1.6 -1.6 
% enrichment: 1
st
 exon -1.7 -3.0 
% enrichment: intergenic region 11.5 7.2 
 
Table 4.1: Description of hypermethylated and hypomethylated differentially methylated 
regions (DMRs) in group-1 Wilms tumour compared to matched nephrogenic rests. Genetic 
features and those relating to CpG islands, shores (within 2kb of islands) and shelves (2-4kb from 
CpG islands) are extracted from the Illumina 450k annotation.  
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Enriched Term in GO biological processes 
Hypergeometric 
fold enrichment 
Raw p-
value 
Axon ensheathment 2.5 1.87E-07 
Body morphogenesis 3.04 1.56E-08 
Cell chemotaxis 3.27 6.35E-13 
Embryonic placenta development 2.74 6.61E-10 
Fat cell differentiation 3.16 4.42E-14 
Head development 2.77 1.44E-07 
Head morphogenesis 3.54 3.44E-10 
Intermediate filament-based process 5.44 4.39E-22 
Labyrinthine layer development 4.07 9.57E-15 
Metanephric nephron development 3.83 2.35E-11 
Myelination 2.57 9.16E-08 
Myelination in peripheral nervous system 4.65 1.18E-09 
Negative regulation of myeloid leukocyte differentiation 6.43 1.48E-22 
Nephron development 2.61 1.28E-07 
Organ regeneration 3.86 1.14E-13 
Palate development 2.8 2.45E-12 
Peripheral nervous system development 2.05 6.43E-05 
Placenta development 2.42 2.43E-09 
Regeneration 2.39 2.63E-08 
Regulation of action potential in neuron 2.19 4.73E-06 
Regulation of GTP catabolic process 2 5.30E-14 
Regulation of myeloid cell differentiation 2.69 3.62E-12 
Regulation of myeloid leukocyte differentiation 3.64 2.07E-14 
Regulation of purine nucleotide catabolic process 2.07 1.01E-16 
Regulation of Ras GTPase activity 2.14 1.27E-10 
Regulation of Ras protein signal transduction 2.02 7.60E-14 
Schwann cell development 4.42 3.10E-09 
Schwann cell differentiation 3.91 3.11E-08 
Stem cell development 2.52 2.46E-09 
Stem cell differentiation 2.03 2.01E-06 
Stem cell maintenance 2.78 8.61E-11 
 
Table 4.2: Significantly overrepresented biological processes identified by hypomethylated WT-
DMRs 
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Enriched Term in GO biological processes 
Hypergeometric 
fold enrichment 
Raw p-
value 
Cell adhesion 2.17 3.45E-16 
Cell-cell adhesion 4.83 3.00E-44 
Homophilic cell adhesion 12.97 5.85E-81 
Intracellular receptor mediated signalling pathway 8.07 2.23E-61 
Negative regulation of biosyntheic process 2.35 5.46E-30 
Negative regulation of cellular biosynthetic process 2.37 1.50E-30 
Negative regulation of cellular macromolecule biosynthetic 
process 2.51 1.22E-33 
Negative regulation of cellular metabolic process 2.13 3.76E-26 
Negative regulation of gene expression  2.58 1.79E-36 
Negative regulation of macromolecule biosynthetic process 2.44 3.08E-32 
Negative regulation of macromolecule metabolic process 2.1 2.59E-25 
Negative regulation of metabolic process 2.03 6.12E-24 
Negative regulation of nitrogen compound metabolic process 2.5 1.70E-33 
Negative regulation of nucleobase-containing compound 
metabolic process 2.51 1.04E-33 
Negative regulation of protein metabolic process 4.19 1.92E-31 
Negative regulation of RNA metabolic process 2.61 5.53E-36 
Negative regulation of transcription from RNA polymerase II 
promoter 3.79 8.10E-54 
Negative regulation of transcription, DNA-dependent 2.67 2.24E-37 
Positive regulation of gene expression 2.06 4.97E-22 
Positive regulation of RNA metabolic process 2.06 1.76E-21 
Positive regulation of transcription from RNA polymerase II 
promoter 2.87 4.43E-35 
Positive regulation of transcription, DNA-dependent 2.13 4.89E-23 
Regulation of gene expression, epigenetic 5.98 2.39E-30 
Regulation of organelle organisation 3.57 3.43E-34 
Regulation of transcription from RNA polymerase II promoter 2.41 9.04E-40 
Transcription from RNA polymerase II promoter 4.87 5.31E-49 
 
Table 4.3: Significantly overrepresented biological processes identified by hypermethylated 
WT-DMRs  
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4.5 Assessing the pluripotency of WTs  
As the methylation data strongly suggested that WTs have stem cell-like 
epigenomes but the RNA sequencing did not validate this, the potency of WTs was 
studied in comparison to NRs and NKs. Embryonic stem cells are pluripotent; they 
have the potential to differentiate into any of the three germ cell layers, endoderm, 
mesoderm or ectoderm and form teratomas when injected into mice. In WT, a mixed 
histology is frequently observed with occasional differentiation into skeletal, fat or 
bone tissue. These observations imply a cell of origin with multipotency and 
potentially pluripotency. Fully pluripotent cells express transcription factors OCT4, 
NANOG, SOX2 and KLF4 and can also be identified by the increase in methylation 
of non-CpG residues (CpA and CpT) (Ramsahoye, Biniszkiewicz et al. 2000) and 
increase in genome-wide hydroxymethylation (H-me). To assess the level of 
pluripotency in WT trios, comparison to publically available data, quantification of 
H-me and analysis of non-CpG methylation was carried out. 
Publically available 450k methylation data were obtained online for embryonic 
kidney (EK; n = 4), induced pluripotent cell lines (IPS; n = 6) and embryonic stem 
cell lines (ESC; n = 6). These were put with the methylation data from the 20 
matched trios with SNPs and sex chromosomes removed (total CpGs = 427,092) to 
compare differences in genome wide methylation. MDS (Figure 4.5) showed a 
progressive relationship between EK, NK, NR and WT but IPS and ESCs clustered 
far away from this trend. Unsupervised clustering analysis with the top 1% most 
variable probes also separated IPS and ESC tissues from EK, NK, NR and WT (data 
not shown) therefore WTs do not show global methylation profiles resembling 
pluripotent cells. 
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Although global methylation profiles did not show any association between WT and 
pluripotent tissues, the sites of methylation associated with pluripotency may have 
been masked by more variable global changes. Embryonic stem cells have 
significant cytosine methylation at CpA and some CpT sites (Ramsahoye, 
Biniszkiewicz et al. 2000) and an increase in methylation at these sites in WT similar 
to EK would imply stem cell likeness. The 450k array platform is designed to 
interrogate 3,091 non-CpG sites within the genome, however after pre-processing 
and normalisation, only 1,845 remained. Therefore, these probes were separated and 
MDS and hierarchical clustering was performed to assess the relationship between 
the trios, embryonic and pluripotent tissue. MDS clustered EK with WT (Figure 4.6), 
which had not occurred previously upon unsupervised clustering of the most variable 
CpGs globally (chapter 3.5). Hierarchical clustering formed two groups, one 
containing the pluripotent samples (ESC and IPS) and one containing all other 
samples (data not shown). Overall, average β-values for each tissue for all non-CpG 
probes were EK=0.07, ESC=0.42, IPS=0.46, NK=0.14, NR=0.14 and WT=0.13 
showing that pluripotent tissue had higher levels of non-CpG methylation as 
expected. NK, NR and WT showed similar levels while EK showed lower levels. 
This data indicates that although WT and EK are more similar in terms of non-CpG 
methylation, these tissues are very distinct from pluripotent samples and do not show 
significant non-CpG methylation. 
Next, genome-wide hydroxymethylation (H-me) was quantified in 6 trios using the 
Global DNA Hydroxymethylation ELISA Kit (Cell Biolabs). The levels of H-me did 
not correlate with histology and were not increased in WT compared to NK or NR 
(Figure 4.7; p=0.68 and p=0.47 for WT compared to NR and NK respectively, 2-
tailed T-test). Unfortunately, as no ES or FK tissue was available for this analysis, 
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comparative levels of H-me methylation in these tissues could not be obtained. 
Therefore, it can only be concluded that levels of hydroxymethylation in WT are not 
significantly higher than in NK or NR. 
 
 
Figure 4.5: Multidimensional scaling to assess potency associated phenotypes. Multidimensional 
scaling of publically available datasets of embryonic kidney (EK; pink), induced pluripotent stem 
cells (IPS; orange), embryonic stem cells (ESC; cyan) with generated datasets of normal kidney (NK; 
green), nephrogenic rest (NR; red) and Wilms tumour (WT; blue). There seems to be a directional 
association between EK, NK, NR and WT, shown by the red arrow. Conversely, IPS and ESC 
samples cluster far away from these samples suggesting they are very different to the kidney 
associated populations. 
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Figure 4.6: MDS of all non-CpG probes on the 450k retained after pre-processing (n=1,845). 
While embryonic stem cells (ESC; cyan) and induced pluripotent stem cells (IPS; orange) cluster far 
away from the more differentiated tissues, several Wilms tumours (WT; blue) cluster closely with 
embryonic kidney (EK; pink) while the majority of samples, including normal kidney (NK; green) 
and nephrogenic rests (NR; red), cluster close by. 
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Figure 4.7: Quantification of hydroxymethylation in normal kidney, nephrogenic rest and 
Wilms tumours. The total nanograms (ng) of hydroxymethylated DNA was quantified using ELISA 
and showed varying levels across all samples of NK (blue), NR (green) and WT (orange). 
 
The parameters tested here indicate that both NRs and WTs do not show 
characteristics of embryonic stem cells. Non-CpG methylation and H-me levels were 
low across all samples and CpG methylation did not cluster NRs or WTs with ES or 
IPS cell lines. Confounding factors in this analysis include the use of cell lines 
instead of primary tissue and batch effects from the experiments being run at 
different times in different locations/machines/chips.  
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4.6 WTs silence tumour suppressor genes by hypermethylation 
After characterising general properties of group-1 WTs, the hyper-WT-
DMRs were specifically studied to identify any methylation changes that could be 
readily associated with the transformation step from NRs, i.e. silencing of tumour 
suppressor genes. There were 123 genes associated with the 165 hyper-WT-DMRs 
which were cross-compared to the list of tumour suppressor genes held within 
TSgene, the Tumour Suppressor Gene Database 
(http://bioinfo.mc.vanderbilt.edu/TSGene/index.html). In total, 5 genes matched 
(Table 4.4) and due to the relationship between hypermethylation and gene silencing, 
these were considered likely targets for inactivation in group-1 WT. Indeed, RNA 
sequencing showed downregulation of CASP8, RB1 and TSPAN32 in WT compared 
to NR (Table 4.4). Due to low sample numbers, these differences did not reach 
statistical significance. As MIR-195 and H19 are a miRNA and ncRNA respectively, 
these were not detected by this assay. 
Of these genes, CASP8 and H19 have been previously associated with WT 
(Okamoto, Morison et al. 1997; Morris, Hesson et al. 2003), whereas RB1, MIR-195 
and TSPAN32 aberrations have not previously been identified in WT, although they 
have been detected in other cancers (Simpson, Hibberts et al. 2000; Nakamura, 
Yonekawa et al. 2001; Gonzalez-Gomez, Bello et al. 2003; Akino, Toyota et al. 
2007; Kim, Chang et al. 2008; Kim, Lebron et al. 2008; Malekzadeh, Sobti et al. 
2009; Lakomy, Sana et al. 2011; Li, Zhao et al. 2011).   
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Gene 
DMR P-
value 
Hypermethylated 
WT 
Average reads 
in NR 
Average reads 
in WT 
CASP8 0.0037 10 OF 13 104 20 
H19 0.0045 11 OF 13 NA NA 
MIR195 0.0049 13 OF 13 NA NA 
RB1 0.0020 13 OF 13 55 11 
TSPAN32 0.0091 10 OF 13 18 8 
Table 4.4: tumour suppressor genes hypermethylated in group-1 Wilms tumours 
 
4.7 Comparison of NRs to healthy tissue suggests that aberrant 
hypermethylation in NR tissue is associated with developmental 
arrest 
After successfully identifying changes in methylation with biological 
significance in WTs, the same approach was applied to NRs. As there was no 
evidence that differences existed between NRs as 18/20 fell into the same cluster 
after the ANOVA analysis (Figure 4.3), despite there being two types of NR present 
(ILNR and PLNR), all NRs were considered equal. 
To identify methylation changes associated with aberrant and incomplete renal 
development, comparative analysis was performed between the 20 NK-NR matched 
pairs as the NK represents the end-point of normal renal development whereas the 
NR represents aberrant disruption of this process. Linear modelling using Limma 
(Smyth 2005) identified 23,667 significant differentially methylated CpGs 
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(FDR<0.01) between the two groups. The champ.lasso algorithm was applied to 
these generating 629 DMRs of which 55% were hypermethylated and 45% were 
hypomethylated. These were termed kidney-rest DMRs (KR-DMRs with hypo-KR-
DMR and hyper-KR-DMR referring to the methylated state in the NR with respect to 
NK), and are summarised in Table 4.5. 
Again, these loci were interrogated using GREAT however analysis of hypo-KR-
DMRs did not identify any biological processes that could be readily associated with 
developmental arrest (Table 4.6). Conversely, analysis of hyper-KR-DMRs showed 
that these DMRs fall into regulatory regions of genes involved in developmental or 
multicellular organismal processes including early embryonic patterning and 
embryonic organ morphogenesis (Table 4.7). 
From this analysis, it appeared that gain of methylation in NRs was occurring at 
regions involved in development, which were not methylated in NK; hence it was 
postulated that this gain of methylation may be occurring at developmental loci 
required for nephrogenesis to complete properly. To test this hypothesis, the hyper-
KR-DMRs were compared to regions known to be involved in development that 
show bivalent chromatin structure in embryonic stem cells (ESCs). Bivalent domains 
in ESCs are regions that show both the active chromatin mark H3K4me3 as well as 
the repressive chromatin mark H3K27me3 and are therefore held in a transient state. 
Depending on the signals received by the ESCs, these loci can be rapidly resolved to 
either silence or activate the underlying gene as required for cellular differentiation 
and are therefore critical for cellular development and specificity. Bivalent domains 
in ESCs were extracted from the literature (Bernstein, Mikkelsen et al. 2006; Pan, 
Tian et al. 2007) and multisampling analysis was performed to identify the 
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proportion of enrichment of hyper-KR-DMRs compared to what would be expected 
by chance. This analysis revealed a strong, significant enrichment of hyper-KR-
DMRs within bivalent domains (10.8%, empirical p-value = 0.01, Figure 4.8; by 
comparison, hypomethylated KR-DMRs were negatively enriched -1.9%).  
As bivalent domains mark key genes involved in development, this positive 
enrichment suggests that aberrant DNA hypermethylation, either deposited to these 
regions actively or passively through failure to resolve the bivalent structures, may 
contribute to the developmental arrest seen in NRs. 
There were 35 genes that showed significant changes in expression between NK and 
NR by RNA sequencing of the four trios (FDR<0.05) and these did not show 
enrichment for developmental processes and none overlapped with the genes 
associated with hyper-KR-DMRs, however 2/35 of these genes (AHSG and 
COBLL1) have previously been implicated in mesoderm and ectoderm development. 
A larger study of gene expression in NK and NR is required to address this question. 
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Hyper-methylated 
DMRs 
Hypo-methylated 
DMRs 
Median size (bp) 646 1513.5 
Mean size (bp) 1418.5 1701.7 
Range (bp) 104-8,088 154-5,807 
Total (bp) 487,962 483,284 
   % enrichment: CpG island -11.5 -21.9 
% enrichment: CpG shore 9.9 2.5 
% enrichment: CpG shelf -1.0 4.1 
% enrichment: 'other' 2.5 15.3 
   % enrichment: ESCs bivalent domain 10.8 -1.9 
% enrichment: ESCs H3K4me3 only -3.0 -15.1 
% enrichment: ESCs H3K27me3 only 3.6 1.7 
% enrichment: ESCs no H3K27 or H3K4-me3 -11.4 15.3 
   
% enrichment: gene body -1.3 16.5 
% enrichment: TSS200 -2.1 -5.6 
% enrichment: TSS1500 -3.3 -6.2 
% enrichment: 3’ UTR 1.0 -0.3 
% enrichment: 5’ UTR 0.0 -0.8 
% enrichment: 1
st
 exon -2.0 -2.4 
% enrichment: intergenic region 7.7 -1.2 
 
Table 4.5: Description of hypermethylated and hypomethylated differentially methylated 
regions (DMRs) in nephrogenic rests compared to matched normal kidney Genetic features and 
those relating to CpG islands , shores (within 2kb of islands) and shelves (2-4kb from CpG islands) 
are extracted from the Illumina 450k annotation. Chromatin data (bivalent, H3K4me3 and H3K27me3 
domains) refer to embryonic stem cells (ESCs) (Pan, Tian et al. 2007).   
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Enriched Term in GO biological processes 
Hypergeometric 
fold enrichment 
Raw p-
value 
Actin cytoskeleton organisation 2.43 1.31E-13 
Actin filamentbased process 2.26 5.07E-12 
Chromosome organisation involved in meiosis 10.76 1.33E-18 
Collagen fibril organisation 6.17 3.30E-19 
Extracellular matrix organisation 2.28 2.23E-07 
Fat cell differentiation 4.94 4.72E-24 
Hormone biosynthetic process 4.43 1.72E-13 
Hormone metabolic process 2.52 7.31E-08 
Induction of apoptosis 2.24 1.70E-13 
Induction of programmed cell death 2.22 2.56E-13 
Meiosis 2.75 3.61E-07 
Meiosis I 4.43 6.91E-11 
Meiotic cell cycle 2.71 4.72E-07 
Negative regulation of transforming growth factor beta 
receptor signalling pathway 6.38 2.22E-23 
Negative regulation of transmembrane receptor protein 
serine/threonine kinase signalling pathway 4.47 3.18E-17 
Positive regulation of GTPase activity 2.48 2.46E-15 
Positive regulation of Ras GTPase activity 3.31 1.89E-16 
Regulation of GTP catabolic process 2.28 1.75E-14 
Regulation of GTPase activity 2.25 1.39E-13 
Regulation of myeloid cell differentiation 3.14 4.19E-12 
Regulation of myeloid leukocyte differentiation 5.43 2.51E-21 
Regulation of Ras GTPase activity 2.63 5.98E-13 
Regulation of Ras protein signal transduction 2.14 1.12E-11 
Regulation of transforming growth factor beta receptor 
signalling pathway 3.99 2.28E-15 
Regulation of transmembrane receptor protein serine/threonine 
kinase signalling pathway 2.7 1.29E-11 
Synapsis 11.04 7.12E-19 
Synaptonemal complex assembly 16.25 5.36E-23 
Synaptonemal complex organisation 13.37 6.78E-21 
White fat cell differentiation 13.41 1.05E-42 
 
Table 4.6: Significantly overrepresented biological processes identified by hypomethylated KR-
DMRs  
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 Enriched Term in GO biological processes Hypergeometric 
fold enrichment 
Raw p-
value 
Amine transport 2.99 9.88E-15 
Anterior/posterior axis specification 2.5 1.16E-04 
Anterior/posterior axis specification, embryo 5.39 4.04E-10 
Anterior/posterior pattern specification 2.13 9.87E-11 
Axis specification 2.24 2.78E-06 
Blastoderm segmentation 4.98 1.36E-10 
Cell-cell adhesion 2.08 2.92E-11 
Cell-cell signalling involved in cell fate commitment 3.73 1.16E-08 
Developmental induction 4.05 2.12E-09 
Embryonic axis specification 3.27 1.28E-06 
Embryonic organ morphogenesis 2.05 1.18E-10 
Embryonic pattern specification 2.17 1.29E-04 
Homophilic cell adhesion 4.91 1.09E-29 
Intracellular receptor-mediated signalling pathway 3.57 7.02E-25 
Negative regulation of kinase activity 3.39 7.73E-23 
Negative regulation of organelle organisation 2.94 1.40E-15 
Negative regulation of protein kinase activity 3.75 9.52E-26 
Negative regulation of protein modification process 2.52 3.46E-11 
Negative regulation of transferase activity 3.35 6.67E-24 
Nitrogen compound transport 3.22 2.34E-19 
Peptidyl-proline modification 4.17 5.81E-10 
Protein peptidyl-prolyl isomerisation 4.6 6.36E-11 
Regulation of adaptive immune response based on somatic 
recombination of immune receptors built from 
immunoglobulin superfamily domains 
2.02 3.71E-03 
Regulation of T-helper 1 type immune response 7.62 2.07E-11 
Transition metal ion transport 3.55 9.90E-10 
 
  
 
Table 4.7: Significantly overrepresented biological processes identified by hypermethylated KR-
DMRs   
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Figure 4.8: Hypermethylated KR-DMRs are enriched in developmental loci. Hypermethylated 
KR-DMRs showed 10.8% enrichment (empirical p ≤ 0.01) for location within domains that are 
bivalent in embryonic stem cells (considered as developmental loci) compared to levels ascertained 
by repeated multiple sampling of all array CpGs.   
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4.8 Key genes in β-catenin signalling are hypermethylated in 
nephrogenic rests 
Next, the Panther pathway analysis tool (http://www.pantherdb.org/) was 
used to highlight any pathways that were commonly targeted by the hyper-KR-
DMRs. Three significant pathways were identified (Figure 4.9A) and of these, both 
the Wnt and Cadherin pathways had overlapping genes (14 in total, Table 4.8) which 
have previously been associated with β-catenin localisation and expression. As 
CTNNB1 is a common mutation in WT (Li, Kim et al. 2004), these data suggest the 
pathway may be hit by other mechanisms including, but not limited to, long range 
epigenetic silencing involving the protocadherin cluster.  
To understand the role of methylation of these genes in the progression of WT, the 
same regions that were significantly associated with the Wnt and Cadherin signalling 
pathways were studied across the full dataset. This analysis showed that WTs had an 
even higher average β-value for these genes than NR (which was higher than NK; 
Figure 4.9B). To validate this, Panther pathway analysis was also performed on 
hyper-WT-DMRs which indeed also identified the Wnt and Cadherin signalling 
pathways as significant (Wnt: p=8.64x10
-39
; Cadherin: p=5.20x10
-69
). 
To associate these methylation changes with changes in gene expression, the RNA 
sequencing data was studied to assess levels of expression of these 18 genes in NK, 
NR and WT. Of the genes listed, none showed significant levels of differential 
expression between NK, NR and WT.   
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This evidence suggests sequential increase of dysregulation of Wnt and 
protocadherin signalling pathway genes in progression towards WT; however this 
was not validated in the small set of samples that underwent RNA sequencing. 
Previous evidence showed that genetic (CTNNB1 mutation) and epigenetic (PCDH 
gene cluster hypermethylation) events resulted in increased activity of β-catenin in 
WT (Maiti, Alam et al. 2000; Fukuzawa, Heathcott et al. 2007; Major, Camp et al. 
2007; Dallosso, Hancock et al. 2009) however this novel evidence indicates that β-
catenin activation may occur as an early event in WT tumourigenesis. This activation 
may in fact be required for cell renewal capacity rather than cellular transformation 
and proliferation as it is in WTs (Miki, Yasuda et al. 2011; Merrill 2012). 
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Figure 4.9: Hypermethylated KR-DMRs are enriched genes involved in β-catenin localisation. 
(a) Significant signalling pathways implicated by aberrant hypermethylation in NR compared to NK 
tissue identified using Panther with the log p-value for each pathway. (b) Protocadherin cluster 
methylation status in NK (green), NR (blue) and WT (pink) shows gain of methylation associating 
with tumourigenesis. Numbers refer to genomic coordinates from genomic built NCBI37.2 (hg19). 
 
 
 
a 
 
 
 
 
 
b 
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Gene CpGs 
ACTC1 4 
CDHR2 4 
EN1 3 
FAT1 3 
FZD10 3 
FZD4 3 
FZD5 6 
PCDHAC2 7 
PCDHB4 3 
PCDHGC5 54 
PLCB4 2 
SRCAP 4 
WNT1 1 
WNT10B 4 
Table 4.8: Genes with hypermethylated CpGs in nephrogenic rest tissue compared to normal 
kidney involved in Wnt and/or cadherin signalling pathways. The “CpGs” column lists the 
number of CpGs differentially methylated per gene.   
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4.9 Summary and conclusions 
In this chapter, regional differences in DNA methylation were identified that 
were able to discriminate between NK, NR and WT. These changes showed 
biological significance with respect to WT progression including that NR formation 
is associated with gain of methylation at developmental loci and that two WT groups 
exist that differ in terms of their relationship with their respective NR. 
No differences were seen in clustering that distinguished ILNRs from PLNRs 
however there were very few numbers of ILNR (n=4) within a total cohort of 20 
rendering any comparative analysis challenging. Therefore, no additional analyses 
were carried out to identify rest-specific methylation changes as a much larger cohort 
would be required. 
This chapter presented novel evidence that the relationship between a WT and its 
respective NR is not consistent. Group-1 WTs had very distinct methylomes from 
their respective NR whereas group-2 WTs had similar methylation profiles that 
showed no significant sites of differential methylation. Transformation in group-2 
WTs, therefore, may be driven by somatic mutation leading to WTs with the same 
general epigenomic properties of the NR with expansion by proliferation. Further 
analysis of a panel of WT associated genes is planned to answer this question. 
Group-1 WTs significantly associated with bilateral disease. The insult that lead to 
tumour formation in patients with bilateral disease likely occurred at an earlier time 
point than patients with unilateral WT as both kidneys are affected. In these cases, 
the cell-of-origin is likely to be more primitive and therefore retain more epigenetic 
plasticity than a more differentiated cell which would allow for the widespread 
remodelling observed here. Conversely, the separation of WT groups may in fact 
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result as a confounder of cell type composition once again. Although, histologically, 
there was no relationship between cell type proportions and grouping, group-1 
tumours may have an underlying shared composition that is not detectable by current 
histopathological review methods (i,e, may be composed of more immature elements 
than group-2 WTs).  
To conclude, this chapter has presented a wide range of evidence of significant 
methylation changes in progression from NR to WT. These analyses were not 
corrected for cell type composition effects however they represent the true 
heterogeneity of the samples included in this study and therefore represent true 
biomarkers of the progression of this childhood malignancy. Several of the results 
were validated by RNA sequencing; however a much larger cohort is required to 
generate sufficient data for effective comparative analyses. 
As these genome-wide and gene-specific assays work well on fresh frozen as well as 
FFPE tissue, there is potential for using these in a clinical setting to aid 
differentiation between NR and WT for patients with bilateral WT. This is essential 
to ensure that a resection margin is clear of tumour and also to aid treatment 
planning as NR can be left in a patient with no additional treatment however residual 
WT requires additional chemotherapy. Furthermore, as nephron-sparing surgery is 
critical for patients with bilateral disease, having the ability to differentiate between 
a NR and WT prior to surgery would enable efficient surgical planning so that less 
tissue is removed and the child can retain maximal renal function. Finally, as group-
1 WTs showed increased epigenetic instability, these patients may be considered for 
epigenetic modifying therapy where few targeted therapies have been identified by 
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mutational analysis. The data described in this chapter has been submitted to 
Genome Medicine as an article. 
  
163 
 
Chapter 5: Analysis with cell type correction 
5.1 Introduction 
As mentioned throughout chapters three and four, cell type composition is a 
major confounder of methylation studies (also reviewed in (Jaffe and Irizarry 2014)). 
Recently, several algorithms have been designed to compensate for mixed cell type 
composition effects that may confound methylation studies. These include correcting 
for mixed blood leukocyte populations between cases and controls using known 
methylation profiles obtained from profiling cell-sorted blood fractions 
(Adalsteinsson, Gudnason et al. 2012; Houseman, Accomando et al. 2012), and two 
case-control comparison algorithms that require no reference dataset EWASher 
(Zou, Lippert et al. 2014) and RefFreeEWAS (Houseman, Molitor et al. 2014). 
EWASher is implemented through Python while RefFreeEWAS is implemented 
through R. Both reference-free algorithms use linear modelling for their comparisons 
and correct for cell type composition effects using estimated cell proportions 
generated by principal component analysis. The algorithms deconvolute the 
methylation signal generating p-values and covariates that represent direct epigenetic 
effects.  
In this chapter, similar comparisons performed in chapter four are carried out using 
the RefFreeEWAS algorithm and the analyses are taken further by also comparing 
tissues to embryonic kidney (EK).  
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5.2 Between-tissue comparisons show that embryonic kidney is more 
similar to NK than to NR or WT. 
To characterise tissue-specific methylation changes for EK (n = 4), NK, NR 
and WT (n = 20 matched trios), pre-processing and normalisation steps were 
repeated, as described in chapter 3.2 using the Dasen algorithm, and probes that bind 
to multiple loci were removed (Price, Cotton et al. 2013) leaving a matrix of 330,731 
CpGs.  
For between-tissue analyses, linear modelling was performed using Bioconductor 
package Limma with correction for cell type composition using the RefFreeEWAS 
algorithm (Houseman, Molitor et al. 2014). Using this method, a total of five 
comparisons were made between tissue groups and the significant methylation 
variable positions (MVPs; defined here as CpGs with <|0.2| change in β-value 
between groups with p<0.01) were identified (Table 5.1). MVPs were focussed on 
throughout this analysis as the RefFreeEWAS package does not include a DMR-
finder algorithm. Although between-array normalisation was carried out, 
comparisons between matched NK, NR and WT identified many less MVPs than 
comparison of each tissue to EK (Table 5.1), likely due to the patient specific 
covariate design used in matched analyses. Based on the number of significant CpGs 
from each analysis, we observed that NK and EK were more similar than NR and 
EK, and that WT was even more different with 8-fold more MVPs. These results 
mirror the unsupervised analyses discussed in chapter 3.5. 
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Group 1 Group 2 Group1-Hypo-MVPs 
Group1-Hyper-
MVPs 
NK NR 42 (35%) 77 (65%) 
NR WT 223 (82%) 48 (18%) 
NK EK 817 (49%) 851 (51%) 
NR EK 2108 (48%) 2349 (52%) 
WT EK 5814 (44%) 7538 (56%) 
Table 5.1: Methylation variable positions identified by between group comparisons 
 
5.3 NRs are hypermethylated at renal development loci compared to 
EK  
To begin with, as NRs morphologically resemble EK, the MVPs that 
differentiate between NRs and EK were studied.  Of the 4,457 MVPs, 2,108 (47%) 
were hypo-MVPs and 2,349 (53%) were hyper-MVPs in NR with respect to EK. 
Although hypo-MVPs did not allow immediate identification of genes that could be 
readily associated with nephrogenic disruption, many of the hyper-MVPs fell within 
key genes involved in renal development including BMP4, BMP7, GATA3, GDNF, 
FOXD1, FOXC1, IRX3, LHX1, OSR1, PAX2, PAX8, SALL1, SIX1, SIX2, SOX4, 
SOX9, WNT4, WNT7B and WT1. Predictably, interrogating hyper-MVPs using 
GREAT (http://bejerano.stanford.edu/great/public/html/), identified enrichment of 
processes involved in nephron morphogenesis, nephron epithelial morphogenesis, 
mesonephros and metanephros development as well as other kidney-related and 
general development-related gene ontology processes (Table 5.2).  
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GO biological processes 
hypergeometric fold 
enrichment 
p-value 
Anterior/posterior pattern specification 2.78 9.26E-39 
Cartilage development 2.84 1.17E-25 
Ear development 2.93 7.17E-38 
Ear morphogenesis 3.53 1.54E-37 
Embryonic morphogenesis 2.35 5.30E-56 
Embryonic organ development 2.33 3.56E-38 
Embryonic organ morphogenesis 2.94 5.54E-50 
Kidney epithelium development 4.03 9.95E-26 
Kidney morphogenesis 4.74 8.66E-31 
Mesonephros development 6.81 2.04E-30 
Metanephros development 3.52 8.96E-30 
Nephron epithelium morphogenesis 5.2 4.39E-30 
Nephron morphogenesis 5.38 2.13E-33 
Organ morphogenesis 2.03 1.20E-53 
Pattern specification process 2.43 2.41E-56 
Regionalisation 2.8 1.31E-59 
Renal vesicle development 6.35 1.31E-25 
Sensory organ development 2.23 2.69E-40 
Skeletal system development 2.34 1.60E-40 
Tube development 2 1.26E-28 
Table 5.2: Biological processes associated with MVPs hypermethylated in NR compared to NK 
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5.4 The PRC2 complex is implicated in developmental arrest by 
aberrant hypermethylation in NRs 
Analysis of hyper-MVPs with GREAT also identified a very significant 
association between CpGs hypermethylated in NRs and regions identified as 
Polycomb Repression Complex 2 (PRC2) targets in ESCs (p=2.79x10
-66
) (Ben-
Porath, Thomson et al. 2008). To assess whether this association was detected due to 
NR cells progressing down a normal differentiation lineage past the embryonic 
stages captured in this experiment, i.e. acquiring NK-like properties, the MVPs 
identified by comparison of EK tissue to NK were studied in further detail. In total, 
851 hyper-MVPs were identified in NK with respect to EK however no association 
between hyper-MVPs and PRC2 regions was observed confirming that the aberrant 
hypermethylation seen is branched away from normal renal development. In general, 
PRC targets include developmental and lineage specific genes, and complexes have 
been shown to recruit DNA methyl-transferase enzymes resulting in aberrant cancer-
associated deposition of methylation at genes required for cellular differentiation 
(Bracken, Dietrich et al. 2006; Vire, Brenner et al. 2006; Bracken and Helin 2009; 
Mohammad, Cai et al. 2009). The regions that were targeted by aberrant 
hypermethylation in NRs included a set of 189 genes and 480 CpGs (20% of hyper-
MVPs). This evidence suggests a role for the PRC2 complex in nephrogenic 
developmental arrest and therefore NR formation. 
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5.5 WTs are expanded NRs with gain of methylation at general 
developmental loci associated with Polycomb targets 
Next, MVPs identified from comparison of WT to EK were analysed, of 
which 5,814 (44%) were hypomethylated and 7,538 (56%) were hypermethylated in 
WT with respect to EK, a relatively even distribution. The primary focus was on WT 
hyper-MVPs which, by interrogation with GREAT, identified similar developmental 
processes as identified in the NR-EK comparison suggesting maintenance of the 
epigenetic landscape from the NR. The surprising difference was that the WT-EK 
comparison highlighted many more processes involved in general embryonic 
development instead of specifically renal development including, for example, 228 
genes involved in embryonic pattern specification and 251 genes involved in 
embryonic morphogenesis (the most methylated included FOXD1, GLI2, HOXA5, 
HOXD10, LBX1, PAX2, SIM2, SIX3, TBX3, UNCX, VAX2 and WNT10A). 
Furthermore, a significant enrichment was again seen for hyper-MVPs within 
regions of PRC2 binding (p=3.92x10
-217
), however there was also a very significant 
enrichment for regions of H3K27me3 (p=2.91x10
-247
), Polycomb EED targets 
(p=1.08x10
-241
) and Suz12 targets (p=8.65x10
-207
) all identified by ChIP on chip in 
human ESCs (Ben-Porath, Thomson et al. 2008). This evidence suggests a further 
dysregulation of methylation at Polycomb targets sites and developmental loci as 
cells progress towards malignancy.  
Verifying the involvement of Polycomb family proteins in Wilms tumourigenesis, a 
previous chromatin profiling study of WTs identified a network of epigenetic 
regulators that had similar narrow H3K4me3 peaks and expected high expression in 
both WT and ESCs but not NK (Aiden, Rivera et al. 2010). This set of genes 
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included Polycomb group proteins JARID2, FBXL10 and CBX2 (Aiden, Rivera et al. 
2010) associating their aberrant high expression with WT. Furthermore, a study of in 
vivo reprogramming in mice associated formation of WT-like lesions with failed 
reprogramming associated specifically with Polycomb group proteins failing to 
silence their targets (Ohnishi, Semi et al. 2014). 
 
5.6 The Ras network is active in WTs 
Next, hypo-MVPs in WT compared to EK were analysed using GREAT 
which identified over-enrichment for GO biological processes involved in RAC, 
RAS and RHO GTPase activity (Table 5.3). RAS, RHO and RAC are an interrelated 
family of proteins involved in cell growth, cell cycle, cytoskeleton reorganisation 
and activation of protein kinases. Their aberrant activation can lead to oncogenesis; 
therefore WTs are likely, in part, driven by an oncogenic network of Ras signalling 
molecules. These aberrantly hypomethylated genes included ABR, ARHGEF16, 
NDEL1, SCRIB and RASA3. In chapter 4, Ras signalling was associated with 
hypomethylated DMRs in both comparison between NK vs NR and NR vs WT. The 
finding that this relationship is not associated with cell type composition backs up 
previous work where a kidney-specific β-catenin activating mutation was shown to 
result in epithelial tumours in mice, however when introduced along-side K-RAS 
activating mutation, bilateral, metastatic, multifocal renal epithelial tumours were 
observed that resembled epithelial WT (Clark, Polosukhina et al. 2011). This 
suggests a synergistic role for these two proteins in WT tumourigenesis. 
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GO biological processes 
Hypergeometric 
fold enrichment 
p-value 
Activation of Rac GTPase activity 6.78 1.09E-58 
Activation of Ras GTPase activity 5.06 1.25E-49 
Activation of Rho GTPase activity 5.77 1.40E-55 
Brown fat cell differentiation 5.32 1.27E-51 
Fat cell differentiation 2.71 7.32E-33 
Negative regulation of granulocyte differentiation 8.04 1.48E-59 
Negative regulation of myeloid leukocyte differentiation 4.04 3.45E-35 
Negative regulation of transforming growth factor beta receptor 
signalling pathway 
2.93 7.73E-26 
Positive regulation of Cdc42 GTPase activity 7.16 3.37E-58 
Positive regulation of establishment of protein localisation in 
plasma membrane 
5.99 6.58E-50 
Positive regulation of Rac GTPase activity 4.47 1.36E-44 
Positive regulation of Ras GTPase activity 2.06 6.65E-22 
Postitive regulation of Rho GTPase activity 2.94 2.30E-31 
Regulation of Cdc42 GTPase activity 5.77 3.41E-49 
Regulation of establishment of protein localisation in plasma 
membrane 
5.43 8.34E-46 
Regulation of generation of precursor metabolites and energy 2.83 1.35E-27 
Regulation of granulocyte differentiation 6.5 1.55E-51 
Regulation of Rho GTPase activity 2.47 3.83E-25 
Tongue development 4.62 2.08E-45 
White fat cell differentiation 5.93 2.06E-60 
Table 5.3: Biological processes associated with MVPs hypomethylated in WT compared to EK 
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5.7 NR and WT are epigenetically remarkably similar  
Considering the similarities observed in MVPs hypermethylated in NR and 
WT compared to EK, the MVPs identified in the NR vs WT comparison were 
studied next. Strikingly, there were very few MVPs: 223 (90%) hyper- and 24 (10%) 
hypo-MVPs in WT with respect to NR and when entered into GREAT to discern 
biological information, no significant signalling pathways were identified. This 
suggests the two tissues are remarkably similar, with major differences associated 
with cell-type composition effects. There were some key genes that were 
hypermethylated in WT compared to NR including SIX2, SIM2, LY6G5C, ULK2 and 
VAX2. Many were general embryonic developmental genes, validating results of 
each tissue comparison to EK. There were 10 genes in the Protocadherin gene cluster 
that were methylated in WT with respect to NR, a pathway previously shown to be 
hypermethylated in WTs and discussed in chapter 4.  
 
5.8 Comparison to EK reveals EK-specific and cancer-associated 
transcription factor families 
Finally, the transcription factors enriched for binding within the MVPs of all 
three tissues compared to EK were examined to identify any common features. This 
analysis found that the CpGs significantly hypomethylated in EK compared to each 
of the other three tissue types significantly associated with HOXL binding sites in 
each comparison (NK: p=6.86x10
-36
, 20 genes, NR: p=7.29x10
-33
, 26 genes and WT: 
p=2.25x10
-77
, 43 genes; total of 47 genes). Therefore, it can be predicted that 
homeobox family genes are expressed during normal renal development and are 
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silenced in the post natal normal kidney and are not associated with developmental 
arrest or malignancy.  
Continuing this strategy, it was next observed that the regions hypermethylated in 
both NR and WT tissues compared to EK showed significant association with four 
gene families: PRD, SIX, FOX and PAX,PRD (Table 5.4). These gene families were 
not detected in comparative analysis between EK and NK suggesting these 
transcription factors are hypomethylated in both EK and NK, and aberrantly 
hypermethylated in Wilms tumourigenesis.  
Furthermore, WTs also showed hypermethylation of WNT and FZD targets 
compared to EK that was not detected in comparison to NK or NR evidencing that β-
catenin/Wnt signalling is aberrant in WTs. As activating CTNNB1 mutations are 
frequently seen in WT, the hypermethylation (and predicted silencing) of β-catenin 
signalling proteins may indicate that activated β-catenin is signalling by a different 
pathway (i.e. the non-canonical Wnt pathway) or that due to the activation, 
expression of Wnt and Fzd proteins becomes redundant.  
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 NR WT 
FOX p=1.29x10
-11
 
17 genes 
59 CpGs 
p=2.90x10
-14
 
25 genes 
139 CpGs 
PAX,PRD p=1.05x10
-7
 
4 genes 
20 CpGs 
p=1.21x10
-7
 
6 genes 
32 CpGs 
PRD p=2.11x10
-5
 
9 genes 
30 CpGs 
p=6.58x10
-23
 
24 genes 
116 CpGs 
SIX p=6.43x10
-5
 
4 genes 
11 CpGs 
p=6.18x10
-21
 
5 genes 
46 CpGs 
   
   
Table 5.4: Significant transcription factor families with targets hypomethylated in NRs and 
WTs compared to EK. Details include p-value for significance, the number of genes targeted and the 
number of CpGs involved. 
 
5.9 Summary and conclusions 
To summarise, analysis of methylation levels in EK, NK, NR and WT has 
shown that NR retention is associated with aberrant hypermethylation of PCR2 
targets at many loci involved in renal development. By comparison of WT to EK and 
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NR, evidence was shown that WTs are also hypermethylated at genes involved in 
development, not limited to renal development, which are associated with a wider 
range of Polycomb group protein binding sites. WTs also showed hypomethylation 
and predicted activation of genes involved in Ras signalling. 
The results of these analyses, although similar to those in chapter 4, reveal novel 
markers of progression that were previously not detected and therefore masked by 
cell type composition effects. To make the most of methylation analysis, it is key to 
perform both corrected and non-corrected analyses to fully understand the 
methylation changes associated with the mixed tissue histology as well as the 
underlying changes associated with malignant progression. 
As mentioned, a common feature of CpGs methylated in NR and WT tissues in 
comparison to EK tissue was location in Polycomb target regions. The normal role 
of Polycomb group proteins is to silence target genes during development, by 
altering the local chromatin structure, i.e. by depositing H3K27me3. Polycomb 
proteins make up Polycomb repressive complex 1 and 2 (PRC1 and PRC2) which 
are comprised of proteins with various functions including chromatin modification. 
In NR tissue the hypermethylated sites were predominantly at genes associated with 
renal development but in WT tissue were more general developmental genes. 
Polycomb target hypermethylation has previously been associated with the cancer 
phenotype and less well-differentiated tumours (Ben-Porath, Thomson et al. 2008). It 
has been proposed that the deregulation of normal Polycomb mechanisms is central 
to tumour initiation (Bracken and Helin 2009), therefore it is perhaps unsurprising 
that dysregulation at these sites is seen as an early event.  
175 
 
Supporting the role of Polycomb protein dysregulation in WTs, evidence from a 
mouse model of in vivo reprogramming associated formation of WT-like lesions 
with failure of Polycomb gene targets to be repressed (Ohnishi, Semi et al. 2014). 
Furthermore, upregulation of Polycomb genes BMI-1, EZH2, SUZ12 and EED were 
seen in progressive blastemal-enriched WT xenografts in mice, suggesting their 
expression correlated with tumourigenesis (Metsuyanim, Pode-Shakked et al. 2008).  
Upregulation of Polycomb genes has been hypothesised as a mechanism by which 
aberrant gain of methylation may occur at target loci (Bracken and Helin 2009). 
Polycomb group proteins EZH2 (Vire, Brenner et al. 2006) and CBX7 (Mohammad, 
Cai et al. 2009) can physically associate with DNMTs and upregulation of these 
genes would cause progressive recruitment of DNMTs to Polycomb targets 
switching temporary silencing to permanent silencing (Bracken and Helin 2009). 
Polycomb group targets are often found to accumulate methylation in cancer cells, 
which has been specifically observed at WT1 and several other genes (Bracken, 
Dietrich et al. 2006). PRC targets are around 7-12 times more likely to be aberrantly 
methylated and silenced in cancer than non-PRC targets (Bracken and Helin 2009). 
Alternatively, Polycomb genes may be lead astray by the factors that are required for 
their association to target genes as Polycomb group proteins do not have the ability 
to bind to specific DNA motifs.  
As Polycomb targets include lineage-specific genes, and many genes involved in 
renal development were associated with aberrant hypermethylation in NR and WT, it 
can be hypothesised that their methylation in Wilms tumourigenesis silences pro-
differentiation genes so that cells fail to normally differentiate. The question that 
remains is what causes PRC overexpression in the first place? Genetic mutation 
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could be involved and exome sequencing projects are currently underway that may 
highlight novel mutations in WT associated with Polycomb gene regulation. 
However no full genome analysis has been published which is more likely to identify 
mutations in significant regulatory regions.  
Analyses in this chapter showed that NR and WT appeared remarkably similar. The 
reason for this is likely that the main differences in methylation between the tissues 
are associated with cell type composition (including the DMRs identified in chapter 
four). They are still true biomarkers for Wilms tumourigenesis, but present due to 
varying cellular compositions. Conversely, the small number of differential CpGs 
may be due to the more stringent cut-off parameters set for these analyses (p<0.01 
and Δβ>0.2 for RefFreeEWAS comparisons and only p<0.01 for non-corrected 
comparisons).  
Cell composition corrected analyses did identify some key genes that were 
hypermethylated in WT with respect to NR (LY6G5C, VAX2, ULK2 and SIX2). Of 
these, LY6G5C is located in the major histocompatibility complex (MHC) cluster. 
Methylation of MHC cluster genes has previously been seen in cancer as a way of 
decreasing expression to avoid immunosurveillance (Jäger, Ringhoffer et al. 1997; 
Degenhardt, Huang et al. 2010; Garrido, Paco et al. 2012). This interesting 
mechanism will be discussed further in chapter seven. Activation of the Wnt 
signalling pathway occurs by activating CTNNB1 mutation in ~15% WT. VAX2 is 
another protein associated with this pathway (a potent dominant-negative Wnt 
antagonist where loss of expression results in failure of VAX2 to prevent Wnt 
binding and therefore activation of Wnt signalling) which may be another 
mechanism of activating the same pathway. ULK2 is a gene involved in autophagy, 
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which is a normal process of the kidney to avoid kidney damage by mTOR 
signalling however its methylation in WT compared to NR doesn’t indicate an 
obvious association with tumourigenesis.  
Gain of methylation at SIX2 has been previously shown in progressive blastemal-
enriched tumour–propagating xenografts which correlated with loss of SIX2 
expression which the authors associated with loss of renal differentiation and WT 
progression diverting the progenitor phenotype away from a renal pathway to a more 
malignant one (Metsuyanim, Pode-Shakked et al. 2008). However, in general, SIX2 
is highly expressed in WTs (Murphy, Pierce et al. 2012). The RNA seq data showed 
an increase in SIX2 expression from 0 in all NRs to an average of 73 reads in two 
out of three WTs. Therefore, gain of methylation at SIX2 may correlate with loss of 
expression and be a marker of more malignant WTs in only a subset of cases. 
The final comparison of transcription factor enrichment in all tissues showed that 
HOXL proteins were hypomethylated in EK but not other tissues. The fact that 
HOXL targets were consistently significantly hypomethylated in EK tissue 
compared to all other tissues suggests that the master transcription factors active in 
EK tissue are HOX family genes which are not active in properly differentiated NK, 
aberrant NR or WT. In fact, Hox proteins are known to be essential for metanephric 
kidney induction (Wellik, Hawkes et al. 2002; Mugford, Sipila et al. 2008; Preger-
Ben Noon, Barak et al. 2009).   
Four TF families were identified that show hypermethylation in NR and WT; SIX, 
FOX, PRD and PAX. These transcription factor families are all involved in 
development. This data further validates that developmental loci required for normal 
development are hypermethylated in NR and WT.  
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Chapter 6: Identifying a tumour-specific biomarker 
6.1 Introduction 
In Europe, most children with a suspected WT commence pre-operative 
chemotherapy without histological diagnosis based on a presumptive clinical 
diagnosis. After four weeks of pre-operative chemotherapy, complete or partial 
nephrectomy provides tumour stage and histological subtype which together dictate 
the post-operative treatment (Lemerle, Voute et al. 1983). Although overall survival 
rates are good (>90% for localised disease), there is a clinical need for a blood or 
urine biomarker that could aid in diagnosis and evaluate patient response to 
chemotherapy and improve prediction of relapse. Circulating cell-free DNA 
(cfDNA) isolated from blood has been used to assess tumour burden in other cancers 
(Gautschi, Bigosch et al. 2004; Mori, O’Day et al. 2005; Ramirez, Rosell et al. 2005; 
Diehl, Schmidt et al. 2008) and due to the low frequency of genetic mutation in WT, 
the methylome, rather than the genome, seems more likely to reveal ubiquitous 
tumour-specific biomarkers. Therefore, the previously derived methylation data was 
interrogated to identify sites of tumour-specific differential methylation that were 
then assessed in cfDNA for use as WT biomarkers.  
 
6.2 Identification of biomarker differentially methylated regions 
To identify tumour-specific methylation variable positions (MVPs), as 
previously defined (Rakyan, Beyan et al. 2011), subset within quantile (SWAN) 
normalisation of β-values was performed on 22 matched pairs of NK and WT using 
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Bioconductor package ChAMP, leaving 462,537 CpGs. As previously discussed, this 
normalisation step was repeated to include the maximum number of CpGs for 
assessment as biomarkers as the analysis pipeline removes any CpGs with a 
detection p-value of <0.01 and therefore the overall number of CpGs decreases with 
an increase in the number of samples. A patient-specific paired linear model was 
performed using Limma, as previously described, however in this instance the 
algorithm TREAT was included which adjusts p-values according to the CpG-
specific Δβ (McCarthy and Smyth 2009). This analysis identified 309 MVPs of 
genome-wide significance (P<5x10
-8
; Figure 6.1). As this analysis was paired, the 
possibility of these being the result of genetic polymorphism, ethnicity or age is 
excluded. The DMR-finder algorithm champ.lasso implemented through the 
Bioconductor ChAMP package was then applied (Morris, Butcher et al. 2013) which 
grouped these MVPs into three discrete clusters (DMRs) of genome-wide 
significance (Table 6.1). All three of these DMRs were hypermethylated in WT with 
respect to NK.  
The DMRs that were identified by this method were indeed biomarkers for WT; 
however they may have resulted from cell composition effects. For example, NK is 
composed of around 95% epithelia and 5% stroma cells whereas WTs are composed 
of varying proportions of blastema, epithelia and stroma. Because of this, the three 
DMRs were termed putative DMRs (pDMRs).  
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Figure 6.1: Identification of differentially methylated loci with genome-wide significance. 
Manhattan plot showing –log10 p-values for all CpGs (462,537) generated by comparison of normal 
kidney (NK) to Wilms tumor (WT). CpGs with genome-wide significance (n = 309) appear above the 
red line. DMRs 1 and 2 on chromosome 6 and DMR-3 on chromosome 11 are shown on separate 
plots below in green. 
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DMR Location First CpG Last CpG Size (bp) 
No. 
CpGs 
DMR p-value 
CpG 
island 
Overlapping 
gene 
1 6p22.1 28956226 28956426 200 8 1.58E-10 CpG:42 none 
2 6p21.32 32116905 32116963 58 3 4.67E-09 CpG:56 PRRT1 
3 11q13.5 76858947 76859056 109 3 2.48E-09 CpG:38 MYO7A 
Table 6.1: Differentially methylated regions hypermethylated in WT compared to NK 
 
6.3 Cell type composition analysis 
To assess possible confounding due to differential cell type composition, two 
further analyses were performed. To begin with, histological analysis was performed 
by a paediatric pathologist who determined the proportions of each cell type (stroma, 
epithelia, blastema, necrotic tissue or tissue showing chemotherapy-induced changes, 
to total 100%) in each sample according to the original H&E stained sections that 
were used as a guide for microdissection (see chapter 2.2). This confirmed that the 
samples were composed of the anticipated major cell types, in the proportions 
expected for NK and with varying proportions in WT samples (Figure 6.2). Next, a 
recently published algorithm that corrects p-values generated through linear 
modelling based on estimated cell type contributions; RefFreeEWAS (Houseman, 
Molitor et al. 2014), was performed. Linear modelling using the RefFreeEWAS 
algorithm identified 7,272 CpGs with genome-wide significance (P<5x10
-8
) of 
which 937 had Δβ>0.3 and were therefore considered MVPs with 82% being 
hypermethylated and 18% hypomethylated in WT with respect to NK. As the 
RefFreeEWAS package is yet to contain a DMR-finder algorithm, the MVPs were 
focussed on.  
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For the MVPs that were hypermethylated in WT there was a striking positive 
enrichment for location within CpG islands (+18% compared to the relative % of 
each feature in all the background CpGs n=462,537). In total, 483 CpG islands 
contained at least one MVP. Two CpG islands that showed the greatest number of 
CpGs were located on chr6 (CpG:56 and CpG:42) with 13 and 11 CpGs respectively 
which overlap with the pDMRs 1 and 2.  Furthermore, by retrospective analysis of 
the MVPs, an overlap of three CpGs within pDMR3 was identified. The results of 
this analysis suggest that all three pDMRs are in fact true DMRs and are not 
mediated by cell composition effects.  
To further confirm these results, it was clear from comparing the known cell 
composition of each sample to the respective methylation level across the three 
DMRs that methylation levels were high despite the sample composition (Figure 
6.2), and in fact the proportion of any of the three cell types showed no correlation 
with DMR methylation status (Figure 6.3). 
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Figure 6.2: Quantification of cell proportions in each micro-dissected section used for DNA 
extraction. Each haematoxylin and eosin stained section was assessed by a paediatric pathologist who 
confirmed the proportion of blastema (dark grey), stroma (yellow), epithelia (light grey) or 
necrosis/chemotherapy induced changes (CIC; black) present in each sample that was micro-
dissected. Samples are labelled by the respective average β-value across all DMR CpGs which shows 
that methylation does not correlate with proportion of any cell type.  
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Figure 6.3: Correlative analysis of DMR methylation levels with cell type composition per 
sample. Correlative analysis between the βmean values of methylation across all three DMRs and the 
proportion of any of the three main cell types did not show any significant correlation with R
2
 values 
of 0.11, 0.05 and 0.03 for blastema, epithelia and stroma respectively. 
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6.4 Replication and validation of DMR hypermethylation 
After confirming that the DMRs were not associated with cell type 
composition, the levels of methylation were explored in two independent datasets. 
The DNA methylation levels across the three DMRs were aggregated to derive βmean 
for an independent replication dataset of 12 pairs of NK and WT as well as an 
independent set of 86 WTs encompassing the seven post-chemotherapy histological 
subtypes classified into two risk groups as defined by the International Society of 
Paediatric Oncology (SIOP) (Vujanic, Sandstedt et al. 2002).  
Comparison of βmean between the NK-WT pairs revealed that WTs were significantly 
hypermethylated compared to NKs, as expected (p=9.26x10
-10
, 2-tailed T-test, 
Figure 6.4A). Furthermore, βmean showed consistent high levels across the second 
independent WT dataset (Figure 6.4B) with a significant difference between WTs 
classified as high risk (average βmean = 0.87) and intermediate risk (average βmean = 
0.78; p=0.0024, 2-tailed T-test). This data confirmed that hypermethylation of the 
three DMRs was not restricted to the discovery dataset. Next, based on methylation 
levels in the initial discovery dataset of n=22 pairs, a support vector machine 
algorithm was applied using R CRAN package e1071. This algorithm used the 
discovery dataset to differentiate NK from WT then applied the learning algorithm to 
the two independent cohorts to discern whether each sample was more similar to NK 
or to WT. In total, the algorithm correctly classified 100% of the replication dataset 
of 12 pairs and 98% of the 86 independent WT samples. These results showed that 
the DMRs were very discriminative and potentially useful as biomarkers. 
Furthermore, as a significant difference in methylation levels between intermediate 
and high risk WT was identified, this could be of diagnostic use for WT patients.  
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Figure 6.4: Methylation levels for DMRs 1-3 significantly distinguish normal kidney from 
Wilms tumor and tumour risk groups.  (a) Aggregated methylation levels across DMRs 1-3 
significantly separated normal kidney (blue) and Wilms tumor (pink) in the replication set (n = 12 
pairs, p=1.47x10
-9
). (b) Methylation levels were high in an independent dataset of WT including high 
risk (dark green, n= 25) and intermediate risk histological subtypes (light green, n = 61). High risk 
WT showed significantly higher methylation levels than intermediate risk WT (p=0.0024).  
  
a                                       b                                              
 Replication set: n = 12 pairs                 Independent set (WT): n = 86 
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6.5 Validation of methylation levels 
Both DMRs 1 and 2 are located within the extended major histocompatibility 
complex (MHC) region (Horton, Wilming et al. 2004) which is known to be highly 
polymorphic (de Bakker, McVean et al. 2006), however the matched study design 
controlled for genetic heterogeneity, ensuring that the observed signal was not 
confounded by copy number or DNA sequence variation. To validate the levels of 
methylation in these regions, high depth coverage sequencing of bisulfite-converted 
DNA was performed in nine pairs of NK and WT. From the number of reads 
showing “C” and those showing “T”, the proportion of methylated reads was 
ascertained which is analogous to the β-value. Sequencing of DMR-1 showed a very 
low number of reads with only 6/18 samples giving 10 or more reads whereas DMR-
2 performed better with 16/18 samples giving sufficient reads (Table 6.2). Of the 
samples where sufficient data was derived, the correlation coefficient for DMR-1 
bisulfite-sequencing derived methylation levels compared to the 450k β-values 
results was R
2
=0.92 and for DMR-2 was R
2
=0.98 with overall correlation coefficient 
for all data of R
2
=0.93 (Figure 6.5). This data shows that the two platforms 
convincingly give the same methylation levels for each sample. 
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Figure 6.5: Comparison of methylation values assessed by 450k array and bisulfite sequencing. 
The average β-value for DMR-1 or DMR-2 discerned by the 450k array (y-axis) compared to the 
average level of methylation detected using bisulfite-sequencing for the same CpGs (x-axis) showed 
good correlation (R
2
 correlation coefficient = 0.929).  
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DMR 
Samples with 
>10 reads 
Correlation 
coefficient 
compared to 
450k array 
Mean difference 
between 450k 
value and 
bisulfite 
sequencing 
Range of 
difference 
between 450k 
value and 
sequencing value 
1 6/18 0.92 0.065 0.01-0.22 
2 16/18 0.98 0.073 0.02-0.16 
Table 6.2: Validation of 450k methylation signal by bisulfite-sequencing 
 
6.6 Methylation status of embryonic and precursor tissue suggests 
DMR hypermethylation is associated with malignancy 
As embryonic blastema is the WT predicted cell-of-origin, and these DMRs 
were identified by comparison to normal kidney, it was not clear whether the DMRs 
existed as a result of retention of an embryonic methylation profile or were solely 
associated with the malignant state. To explore this question, DNA was extracted 
from three specimens of human embryonic kidney (EK; at gestational weeks 22, 22 
and 23) as well as separately microdissested embryonic blastema from the same 
specimens (n=3). Bisulfite-sequencing was then carried out on this DNA using the 
Illumina MiSeq. Bisulfite sequencing identified average levels of methylation 
(comparative to β-values; on a scale of 0=unmethylated to 1=methylated) for DMRs 
1 and 2 of 0.007 and 0.12 for EK and embryonic blastema respectively. This data 
showed that the embryonic tissue was not methylated. Next, the levels of 
methylation in 20 cases with matched NRs were examined. These showed 
intermediate levels of methylation in comparison to NK and WT (Figure 6.6). Put 
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together, this data suggests that the increase in methylation levels seen in WTs must 
be associated with transformation of embryonic precursor cells towards a malignant 
phenotype instead of retention of an embryonic methylome.  
 
 
 
Figure 6.6: WT precursor lesions show intermediate methylation at significant DMRs. Of the 22 
cases where genome-wide methylation profiling was carried out on matched normal kidney (NK) and 
Wilms tumour (WT), 20 had nephrogenic rests (NRs) that were also profiled. The average 
methylation levels for WT (green), NR (orange) and NK (black) across these 20 cases is shown at 
each DMR with dotted lines representing the standard deviation. In every case, WT is 
hypermethylated with respect to NK, and the NR appears at an intermediate state of methylation.  
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6.7 DMRs as blood biomarkers 
As the three DMRs showed high levels of methylation, they were potentially 
interesting targets for blood biomarkers however if any leukocyte subpopulation was 
also methylated at these loci, they would mask any methylated DNA released from 
the tumour (Adalsteinsson, Gudnason et al. 2012). Therefore, to assess the potential 
influence that the methylomes of each blood subpopulation may have on detection of 
these DMR biomarkers in patient blood, two analyses were carried out. Firstly, 
publically available methylation signatures that define normal peripheral blood 
subgroups were examined (Koestler, Marsit et al. 2012) and secondly, methylation 
levels for the three DMRs in normal whole blood were examined by extracting 450k 
methylation data from 411 healthy whole blood samples using Marmal-aid (Lowe 
and Rakyan 2013) (http://marmal-aid.org/).  These analyses showed that DMRs 1-3 
did not overlap with any blood-related methylation signature, and that normal blood 
methylation levels for DMRs 1-3 were extremely low (average βmean= 0.12, Figure 
6.7). Therefore, it can be concluded that the hypermethylated DMRs are good targets 
for detection in the circulation above a low methylation background. Furthermore, 
they will not be confounded by varying leukocyte populations.  
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Figure 6.7: Methylation levels of DMRs 1-3 in whole blood. Aggregated methylation levels for 
DMRs 1-3 in healthy whole blood (n = 411) shows low methylation levels. 
 
6.8 DMRs as biomarkers for other cancers 
As previously mentioned, DMRs 1 and 2 are located within the MHC cluster. 
Methylation of genes in this cluster and reciprocal loss of expression is a common 
feature of many cancers, as cells use this mechanism to evade immunosurveillance 
(Doyle, Martin et al. 1985; Jäger, Ringhoffer et al. 1997; Degenhardt, Huang et al. 
2010; Garrido, Paco et al. 2012). To see whether other cancers shared the same 
hypermethylated DMRs, as these appear strong candidates for blood biomarkers over 
a low blood background, β-values for the three DMRs were extracted for 28 different 
cancers (n=5,278) using Marmal-aid. The SVM analysis previously used to classify 
the replication and independent datasets, was used to classify each cancer sample as 
   Normal whole blood: n = 411 
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“tumour-like” (hypermethylated) or “normal-like” (hypomethylated; Table 6.3). This 
analysis showed that 8 cancers had >90% cases with hypermethylation at the same 
loci including prostate adenocarcinoma, uterine corpus endometrial carcinoma, brain 
low grade glioma, rectal adenocarcinoma, breast invasive carcinoma and bladder 
urothelial carcinoma. Therefore, these DMRs may act as potential blood biomarkers 
for several adult and other childhood cancers if the tumour DNA is indeed released 
into the circulation. Cancer-specific hypermethylation of these loci may in fact be 
representative of the tissues from which these samples were derived, however as no 
methylation was detected in any healthy whole blood samples; any tumour-released 
DNA should still be detected at higher levels in cancer patients compared to cancer-
free blood.  
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Cancer Total Hypermethylated % 
Embryocarcinoma 5 5 100.0 
Neuroblastoma 3 3 100.0 
Prostate Adenocarcinoma 185 183 98.9 
Uterine Corpus Endometrioid Carcinoma 383 366 95.6 
Rectum Adenocarcinoma 96 90 93.8 
Brain Lower Grade Glioma 205 192 93.7 
Breast Invasive Carcinoma 586 546 93.2 
Bladder Urothelial Carcinoma 153 141 92.2 
Lymphoid Neoplasm Diffuse Large B cell Lymphoma 17 15 88.2 
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma 122 107 87.7 
Glioblastoma Multiforme 323 280 86.7 
Colon Adenocarcinoma 330 273 82.7 
Liver Hepatocellular Carcinoma 98 80 81.6 
Cholangiocarcinoma 50 38 76.0 
Stomach Adenocarcinoma 178 126 70.8 
Lung Squamous Cell Carcinoma 230 148 64.3 
Head and Neck Squamous Cell Carcinoma 412 265 64.3 
Lung Adenocarcinoma 380 223 58.7 
Skin Cutaneous Melanoma 278 155 55.8 
Bone Sarcoma 38 19 50.0 
Kidney Renal Papillary Cell Carcinoma 87 38 43.7 
Pancreatic Adenocarcinoma 50 17 34.0 
Kidney Renal Clear Cell Carcinoma 283 88 31.1 
Kidney Chromophobe 65 10 15.4 
Thyroid Carcinoma 441 41 9.3 
Acute Myeloid Leukaemia 242 20 8.3 
Childhood Acute Lymphoblastic Leukaemia 29 2 6.9 
Acute Promyelocytic Leukaemia 9 0 0.0 
Table 6.3: Classification of 28 tumour types (n=5,278 tumours) showed that other cancers are 
hypermethylated at DMRs 1-3  
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6.9 DMR-2 as a biomarker detected in the circulation 
As these DMRs appeared to be suitable targets for detection in the 
circulation, and DMR-2 was successfully sequenced in FFPE tissue, the same assay 
was performed on DNA extracted from patient serum. Circulating cell-free DNA 
(cfDNA) is released into the blood by dying cells and can be a marker for a 
particular disease state. However, only very low concentrations are obtainable.  
Serum was taken from 10 patients at serial time points during treatment for WT 
including pre-chemotherapy (n=5), pre-operative (n=8) and post-operative (n=8) 
according to the IMPORT study (see chapter 2.4). Due to the difficulty in collecting 
serum from patients at serial time points, and as the prospective clinical study had 
only recently opened, not all patients had a full set of samples, and at the time of this 
experiment, none had an end-of-treatment sample available. Serum samples from 
age-matched cancer-free controls were also included (n=7) and cfDNA was extracted 
from these samples using the QIAamp Circulating Nucelic Acid kit (QIAGEN). 
In total, 3 pre-operative, 2 post-operative and 3 control samples failed to generate 
enough DNA for amplification by PCR leaving a set of 20 cfDNA samples for 
sequencing (Table 6.4). These samples were bisulfite-converted, amplified with 
primers specific for DMR-2 and sequenced using the Illumina MiSeq. All samples 
generated sufficient reads for analysis. The entire region sequenced (319 bp: 
chr6:32,116,940-32,117,259) included 44 CpGs, which did not all follow the same 
pattern as some showed extreme variation between samples whereas some did not 
vary at all (i.e. 0.0 across all samples). Those showing no variation were removed as 
they showed no biological significance.  
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To identify CpGs that showed consistent methylation at one time-point and 
differential methylation between time-points, i.e. that gave a reliable, consistent 
signal, the samples were grouped and an ANOVA test was performed in R which 
generated CpG-specific statistics for differential methylation. As groups were very 
small, these statistics were non-significant overall however 14 CpGs showed 
moderated F-scores greater than 1 which indicated that any of the between-group 
comparisons were non-zero (i.e. were comparatively different). Therefore, the 
methylation data for these 14 CpGs was aggregated for each group (to give the % of 
methylated DMR-2 in patient blood, or %Mmean) giving totals of 13.4 for controls, 
14.5 for diagnostic samples, 19.9 for samples taken during pre-operative 
chemotherapy and 19.2 for samples taken in the early post-operative period (Figure 
6.8). 
These data showed that control samples had the lowest levels of methylated DMR-2 
DNA in circulation. Patients had increased levels at diagnosis which then 
substantially and significantly increased during pre-operative treatment (p=0.028). 
This high level continued into the immediate post-operative phase.  
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Figure 6.8: Levels of methylation in serum cfDNA during WT treatment (n = 10 patients). 
Levels of %Mmean (for 14 CpGs within DMR-2) show significant differences between controls and 
pre-op samples (p=0.010), controls and post-op samples (p=0.017), pre-chemotherapy and pre-op 
(p=0.028) and pre-chemotherapy and post-op (p=0.047; all by 2-tailed T-test). Data show increasing 
levels of methylated cfDNA after exposure to chemotherapy. Level of significance is shown by * 
(<0.05) or ** (<0.01) with horizontal lines indicating the respective comparison. 
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6.10 Summary and conclusions 
This chapter described the identification of three differentially methylated 
regions that were present in 118/120 WTs studied (98%). These biomarkers are 
therefore far more ubiquitous that any previously identified genetic or epigenetic 
marker for WT. The RefFreeEWAS algorithm was used to confirm that these were 
not mediated by cell type composition, which was also shown by comparison of 
DMR methylation levels to known cell type composition patterns and by the fact that 
84/86 WTs that were stratified across all seven post-chemotherapy histological 
subtypes showed consistently high levels of methylation. It can be concluded that all 
cells of the tumour acquire gain of methylation at these loci.  
Patients treated according to the SIOP protocol generally receive pre-operative 
chemotherapy, however one patient included in the initial 22 paired discovery set did 
not, however the tumour still showed high levels of DNA methylation at all three 
loci indicating that detectable, increased methylation is not chemotherapy-mediated.  
To discern the origin of these methylation marks, embryonic kidney, embryonic 
blastema and nephrogenic rest methylation levels were studied which showed that 
the embryonic tissue was not methylated while the NRs showed intermediate 
methylation levels. This analysis confirmed that DMR methylation was not 
association with retention of an embryonic methylome but associated with malignant 
transformation. 
As a proof-of-principle experiment, it was shown that tumours release methylated 
DMR-2 DNA into the circulation during treatment. Studying methylation levels in 
whole blood as well as separated leukocyte population indicated that these DMRs 
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were not methylated in healthy blood and therefore any methylation observed should 
be associated with a disease state. The data showed that levels of methylated DMR-2 
DNA in the circulation increase during treatment with chemotherapy supporting the 
idea that the methylated DNA originates from the WT as tumour necrosis is seen in 
response to chemotherapy. This is validated by the fact that a higher proportion of 
methylated DNA in the circulation was detected in serum taken from two patients 
with regressive type WT (defined as >2/3 necrosis at nephrectomy (Vujanic, 
Sandstedt et al. 2002)) compared to those with non-regressive WTs (23.6% 
compared to 17.3% respectively).  
After nephrectomy, the serum samples showed continued high levels of methylated 
DNA in the circulation. This was unexpected but may be explained by the fact that 
serum was sampled between 4 and 24 days post-surgery. The short-term persistence 
observed may be related to the methylated cfDNA retaining interaction with 
nucleosome proteins which protect it from degradation (Rumore and Steinman 
1990). To fully assess the extent of methylated DNA post-surgery, a full time course 
up to the end-of treatment included follow-up would be required and is planned for a 
future study. Indeed, a high level of methylated DNA post-surgery may relate to 
residual tumour left in the patient. In one patient included in this study, very high 
levels were observed post-surgery and three months later, bone metastasis was 
detected. 
In conclusion, this study has defined the first epigenetic biomarker applicable to 
analysis of circulating cfDNA in patients with WT. This biomarker may be useful in 
determining tumour response during pre-operative chemotherapy. As relapse rate is 
low in WT patients, a much larger, prospectively collected sample series is needed to 
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demonstrate clinical utility. This is currently in progress with a multi-centre 
European clinical trial planned to collect the required samples. These data have been 
published in Genome Biology, see Appendix 4. 
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Chapter 7: Final summary 
Based on the paucity of frequent genetic mutations in WT, the high 
frequency of WTs with epigenetic aberration at 11p15 and the embryonic nature of 
the tumour, six hypotheses were initially proposed. Here, evidence in support of 
these hypotheses is described and summarised and potential future work is 
suggested. 
The initial aims were to determine genome-wide methylation profiles for normal 
kidney, nephrogenic rest and Wilms tumour and to identify epigenetic changes 
associated with the persistence of NR in post-natal kidney as well as evolution of WT 
from its presumed precursor in normal embryonic kidney. 
Genome-wide methylation profiles for each tissue were indeed generated showing 
that DNA methylation can distinguish between tissue types. DNA methylation 
analysis of NR compared to NK or EK showed that NR formation is associated with 
hypermethylation of genes involved in renal development and loci that show bivalent 
chromatin marks in ESCs as well as hypermethylation of PCR2 binding sites. These 
findings, from analyses performed with and without correction for cell type 
composition, suggest that the initiating step in Wilms tumourigenesis, i.e. NR 
retention in post natal kidney, involves PRC2-associated gain of methylation at renal 
developmental loci, by either an active or passive mechanism, which is not cell 
composition-mediated. This aberrant methylation at loci required for normal 
nephrogenic differentiation would therefore result in lesions that cannot complete 
normal differentiation and remain as embryonic-like tissue in the post natal kidney 
but with epigenomes arrested from a more primitive stage.  
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In terms of WT evolution from its associated NR, the evidence presented in this 
thesis suggests that only a subset of WTs (predominantly those with bilateral 
disease), show large epigenetic remodelling during evolution from their precursor 
lesion. Cell composition corrected analysis showed how remarkably similar the two 
tissues were and how they shared common properties such as hypermethylation of 
polycomb protein targets. Furthermore, a progressive increase in methylation was 
shown for genes involved in Wnt/cadherin signalling and for the three biomarker 
DMRs. Although this evidence suggests that they are true precursor lesions, not 
every NR transforms into a WT and of the NRs sampled, some may be tumour-
associated instead of tumour initiating. In fact, the true NR from which the WT 
evolved is likely surrounded and compressed by WT and may therefore have been 
rejected from the stringent selection criteria for this study. This confounding factor 
may be associated with the identification of two WT groups. Indeed, the WTs in 
group-1 that appear distinct from their NRs may show a distinct methylation profile 
due to analysis of a NR that was not a true precursor to the paired WT analysed. 
Although this seems unlikely, given the strong association between group-1 WTs 
and bilateral disease, it is however a possible confounder in this analysis. Whether 
the two WT groups were associated with cell type composition cannot currently be 
determined as the RefFreeEWAS package does not output a cell type corrected 
matrix of β-values for MDS analysis or hierarchical clustering.  
It is interesting to speculate whether those WTs that are not visibly associated with 
NRs truly arise without a precursor stage or whether NRs are always present but not 
visible in many cases. Evidence presented in this thesis shows that both NRs and 
WTs have hypermethylation of genes involved in renal development which is 
associated with arrested development. The DNA methylation profile for WTs with 
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no visible NR would need to be examined to assess whether the hallmarks of NRs 
described above are present, including hypermethylation of developmental loci. This 
would suggest that the cells have gone through the step-wise progression from a 
developmentally arrested precursor prior to transformation.   
 
The next aim was to identify epigenetic markers that will be useful in distinguishing 
NR from WT – a particularly challenging differential diagnosis for histopathology, 
especially in the context of chemotherapy-treated WT. Although this was detected for 
group-1 WTs, group-2 tumours showed no significantly different sites of 
methylation when compared to their precursor NR. The work described in chapter 3 
on MDS of the 1% most variable CpGs in the dataset showed an increase in 
methylation variability between NR and WT samples compared to NK samples. In 
chapter 4, this was analysed in more detail and the number of probes with significant 
difference in variance were found to be much higher in WTs than NRs compared to 
NK. A previous study analysed methylation variability in cancer progression from its 
precursor in adenocarcinoma and found that it increased during progression towards 
cancer (Timp and Feinberg 2013) whereas another study found the peak of 
variability to occur within the intraepithelial neoplasia prior to transformation to 
cervical cancer (Teschendorff, Liu et al. 2014). The data in this thesis supports the 
first study as WTs showed increased variability, however if the same comparison 
were possible for cell composition corrected analyses, the opposite may be seen as 
the mixed populations seen in WTs will skew variability measures. NRs likely show 
a great deal of intra-sample variability as they have many different fates, as 
described in chapter 1.6.2, including dormancy, sclerosis, neoplasia or hyperplasia 
205 
 
(Beckwith, Kiviat et al. 1990) and they have been present since birth and therefore 
have had time to acquire a variable epigenome.  Despite this, the non-corrected 
findings, showing increase in methylation variability in WT over NR, may prove to 
be an accurate biomarker for distinguishing WT from NR. Evaluating the clinical use 
for this biomarker would require a larger study to determine the precise parameters 
for tissue-specific methylation variability compared to NK.  
 
A pilot analysis of cell-free methylated DNA in the circulation supported the aims: 
identify tumour-specific sites of methylation that can be detected in blood serum for 
use as a biomarker and confirm that the blood methylation biomarkers are 
discriminative in an independent cohort and have clinical utility 
A biomarker common to 118/120 WTs was identified that was detectable in blood. 
This biomarker encompassed three regions at 6p22.1, 6p21.32 and 11q13.5 that were 
hypermethylated in WT compared to NK. In particular, DMR-2 at 6p22.32 was 
found to be methylated in the circulation of patients with WT, with the highest levels 
detected after a short period of pre-operative chemotherapy. This marker may be 
useful for assessing response to chemotherapy or, if sensitivity can be increased, for 
diagnosis. This requires testing in a much larger series of patients and suitable 
samples are being collected through the ongoing IMPORT trial for future testing of 
this hypothesis. 
Both regions on chromosome 6 were within the extended major histocompatibility 
complex (MHC) cluster. Furthermore, LY6G5C hypermethylation, also within the 
MHC cluster, was seen in WTs compared to NR in chapter 5. Hypermethylation of 
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MHC genes is seen in many cancers associate with avoiding immunosurveillance 
(Doyle, Martin et al. 1985; Jäger, Ringhoffer et al. 1997; Degenhardt, Huang et al. 
2010; Garrido, Paco et al. 2012). Class I and II MHC antigen expression was 
observed in mature glomeruli and tubule structures in embryonic kidney from 8-13 
weeks gestation (Borthwick, Hughes et al. 1988). However in WT, blastemal 
elements were negative for class I gene expression whereas differentiated elements 
were positive while class II antigens were not expressed at all in WT (Borthwick, 
Hughes et al. 1988). This supports that MHC genes show reduced expression in WT. 
Little further evidence exists on MHC expression or methylation in WTs and is 
therefore an exciting avenue for future research 
 
The final aim: To identify changes in methylation associated with 
progression towards malignancy rather than mixed cell populations by performing 
both non-corrected and corrected analyses, was shown to be true as, although some 
results were common between analyses, different results were also found by both 
corrected and non-corrected analyses that gain biological insight into WT biology 
(Figure 7.1).  
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Figure 7.1: A summary of the key findings from both cell type corrected (right panel) and non-
corrected (left panel) analyses. Arrows between tissues (EK = embryonic kidney; blue, NK = 
normal kidney; green, NR = nephrogenic rest; orange, WT = Wilms tumour; red) indicate the 
direction of the relative description, i.e. an arrow pointing from NK to NR with “hypermethylation” 
indicates hypermethylation in the NR compared to the NK. In the left panel are findings identifies 
through analysis of NK, NR and WT whereas in the right panel, the findings of cell-composition 
corrected analyses including EK are shown. Similar findings between studies are circled in blue or 
green. 
 
This thesis increases knowledge on NR formation and progression in WTs but also 
opens up several avenues for future research. Firstly, further study into MHC cluster 
methylation and expression in WTs is an interesting avenue to aid understanding into 
why the biomarker DMRs are so significantly hypermethylated in WT. As the costs 
for 450k analysis are decreasing, a follow-up study to validate the methylation 
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signature in bilateral WTs may be possible. The limiting element is generation of 
quality DNA from NRs however with the advance of technology improving the 
quality of FFPE DNA this may be feasible from less material. By these means it will 
be possible to test whether any of the biomarkers identified are suitable for clinical 
use. Combination of methylation data with whole genome sequencing may enlighten 
which tumours show true epigenetic drivers and which result from genetic mutations 
and combination with a larger expression dataset by RNA sequencing may further 
validate the relationship between methylation and gene expression supporting the 
promising initial evidence in this thesis. Finally, analysing a large cohort of patient 
serum samples to assess levels of methylated DMR-2 in cell-free DNA will allow for 
proper interrogation of the potential diagnostic or therapeutic benefits of this blood-
borne epigenetic biomarker. 
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Appendix 
1: Table A1 – Wilms tumour staging classifications for patients treated according to 
the SIOP protocol, from Vujanic et al (Vujanic, Sandstedt et al. 2002) 
Stage Criteria 
I (a) The tumour limited to kidney or surrounded with fibrous pseudocapsule if 
outside of the normal contours of the kidney, the renal capsule or pseudocapsule 
may be infiltrated with the tumour but it does not reach the outer surface, and it is 
completely resected (resection margins ‘clear’) 
(b) The tumour may be protruding (‘bulging’) into the pelvic system and ‘dipping’ 
into the ureter (but it is not infiltrating their walls) 
(c) The vessels of the renal sinus are not involved 
(d) Intra-renal vessel involvement may be present 
II (a) The tumour extends beyond kidney or penetrates through the renal capsule 
and/or fibrous pseudocapsule into perirenal fat but is completely resected (resection 
margins ‘clear’) 
(b) The tumour infiltrates the renal sinus and/or invades blood and lymphatic 
vessels outside the renal parenchyma but it is completely resected 
(c) The tumour infiltrates adjacent organs or vena cava but is completely resected 
III (a) Incomplete excision of the tumour which extends beyond resection margins 
(gross or microscopical tumour remains postoperatively) 
(b) Any abdominal lymph nodes are involved 
(c) Tumour rupture before or intraoperatively (irrespective of other criteria for 
staging) 
(d) The tumour has penetrated through the peritoneal surface 
(e) Tumour implants are found on the peritoneal surface 
(f) The tumour thrombi present at resection margins of vessels or ureter, transsected 
or removed piecemeal by surgeon 
(g) The tumour has been surgically biopsied (wedge biopsy) prior to preoperative 
chemotherapy or surgery 
IV  Haematogenous metastases (lung, liver, bone, brain, etc.) or lymph node metastases 
outside the abdomino-pelvic region 
V Bilateral renal tumours at diagnosis. Each side should be substaged according to the 
above criteria. 
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Lin28 sustains early renal progenitors
and induces Wilms tumor
Achia Urbach,1,2,3,4 Alena Yermalovich,1,2,3,4 Jin Zhang,1,2,3,4 Catherine S. Spina,1,2,3,4 Hao Zhu,5,6,7
Antonio R. Perez-Atayde,8 Rachel Shukrun,9,10 Jocelyn Charlton,11 Neil Sebire,12 William Mifsud,12
Benjamin Dekel,9,10 Kathy Pritchard-Jones,11 and George Q. Daley1,2,3,4,13
1Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Children’s Hospital Boston, Boston,
Massachusetts 02115, USA; 2Howard Hughes Medical Institute, Boston, Massachusetts 02115, USA; 3Department of
Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA; 4Harvard
Stem Cell Institute, Boston, Massachusetts 02115, USA; 5Children’s Research Institute, 6Department of Pediatrics, 7Department
of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA; 8Department of Pathology,
Boston Children’s Hospital, Boston, Massachusetts 02115, USA; 9Pediatric Stem Cell Research Institute, 10Division of Pediatric
Nephrology, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv 52621, Israel; 11Institute of Child
Health, University College London, London WC1H 0AJ, United Kingdom; 12Department of Histopathology, Camelia Botnar
Laboratories, Great Ormond Street Hospital for Children, London WC1N 3JH, United Kingdom
Wilms Tumor, the most common pediatric kidney cancer, evolves from the failure of terminal differentiation of
the embryonic kidney. Here we show that overexpression of the heterochronic regulator Lin28 during kidney
development in mice markedly expands nephrogenic progenitors by blocking their final wave of differentiation,
ultimately resulting in a pathology highly reminiscent of Wilms tumor. Using lineage-specific promoters to target
Lin28 to specific cell types, we observed Wilms tumor only when Lin28 is aberrantly expressed in multiple
derivatives of the intermediate mesoderm, implicating the cell of origin as a multipotential renal progenitor.
We show that withdrawal of Lin28 expression reverts tumorigenesis and markedly expands the numbers of
glomerulus-like structures and that tumor formation is suppressed by enforced expression of Let-7 microRNA.
Finally, we demonstrate overexpression of the LIN28B paralog in a significant percentage of human Wilms tumor.
Our data thus implicate the Lin28/Let-7 pathway in kidney development and tumorigenesis.
[Keywords: kidney development; Wilms tumor; Lin28]
Supplemental material is available for this article.
Received December 24, 2013; revised version accepted March 25, 2014.
Wilms tumor, a common pediatric kidney cancer affect-
ing one in 10,000 children in North America, arises from
the failure of embryonic nephrogenic cells to undergo
terminal differentiation (Rivera and Haber 2005). The
development of the kidney is a complex process that re-
quires reciprocal inductive interactions between the
ureteric bud (UB) and metanephric mesenchyme (MM),
which leads to proliferation and expansion of the primi-
tive capmesenchyme (CM) (Grobstein 1955, 1956; Hatini
et al. 1996; Davidson 2009). The CM cells differentiate
into mature nephrons by a mesenchymal-to-epithelial
transition (MET). As they also possess self-renewal ca-
pacity, CM cells represent embryonic kidney stem cells
(Kobayashi et al. 2008; Pleniceanu et al. 2010). CM cells
proliferate and differentiate in the outer nephrogenic
zone of the kidney until the second postnatal day in mice
(Hartman et al. 2007) and the 36th week of gestation in
humans (Hinchliffe et al. 1991), after which time all
remaining CM cells synchronously differentiate to estab-
lish the final number of nephrons in the adult kidney
(Hartman et al. 2007). Wilms tumor shares histological
features with the developing kidney and is frequently
associatedwith persistent areas of embryonic tissue known
as nephrogenic rests, which contain blastemal cells with
varying degrees of differentiation (Rivera and Haber 2005).
Lin28 is an RNA-binding protein that regulates gene
expression via two different mechanisms: one that blocks
the processing of the Let-7 family ofmicroRNAs (miRNAs)
(Heo et al. 2008; Newman et al. 2008; Rybak et al. 2008;
Viswanathan et al. 2008) and another that involves direct
 2014 Urbach et al. This article is distributed exclusively by Cold
Spring Harbor Laboratory Press for the first six months after the full-issue
publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After
six months, it is available under a Creative Commons License (Attribution-
NonCommercial 4.0 International), as described at http://creativecommons.
org/licenses/by-nc/4.0/.
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binding to a wide array of mRNA targets (for review, see
Shyh-Chang and Daley 2013). The Let-7-dependent mech-
anism entails binding to the terminal loop of pri/pre-Let-7
miRNAs, which prevents their maturation and thus en-
ables the translation of genes that are suppressed by Let-7
miRNAs (Viswanathan et al. 2008). Oncogenes such as
K-Ras and c-Myc are prominent Let-7 targets (Viswanathan
and Daley 2010). In mammals, Lin28A and its closely
related paralog, Lin28B, are highly expressed in pluripo-
tent cells, where they play an important role in the
maintenance of self-renewal and proliferation (Shyh-
Chang and Daley 2013). Both Lin28 proteins are highly
expressed in early embryonic development but become
down-regulated over time, while levels of mature Let-7
family members rise as stem cells differentiate into
specialized tissue types (Viswanathan and Daley 2010).
Overexpression of LIN28 is common in various tumor
types and facilitates cellular transformation (Viswanathan
et al. 2009). Lin28 also promotes reprogramming of so-
matic cells into induced pluripotent cells (Yu et al. 2007).
Given that Lin28 is highly active in embryonic tissues
and was originally described as a heterochronic gene that
regulates developmental timing in Caenorhabditis ele-
gans (Ambros and Horvitz 1984; Moss et al. 1997), we
hypothesized that Lin28 overexpression might play a role
in pediatric tumor formation by altering the timing of
tissue differentiation and organogenesis during embry-
onic development. Indeed LIN28A overexpression has
been implicated in type II germ cell tumors (Gillis et al.
2011), which result from a failure of differentiation of
primordial germ cells (PGCs) (Oosterhuis and Looijenga
2005), while LIN28B has been linked to neuroblastoma
(Diskin et al. 2012), a pediatric tumor derived from neural
crest tissues that fail to complete their differentiation
program (Maris 2010; Molenaar et al. 2012). Last, we
reported previously that in rare cases of human Wilms
tumor, LIN28B overexpression is caused by translocation
at the LIN28B locus (Viswanathan et al. 2009). Here we
describe a novel murine model of Wilms tumor caused by
enforced overexpression of Lin28 during embryonic kid-
ney development and demonstrate by immunohisto-
chemistry that LIN28B is overexpressed in up to 30% of
cases of human Wilms tumor. These data, together with
recent insights from whole-genome sequencing of Wilms
tumor, implicate defects in miRNA regulation as a major
mechanism of kidney tumorigenesis.
Results
Lin28 overexpression during embryonic kidney
development leads to Wilms tumor
Previously, we and others have shown that LIN28 plays
an important role in germ cell development (West et al.
2009; Shinoda et al. 2013a) and is associated with human
germ cell tumors (Gillis et al. 2011; Murray et al. 2013).
Thus, we endeavored to overexpress Lin28 in PGCs by
crossing mice containing a Lox-stop-Lox-Lin28a cassette
(LSL-Lin28a) (Supplemental Fig. S1A) with mice carrying
a Vasa-Cre transgene, which we anticipated would express
Cre in PGCs when transmitted paternally, allowing us to
test the potential for Lin28 to induce germ cell tumors
(Gallardo et al. 2007). Contrary to expectations, however,
the cross between a LSL-Lin28a female and VasaCremale
did not yield the predicted germ cell phenotype (zero out
of 50) but unexpectedly produced renal tumors in 10% of
the offspring (five out of 50; four bilateral and one
unilateral) (Fig. 1A, top left). Tumors expressed the
Lin28a transgene, apparently a consequence of aberrant
‘‘leaky’’ activation, whereas normal kidneys showed no
transgene expression (Fig. 1B). Crosses of LSL-Lin28a
males with females carrying the Vasa-Cre allele resulted
in constitutional overexpression in all tissues by virtue of
Cre expression in oocytes (Gallardo et al. 2007) and
perinatal lethality. Interestingly, the kidneys of transgenic
embryonic day 18.5 (E18.5) embryos were larger than the
kidneys of their littermate controls and contained fewer
mature proximal tubules (Supplemental Fig. S1B). When
we harvested the kidneys from E18.5 transgenic and
control embryos and transplanted them under the kidney
capsule of immunodeficient mice, tumors developed in
a high percentage of recipients (seven out of 10) (Fig. 1A,
top right panel; Supplemental Fig. S1C). No tumors formed
in transplant recipients of control kidneys (zero out of nine).
Analysis of tumor gene expression (Fig. 1C) and histology
(Fig. 1D) indicated that the Lin28a-derived tumors were
highly similar to human Wilms tumor.
Previously, we reported two cases of human Wilms
tumor in which LIN28B was overexpressed as a result of
chromosomal translocation (Viswanathan et al. 2009). To
determine whether human LIN28B overexpression would
replicate Wilms tumor formation in mice, we engineered
a transgenic strain that afforded spatial and temporal
control of human LIN28B (or mouse Lin28a) overexpres-
sion by crossing the Rosa26-Lox-stop-Lox-rtTA allele with
the Col1A1-TRE-LIN28B allele (Lox-TetOn-LIN28Bmice)
(Supplemental Fig. S1D; Zhu et al. 2010). To achieve
global LIN28B overexpression in the developing and/or
adult kidney, we crossed Lox-TetOn-LIN28B mice with
Wt1Cre mice (Zhou et al. 2008), as Wt1 is expressed in
the intermediate mesoderm (Huff 2011), the origin of the
metanephric kidney (Davidson 2009). AllWt1Cre-LIN28B
mice (15 out of 15) developed kidney tumors (Fig. 1A,
bottom panel) within the first 2 wk of life when exposed to
doxycycline (Dox) induction during embryonic develop-
ment (E0, E14.5, or even as late as E18.5) (see below).
Importantly, the histology of the LIN28B-derived tumors
was similar to Lin28a-derived tumors (Fig. 1D). Taken
together, these results establish that overexpression of
either murine Lin28a or human LIN28B during kidney
development in transgenic strains of mice leads to kidney
tumor formation that is highly reminiscent of human
Wilms tumor (Fig. 1E).
Lin28 overexpression sustains the CM cells in the adult
kidney
During kidney development, the nephronogenic progen-
itor cells of the CM cells differentiate into pretubular
epithelial aggregates by a MET at around E12.5 (Rivera
Urbach et al.
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and Haber 2005). Normally, a balance between differen-
tiation and proliferation of CM cells is sustained in the
nephrogenic zone of the developing kidney until post-
natal day 2 (P2), after which time all CM cells undergo
a terminal wave of differentiation (Rumballe et al. 2011).
In contrast to normal kidneys, the Lin28-derived tumors
continue to sustain proliferating CM cells, as evidenced
by the expression of CM-specific transcription factors
(e.g., Six2, Cited1, and Eya1) and Ki67 staining (Fig. 2A,B;
Supplemental Fig. S2A). Moreover, H&E (Fig. 2C) and
immunofluorescence (Fig. 2D; Supplemental Fig. S2B,C)
staining of the tumors demonstrates that the tumor con-
sists of keratin8-positive UB cells surrounded by Six2-
positive CM cells, similar to the structures that normally
exist in the nephrogenic zone of the developing kidney.
Taken together, these data indicate that Lin28 overexpres-
sion prolongs the timing of kidney development, sustaining
proliferation of the CM cells into adulthood. Interestingly,
the CM cells of the tumor retain their differentiation
capacity, as evident by gene expression for markers of
epithelialization, such asWnt4 and CDH6 (K-cadherin)
(Fig. 3A; Supplemental Fig S3A); gross histology (Fig. 3B;
Supplemental Fig S3B); and histologic staining for Lotus
tetragonolobus lectin (LTL), a specific marker for mature
proximal tubules (Fig. 3C). Importantly, the fact that the
differentiated epithelial cells are Flag-positive (Supplemen-
tal Fig. S3C) indicates that these cells are indeed derived
from the Lin28-overexpressing cells. Furthermore, the
Lin28-derived tumors also contain structures resembling
differentiated glomeruli (Supplemental Fig. S3D,E). Thus,
the CM cells within the tumor retain a differentiation
capacity that recapitulates normal kidney development.
Figure 1. Lin28 overexpression in embryonic kidneys leads to Wilms tumor. (A) Kidney tumors as a result of Lin28 overexpression in
the kidney. (Top left panel) Renal tumor in a 17-wk-old kidney from the crossing between a LSL-Lin28a female and a VasaCre male. The
smaller kidney is the normal kidney from the opposite side in the same mouse. (Top right panel) Tumor derived by transplantation of
a Lin28a-overexpressing kidney (from the crossing between a LSL-Lin28a male and a VasaCre female) under the kidney capsule of an
immunodeficient mouse 17 wk post-transplantation. (Bottom panel) LIN28B-derived tumors in 3-wk-old kidneys (Dox induction [1g/L]
from E0). (B) Western blot analysis of tumors and age-matched normal kidneys with antibodies against Lin28a, Flag, and Tubulin. The
expression of the Flag tag shows activation of the transgenic Lin28a in the tumor. (C) Gene set enrichment analysis (GSEA) of
microarray data from Lin28a-derived tumors and control kidneys showing statistically significant up-regulation of ‘‘Wilms tumor
signature genes’’ in the tumor compared with the control. (D) Typical histology of a human Wilms tumor, a Lin28a-derived tumor, and
a LIN28B-derived tumor. The tumors are triphasic and contain structures of blastema (B), epithelium (E), and mesenchymal stromal (S)
cells. Bar, 100 mm. (E) Schematic representation of the UB and CM cells, which normally exist in the nephrogenic zone of the mouse
kidney only until P2. Global Lin28a or LIN28B overexpression in the developing kidney leads to a pathology similar to human Wilms
tumor. However, lineage-specific overexpression did not cause renal tumor formation (see below).
Lin28 overexpression leads to Wilms tumor
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Lin28 prevents the postnatal wave of differentiation
of the CM cells
We documented that Lin28 overexpression leads to
persistent proliferation of CM cells in adult mice. During
normal kidney development, Lin28a is expressed in CM
cells until E13.5, after which expression wanes, while
Lin28b is not expressed at all (Fig. 4A; Supplemental Fig.
S4A). Interestingly, however, the nephrogenic zone of
E18.5 transgenic embryos appears normal, without aber-
rant expansion of the CM cells (Fig. 4B; Supplemental Fig.
S4B), suggesting normal proliferation of the CM cells in
the nephrogenic zone during embryonic development in
the presence of Lin28. Importantly, induction of Lin28
overexpression as late as E18.5 was enough to sustain
proliferation of CM cells into adulthood (Supplemental
Fig. S4C). To discern whether ectopic Lin28 expression
could reactivate proliferation of nephrogenic cells after
the early postnatal period of terminal differentiation,
we induced LIN28B overexpression in renal tissues by
virtue of gene activation via Wt1Cre at P10, when no
CM cells exist in the normal kidney. When LIN28B was
overexpressed at P10, tumors failed to develop, and
expansion of Six2-positive cells was not detected (Sup-
plemental Fig. S4D). Instead, late LIN28B induction
resulted in a cystic kidney phenotype (Supplemental
Fig. S4E). Collectively, these data suggest that the CM
cells retain their differentiation capacity in the pres-
ence of Lin28 expression but that Lin28 delays the
timing of the final postnatal wave of synchronous differ-
entiation, allowing the nephrogenic process to persist,
eventually producing Wilms tumor.
Wilms tumor arises when Lin28 is overexpressed
in multiple early kidney lineages
We then sought to determine in which cells of the
developing kidney overexpression of Lin28 was re-
quired to promote Wilms tumor formation. We overex-
pressed LIN28B or Lin28a specifically in CM cells by
crossing Lox-tetOn-LIN28B and Lox-TetOn-Lin28a
transgenic mice with Six2-Cre mice (Kobayashi et al.
2008). Contrary to expectation, overexpression of Lin28a
or LIN28B in the CM cells failed to induce tumor forma-
Figure 2. Lin28-derived tumors harbor proliferating
CM cells. (A) Overexpression of CM-specific tran-
scription factors in the tumor. Microarray data
(tumor, n = 4; control, n = 4). (B) Six2 and Ki67
immunohistochemistry in normal kidneys and
LIN28a-derived tumors. Bar, 100 mm. (C) Histol-
ogy of the E18.5 nephrogenic zone and adult
tumors. Note that embryonic structures consist-
ing of a branched UB surrounded by CM cells
appears in the adult tumors. Bar, 50 mm. (D) Six2
and Keratin8 coimmunostaining in a normal
embryonic kidney, a normal adult kidney, and
an adult tumor. (Note: Keratin 8 is a marker for
UB cells during kidney development and for the
collecting duct in the adult kidney). In contrast
to normal adult kidneys, in which Six2 is not
expressed and keratin8 expression is restricted to
the collecting duct, the expression pattern of
Six2 and Keratin8 in the tumors is similar to
the nephrogenic zone during kidney develop-
ment. Bar, 100 mm.
Urbach et al.
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tion (zero out of 15) but instead produced a cystic kidney
phenotype. The cystic phenotype appeared in the Six2-
Cre-Lin28 mice when Lin28 overexpression was induced
early in embryonic development (Supplemental Figs. S5A,B)
or in adult mice (Supplemental Fig. S5C). We crossed
Lox-TetOn-Lin28a/LIN28B mice with mice carrying
FoxD1Cree (n = 10) to effect stromal cell-specific expres-
sion (Humphreys et al. 2010) and with mice carrying
Cdh16Cre (n = 7) to effect UB cell-specific expression (Shao
et al. 2002), but neither of these crossings reproduced the
tumor phenotype. Interestingly, however, overexpression of
LIN28B in stromal cells (FoxD1Cre) led to hydronephrosis
in the adult kidney (Supplemental Fig. S5D), while no
pathology was seen in the Cdh16Cre mice. Therefore, in
the murine model, Lin28 activation is required in the
earliest renal progenitor that gives rise to the multiple
cell types of the developing kidney, implying that Lin28
promotes a coordinated prolongation of nephrogenesis,
which ultimately progresses to Wilms tumor formation
(see Fig. 1E).
Lin28 expression is required for the maintenance
of CM cells within the tumor
Our data firmly establish a role for Lin28 overexpression
in tumor initiation, but to determine whether continued
Figure 3. Differentiation capacity of the CM cells in the tumor. (A) Overexpression of epithelialization markers Wnt4 and Cdh16 in
the tumor. Microarray data (tumor, n = 4; normal kidney, n = 4). (B) Epithelial structures in a normal embryonic kidney and a Lin28-
derived tumor. (E) Epithelial structures of comma-shaped/S-shaped bodies differentiated from the CM cells. Bar, 20 mm. (C) Mixture of
progenitor cells (Six2-positive) and mature proximal tubule cells (LTL-positive) in the tumor. Bar, 100 mm.
Figure 4. Lin28 overexpression prevents the post-
natal wave of differentiation of the CM cells. (A)
Analysis of Lin28a expression during mouse em-
bryonic kidney development. Lin28a is expressed
in the CM (Six2-positive) cells of the developing
kidney until E13.5. All panels are at the same
scale. (B, top panel) Six2 expression in E18.5
normal and transgenic kidneys. (Bottom panels)
Lin28a expression in normal and transgenic kid-
neys. Note that there is no expansion in CM cells
of the transgenic kidney compared with the
control. Bar, 100 mm.
Lin28 overexpression leads to Wilms tumor
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Lin28 expression is necessary for tumor maintenance,
we studied the effect of Lin28 down-regulation by
withdrawal of Dox commencing at P7. While signifi-
cant numbers of Six2/Eya1-positive CM cells persist
2 wk after Dox withdrawal (Fig. 5A; Supplemental Fig
S6), at 3 wk after Dox withdrawal, there was a signifi-
cant decrease in CM cells in the kidneys of the transgenic
mice, and not overt tumors, but a markedly increased
number of well differentiated glomerulus-like structures
(Fig. 5B,C). Thus, we conclude that expression of Lin28 is
sufficient for tumor initiation and necessary for tumor
maintenance.
Figure 5. Lin28 down-regulation leads to differentiation of the CM cells in the tumor. (A) qRT–PCR analysis of LIN28B, Six2, and
Eya1 (markers form CM cells) in transgenic and control kidneys 1 and 2 wk after Dox withdrawal. (2W) 2-wk-old mice (1 wk without
Dox); (3W) 3-wk-old mice (2 wk without Dox). Note that Six2 and Eya1 are still expressed 2 wk after Dox is withdrawn. (B) Average
glomerulus number per 103 magnification field in the microscope in transgenic and control kidneys 3 wk after Dox withdrawal (n = 12).
(C) Representative H&E staining of transgenic kidneys 3 wk after Dox withdrawal (transgene 3 wk w/o Dox) compared with a control 4-wk-
old kidney and transgenic 1-wk-old and 4-wk-old kidneys maintained on Dox (transgene with Dox). Dox was induced from E0. Note that
3 wk after Dox withdrawal, the transgenic kidneys contain many glumerulus-like structures and do not contain CM cells. Yellow arrows
point to glomerulus-like structures. Bar, 100 mm.
Urbach et al.
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Lin28-induced Wilms tumor is suppressed by enforced
expression of Let-7
Analysis of miRNA expression in Lin28-induced tumors
demonstrated significant suppression of mature Let-7
species (Supplemental Fig. S7A) but no significant change
in steady-state levels of pri/pre-Let7 (Supplemental Fig.
S7B). In accordance with this, Let7 target genes were up-
regulated in the tumors compared with control kidneys
(Supplemental Fig S7C). To determine whether Lin28-
induced tumorigenesis could be suppressed by enforced
restoration of Let-7, we crossed the tumor-prone LIN28B
transgenic mice with a strain that expresses a chimeric
Let-7g (i7s) species whose processing is not inhibited by
Lin28 (Piskounova et al. 2008). We verified by immuno-
histochemistry staining that the transgenic kidneys over-
expressed LIN28B (Supplemental Fig. S7D), that endoge-
nous Let-7was down-regulated when the chimeric Let-7g
transgene was overexpressed in the LIN28B-i7s kidneys
(Fig. 6A), and that Let-7 targets were down-regulated in
the Lin28B;i7s kidneys compared with Lin28B kidneys
(Supplemental Fig. S7E). We showed previously that the
‘‘i7s’’ mice are smaller than their littermate controls (Zhu
Figure 6. Lin28 acts thorough the Let7 pathway to prevent normal kidney development. (A) qRT–PCR analysis of mature Let7 levels in
LIN28B, LIN28B;i7s, and control kidneys. Dox was provided from E14.5 until the end of the experiment. (B) Morphology of LIN28B,
LIN28B;i7s, and control kidneys. (C) qRT–PCR analysis of the CMmarkers Six2 and Eya1 in LIN28B, LIN28B;i7s, and control kidneys. (D)
H&E staining of LIN28B, LIN28B;i7s, and control kidneys. Note that the Lin28B;i7s kidneys have a normal histology. Bar, 100 mm.
Lin28 overexpression leads to Wilms tumor
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et al. 2011). Accordingly, kidneys of compound LIN28B-
i7s mice appeared smaller than normal kidneys (Fig. 6B).
Importantly, however, there were no evidence of persis-
tent CM cells in the LIN28B-i7s kidneys, as demonstrated
by quantitative RT–PCR (qRT–PCR) (Fig. 6C) and histol-
ogy (Fig. 6D). These results demonstrate that enforced Let-7
expression can counteract the effect of LIN28B overexpres-
sion, suggesting that LIN28B induces Wilms tumor at least
in part by suppressing Let-7 miRNAs.
LIN28B expression in human Wilms tumor
Cancer-initiating cells (CICs) have recently been isolated
from humanWilms tumor (Pode-Shakked et al. 2013). We
detected overexpression of LIN28B (but not LIN28A) in
NCAM1+ALDH1+ wild-type CICs isolated from early-
generationWilms tumor xenografts (harboring a blastemal
predominant phenotype) and to a lesser extent in primary
Wilms tumor when compared with developing human
kidneys (Supplemental Fig. S8A). To determine whether
LIN28 expression is a prominent feature of human Wilms
tumor, we analyzed the expression of LIN28A and LIN28B
in human Wilms tumor samples from Boston Children’s
Hospital (USA, n = 28) and an independent set from Great
Ormond Street Hospital/University College London In-
stitute of Child Health (UK, n = 77). Indeed, immunohis-
tochemical staining of these samples revealed overex-
pression of LIN28B (Fig. 7A) in eight out of 28 and 10 out
of 77 samples, respectively, compared with normal kid-
neys. Conversely, LIN28A expression was not detected in
any sample. This observation was further supported by
our analysis of published microarray data that indicated
frequent expression of LIN28B but not LIN28A in human
Wilms tumor (Fig. 7B; Supplemental Fig. S8B).
In our tissue microarray analyses (UK samples), we
noted that LIN28B expression was restricted to blastemal
cells, which are the most undifferentiated tumor compo-
nent. Clinical outcome data were available for 76 out of
77 UK patients who had been uniformly treated with
prenephrectomy chemotherapy. Among the nine LIN28B-
positive tumors, five patients relapsed, and three died.
Among the 67 LIN28B-negative tumors, eight patients
relapsed, and two died, thus suggesting a significant asso-
ciation of LIN28B expression with relapse and death (P =
0.0059 and P = 0.0105, respectively, two-tailed Fisher’s
test). Detailed histological and statistical analysis of the
LIN28B-positive and LIN28B-negative tumors can be found
in Supplemental Tables 1 and 2. Taken together, these data
indicate that expression of LIN28B is a feature of a signifi-
cant minority of cases of human Wilms tumor, which,
together with our prior report of activation of LIN28B by
chromosomal translocation in two cases, implicates LIN28
in the pathogenesis of human Wilms tumor.
Discussion
It has been argued that pediatric cancer can arise from the
failure of embryonic cells to complete their differentiation
program (Maris and Denny 2002; Messahel et al. 2005),
indicating that the pathogenesis of pediatric tumors is
Figure 7. LIN28B expression in human Wilms tumor.
(A) LIN28B immunohistochemistry in human Wilms
tumor. (B) LIN28B and LIN28A expression levels in
diverse types of human renal tumors based on published
microarray data (GSE11151).
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directly linked to dysregulated embryonic development
and organogenesis (Scotting et al. 2005). Here we demon-
strate that overexpression of Lin28, an RNA-binding pro-
tein linked to pluripotency, stem cell self-renewal, and
delayed larval development in C. elegans, prolongs kidney
development and promotesWilms tumor formation. Rem-
iniscent of its association with heterochronic phenotypes
in C. elegans, Lin28 overexpression prevents the synchro-
nous wave of differentiation of CM cells in the developing
kidney, which, under normal conditions, is complete by P2
in mice (Hartman et al. 2007) and by 36 wk of gestation in
humans (Hinchliffe et al. 1991). In transgenic mice engin-
eered for kidney-specific Lin28 overexpression, CM cells
continue to proliferate into adulthood, resulting in con-
version to a tumor highly reminiscent of human Wilms
tumor. When activation of Lin28 was targeted to specific
cellular compartments such as UB, stroma, or CMcells, we
failed to observe tumor formation; instead, in our model,
Cre excision in the intermediate mesoderm, the origin of
the entire kidney, was required to induce tumor formation.
Theoretically, this observation suggests that Lin28 activa-
tion is required in either a stage-specific manner in the
earliest kidney progenitor cells or more than one kidney
cell lineage. The fact that tumors formed when Lin28
overexpression was induced as late as E18.5, when the
earliest progenitors no longer exist, suggests that the
second explanation is more likely. Our model implies
that aberrant Lin28 expression produces a coordinated
expansion of the nephrogenic zone, resulting in pro-
liferating blastema and nephrogenic rests, which are
characteristic of human Wilms tumor.
Previously, a murine model of Wilms tumor was gener-
ated by Wt1 ablation and Igf2 overexpression (Hu et al.
2011), which established that Wt1 ablation prevents the
MET of CM cells that is essential for nephrogenesis. In
contrast, in our model, the CM cells persist beyond the
period when synchronous differentiation typically occurs
and retain their capacity to undergo MET, resulting in
a markedly expanded period of nephrogenesis that ulti-
mately progresses to frank tumorigenesis. The differences
between these two models demonstrate that pediatric
Wilms tumor formation can occur at diverse stages of
development and through different molecular mechanisms.
Lin28 has profound effects on both the proliferative and
metabolic machinery of tumor cells. By virtue of blocking
Let-7 biogenesis, Lin28 leads to derepression of known
oncogenic targets of Let-7 such as Myc (Sampson et al.
2007), Ras (Johnson et al. 2005), Hmga2 (Lee and Dutta
2007; Mayr et al. 2007), and cyclins (Legesse-Miller et al.
2009; Chang et al. 2012). Moreover, Lin28 has been shown
to promote glycolytic metabolism in tissues and cancer
cells and thus is a central regulator of cellular bioenerget-
ics (Shyh-Chang et al. 2013). It appears that Lin28 func-
tions to balance the proliferative and metabolic needs of
rapidly growing cells in the early embryo (Shinoda et al.
2013b) and that this function becomes reactivated inmany
adult tumors. In cases of pediatric malignancy, Lin28
appears to prolong the embryonic patterns of tissue growth
(as we showed here for Wilms tumor), which is likely the
case for germ cell tumors and neuroblastoma.
Point mutations in WT1, WTX, b-catenin, and abnor-
malities involving translocations in chromosome 6 have
been linked to Wilms tumor (Knudson and Strong 1972;
Rivera and Haber 2005; Hu et al. 2011), and several
susceptibility loci for Wilms tumor were recently identi-
fied by a genome-wide association study (Turnbull et al.
2012). However, the underlying genetic basis of most
cases of Wilms tumor remains unknown (Turnbull et al.
2012). Here we report that up to a third of human Wilms
tumors overexpress LIN28B. Moreover, our data suggest
an association of LIN28B expression with a ‘‘high-risk’’
subtype of Wilms tumor called ‘‘blastemal type’’ (Vujanic
et al. 2002) that is defined by the persistence of a large
proportion of blastemal cells in the viable tumor compo-
nent after prenephrectomy chemotherapy. Therefore,
LIN28B expression may be a marker of such therapy-
resistant blastemal cells, which currently cannot be
identified in chemo-naı¨ve tumors treated according to
the North American approach of immediate nephrec-
tomy, but a much larger unselected cohort of tumors
would be required to investigate this properly. Prior
studies have implicated aberrant expression of the
HACE1 locus on chromosome 6 in Wilms tumor (Slade
et al. 2010), but LIN28B is tightly linked to this locus,
and our detection of aberrant overexpression of LIN28B
in a significant minority of human Wilms tumors
suggests the possibility of coordinate dysregulation. Pre-
viously, we reported that rare cases of Wilms tumor result
from activation of LIN28B by chromosomal translocation
and that amplification of the LIN28B locus occurs in only
;2% of tumors (Viswanathan et al. 2009); thus, the
mechanism of LIN28B activation remains unexplained in
most cases. Based on our demonstration that both murine
Lin28a and human LIN28B are competent to induce
Wilms tumor in our mouse model, we speculate that the
prevalence of LIN28B activation and the absence of
aberrant LIN28A expression in human Wilms tumor is
likely due to a specific mechanism of LIN28B up-regula-
tion and not differences in the transforming potential of
the genes. In support of this hypothesis, it has been shown
recently (Aiden et al. 2010) that the promoter of LIN28A in
human Wilms tumors is enriched with histone K27me3.
The miRNA pathway is a common target for dysregu-
lation in different types of tumors (Merritt et al. 2008;
Bahubeshi et al. 2011). Recently, it was demonstrated that
DIS3L2, the gene responsible for Perlman syndrome,
which entails a predisposition to Wilms tumor, is a nu-
clease responsible for degrading Let-7miRNAs that have
become polyuridylated due to Lin28-mediated recruitment
of a terminal uridylyl transferase (Chang et al. 2013). Taken
together with the observation of LIN28B overexpression in
up to 30% of humanWilms tumors and our demonstration
that enforced expression of Let-7 abrogates Lin28-induced
kidney tumorigenesis, these data suggest that a common
mechanism of Wilms tumor pathophysiology is dysregula-
tion of LET-7miRNA biogenesis or function. This hypoth-
esis would be reinforced if indeed Drosha and Dicer1
mutations or other mutation in the miRNA processing
machinery are likewise found inWilms tumor. The LIN28/
LET-7 pathway represents an appealing therapeutic target
Lin28 overexpression leads to Wilms tumor
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for Wilms tumor through either inhibition of LIN28 func-
tion or delivery of LET-7 to tumor cells.
Materials and methods
Mice
All animal procedures were conducted according to animal care
guidelines approved by the Institutional Animal Care and Use
Committee at Boston Children’s Hospital.
LSL-Lin28a mice
A Lox-stop (four PGK-polyA and three sv40 polyA) Lox cassette
and a Flag-tagged murine Lin28a ORF were cloned into pEF6
plasmid (Invitrogen, catalog no. V962-20) downstream from a
PEF-1a promoter, and targeting was performed into V6.5 embry-
onic stem cells. Chimeric mice were generated by injection of
embryonic stem cells into BALB/c blastocysts and then bred to
CD-1 females to generate germline-transmitted pups.
Lox-TetOn-Lin28 mice were previously generated in our labo-
ratory as described in Zhu et al. (2010, 2011).
The following Cre mice were obtained from Jackson labora-
tory: VasaCre (stock no. 006954), Six2Cre (stock no. 009606),
FoxD1Cre (stock no. 012463), and Cdh16Cre (stock no. 012237).
The Wt1Cre mice were contributed by the laboratory of
Dr. William Pu at Boston Children’s Hospital. Cre mice were
crossed to the Lox-TetOn-Lin28 mice, and 1 mg/mL Dox was
administered to the drinking water at different time points to
induce LIN28B/Lin28a expression. To achieve co-overexpression
of Lin28 and Let7, we crossed Wt1Cre mice with TRE-7S21L
(‘‘i7s’’ mice) mice and then crossed the Wt1Cre;i7s mice with
Lox-TetOn-Lin28 mice.
For the transplantation experiments, embryos were harvested
by cesarean section at E18.5. Kidneys were harvested from trans-
genic and control embryos, dissected to smaller pieces, and then
transplanted under the kidney capsules of NSG mice.
qRT–PCR
RNA was isolated by TRIzol and reverse-transcribed using
SuperScript III (Invitrogen, catalog no. 18080-051) or miScript II
RT kit (Qiagen, catalog no. 218161). mRNA expression was
measured by qPCR using the DDCT method with the following
primers: mLin28a: mSix2 (forward primer, GCAAGTCAGCA
ACTGGTTCA; reverse primer, CTTCTCATCCTCGGAACT
GC), mEya1 (forward primer, TTTCCCTGGGACTACGAATG;
reverse primer, GGAAAGCCATCTGTTCCAAA), mGapdh (for-
ward primer, GCAGTGGCAAAGTGGAGATTG; reverse primer,
AATTTGCCGTGAGTGGAGTCATC), and mbActin (forward
primer, TACTCCTGCTTGCTGATCCAC; reverse primer, CA
GAAGGAGATTACTGCTCTGGCT); and hLIN28B (forward
primer, GCCCCTTGGATATTCCAGTC; reverse primer, TGACT
CAAGGCCTTTGGAAG). For qRT–PCR of mature Let7 miRNA
and pre/pri-Let7, we usedQiagenmiScript target as described in the
miScript protocol.
Microarray
RNA from four Lin28a-derived Wilms tumor samples and four
control kidneys was harvested and processed using TRIzol. The
Illumina Ref-8 microarray platform was used by the Boston
Children’s Hospital Intellectual and Developmental Disabilities
Research Center (IDDRC) Molecular Genetics Core Facility. The
microarray data have been deposited in Gene Expression Omnibus
(GEO) and given the series accession number GSE56323. Gene set
enrichment analysis (GSEA) was used to identify gene sets and
pathways associated with a set of up-regulated or down-regulated
genes. Published microarray data from GEO (GSE3822, GSE6890,
and GSE12588) were used for the analysis of Lin28a and Lin28b
during mouse kidney development. Data fromOncomine (https://
www.oncomine.org) were used for the analysis of LIN28A and
LIN28B expression in human Wilms tumor samples.
Histological analysis
Tissue samples were fixed in 10% buffered formalin and embed-
ded in paraffin. Immunostaining was performed using the follow-
ing antibodies: LIN28A (1:250; Cell Signaling, catalog no. 8641S),
LIN28B (1:250; Cell Signaling, catalog no. 4196S), SIX2 (1:400;
Proteintech Group, catalog no. 11562-1-AP), LTL (1:500; Vector
Laboratories, catalog no. FL-1321), and Keratin 8 (1:50; Develop-
mental Studies Hybridoma Bank [DSHB], catalog no. TROMA-I-s
[TROMA-I-s]).
Slides were dewaxed with xylene and rehydrated through a series
of washes with decreasing percentages of ethanol. Antigen retrieval
was performed in 10 mM sodium citrate buffer (pH 6.0) by
placement in a decloaking chamber for 30min on high temperature.
Immunohistochemistry was performed with Elite ABC kit
and DAB substrate (Vector Laboratories) according to the man-
ufacturer’s protocol. For immunofluorescence, Alexa 488- or
Alexa568-conjugated goat anti-rabbit or goat anti-mouse second-
ary antibodies were used. Lin28B immunohistochemistry was
scored as positive versus absent staining. In all cases, positive
staining was seen in groups of blastemal cells.
To compare the nephron number between transgenic mice and
controls, we count the number of glomerulus-like structures in 12
random fields (from the kidney cortex) under 103 magnification.
Statistical analysis
Data are presented as mean 6 SEM, and Student’s t-test (two-
tailed distribution, two-sample unequal variance) was used to
calculate P-values. Statistical significance is displayed as P <
0.05 (*) or P < 0.01 (**) unless specified otherwise. The tests
were performed using Microsoft Excel, with the test type
always set to two-sample equal variance.
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3: Table A2: General laboratory equipment used in this project 
Equipment Details Supplier 
Benchtop centrifuge Eppendorf Microcentrifuge 
5415D 
Eppendorf AG, Hamburg, 
Germany 
Eppendorfs RNase-free: 0.2-1.5ml Anachem Ltd, Bedfordshire, 
UK 
Heat block Techne Dri-Block DB.2A Bibby Scientific France, 
Paris, France 
Large centrifuge Hettich, Rotina 46R Gemini BV, Apeldoorn, The 
Netherlands  
Light microscope Invertoskop ID03 Carl Zeiss Microscopy 
GmbH, Gottingen, Germany 
Microtome Accu-cut SRM 200 Rotary 
Microtome 
Sakura Finetek USA Inc, 
California, USA 
Nanodrop ND-1000 Thermo Fisher Scientific, 
Waltham, MA, USA 
Nuclease free water W4502 Sigma Aldrich, St Louis, 
MO, USA 
PCR thermal cycler Biorad Tetrad 2 Thermal Cycler Life Science, Hertfordshire, 
UK  
Pipette tips 0.1-1000μl ELKAY, Basingstoke, UK 
Pipettes Discovery Comfort P2-P1000 HTL Lab Solutions, 
Warsaw, Poland 
Qubit machine Qubit 2.0 Fluorometer Life Technologies Ltd, 
Paisley, UK 
Vortex Vortex Genie 2 Scientific Industries Inc, 
New York, USA 
Water bath Grant SUB6 Keison Products, 
Chelmsford, UK 
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Abstract 
Background 
Wilms tumor is the most common pediatric renal malignancy and there is a clinical need for a 
molecular biomarker to assess treatment response and predict relapse. The known mutated 
genes in this tumor type show low mutation frequencies, whereas aberrant methylation at 
11p15 is by far the most common aberration. We therefore analyzed the epigenome, rather 
than the genome, to identify ubiquitous tumor-specific biomarkers. 
Results 
Methylome analysis of matched normal kidney and Wilms tumor identifies 309 preliminary 
methylation variable positions which we translate into three differentially methylated regions 
(DMR) for use as tumor-specific biomarkers. Using two novel algorithms we show that these 
three DMRs are not confounded by cell type composition. We further show that these DMRs 
are not methylated in embryonic blastema but are intermediately methylated in Wilms tumor 
precursor lesions. We validate the biomarker DMRs using two independent sample sets of 
normal kidney and Wilms tumor and seven Wilms tumor histological subtypes, achieving 
100% and 98% correct classification, respectively. As proof-of-principle for clinical utility, 
we successfully use biomarker DMR-2 in a pilot analysis of cell-free circulating DNA to 
monitor tumor response during treatment in ten patients. 
Conclusions 
These findings define the most common methylated regions in Wilms tumor known to date 
which are not associated with their embryonic origin or precursor stage. We show that this 
tumor-specific methylated DNA is released into the blood circulation where it can be 
detected non-invasively showing potential for clinical utility. 
Background 
Wilms tumour (WT) is the most common paediatric renal cancer with a prevalence of one in 
10,000 children [1]. In Europe, most patients receive four weeks of pre-operative 
chemotherapy prior to complete or partial nephrectomy, followed by tumour stage and 
histology-dependent post-operative treatment [2]. Although overall survival rates are good, 
there is a clinical need for a biomarker to evaluate patient response to chemotherapy and 
improve prediction of relapse. 
Circulating cell-free DNA (cfDNA) isolated from blood has been used to assess tumour 
burden in other cancers [3–6]. In WT, the few genes that are recurrently mutated show low 
mutation frequencies; WTX (18%) [7], CTNNB1 (15%) [8] and WT1 (12%) [8] and do not 
account for the majority of WTs. However, epimutation affecting the IGF2/H19 locus at 
11p15.5 is much more common, (69%) [8]. Additional genes and regions known to be 
affected by methylation in WT include GLIPR1 [9], imprinted genes NNAT [10] and the 
WT1-antisense region [11], various satellite regions [12,13], HACE1 [14], RASSF1A [15], 
P16 and the protocadherin cluster at 5q31 [16]. Consequently, we concluded that 
interrogation of the methylome rather than the genome may be more likely to reveal 
ubiquitous tumour-specific biomarkers. Therefore, we performed genome-wide methylome 
analysis of matched WT and surrounding normal kidney (NK) to identify WT-specific sites 
of methylation which we then assessed in cfDNA for use as WT biomarkers. 
Results 
To identify tumour-specific methylation variable positions (MVPs), as previously defined 
[17], we derived methylation levels (β; 0 = unmethylated to 1 = methylated) for 462,537 CpG 
sites at single base-pair resolution using the Illumina Infinium HumanMethylation450 
platform and performed linear modelling to compare 22 matched pairs of NK and WT (full 
clinical details in Additional file 1: Table S1). We identified 309 MVPs of genome-wide 
significance (P < 5x10−8; Figure 1). Due to the matched study design there was no need to 
adjust for age, race or gender and we can exclude the possibility of MVPs being confounded 
by genetic polymorphism(s). We then applied the novel pipeline Lasso, recently developed 
for analysis of Illumina 450 k data, which considers the local CpG density to group MVPs 
into functionally more relevant differentially methylated regions (DMRs) [18]. Using this 
method, we identified 3 DMRs which were hypermethylated in WT with respect to NK 
(Table 1). 
Figure 1 Identification of differentially methylated loci with genome-wide significance. 
Manhattan plot showing –log10 p-values for all CpGs (462,537) generated by linear 
modelling of normal kidney (NK) against Wilms tumour (WT). CpGs with genome-wide 
significance (n = 309) appear above the red line. DMRs 1 and 2 on chromosome 6 and DMR-
3 on chromosome 11 are shown in green. 
Table 1 Differentially methylated regions hypermethylated in WT compared to NK 
DMR Location First CpG Last CpG Size (bp) No. CpGs DMR p-value CpG island Nearest gene 
1 6p22.1 28956226 28956426 200 8 1.58E-10 CpG:42 ZNF311 
2 6p21.32 32116905 32116963 58 3 4.67E-09 CpG:56 PRRT1 
3 11q13.5 76858947 76859056 109 3 2.48E-09 CpG:38 MYO7A 
To assess possible confounding due to differential cell type composition, we carried out two 
analyses. First, we conducted histological analysis confirming our samples to be composed of 
the expected major cell types, consisting of 95% epithelia and 5% stroma in NKs while WTs 
showed varying proportions of immature stroma, epithelia and blastema (Additional file 2: 
Figure S1). Second, we used a recently published algorithm, RefFreeEWAS [19] which 
corrects p-values based on estimated cell type contributions. Performing linear modelling 
using this algorithm, we identified 7,272 CpGs with genome-wide significance (P < 5x10−8; 
Figure 2) of which 937 had ∆β > 0.3 and were therefore considered cell-composition 
corrected MVPs. Of these, 766 were hyperMVPs and 171 were hypoMVPs in WT with 
respect to NK (Additional file 3: Table S2). For hyperMVPs in particular, we saw a striking 
positive enrichment for location within CpG islands (+18% compared to background). There 
were 483 CpG islands targeted by aberrant methylation in total (Additional file 4: Table S3) 
with a varying number of corrected MVPs per island. The greatest enrichment of MVPs 
occurred in two CpG islands on chr6 (CpG:56 and CpG:42) with 13 and 11 MVPs 
respectively which overlapped with DMRs 1 and 2. Using a threshold of ≥3 MVPs per DMR, 
we then mapped the cell-type corrected MVPs onto the DMRs identified with Lasso, 
confirming that all three DMRs were not confounded by cell composition effects. We 
therefore continued our analysis focussing on DMRs 1–3. 
Figure 2 Methylation levels for DMRs 1–3 significantly distinguish normal kidney from 
Wilms tumour and whole blood. (a) Aggregated methylation levels across DMRs 1–3 
significantly separate normal kidney (blue) and Wilms tumour (pink) in the test set (n = 22 
pairs, P = 3.85x10−17) and in (b) the replication set (n = 12 pairs, P = 1.47x10−9). (c) 
Methylation levels were high in an independent dataset of WT including high risk (dark 
green, n = 25) and intermediate risk histological subtypes (light green, n = 61). High risk WT 
showed significantly higher methylation levels than intermediate risk WT (P = 0.0024). (d) 
Whole blood (n = 411) shows low methylation levels (red). 
Aggregating DNA methylation across DMRs 1–3 (βmean), we found that WT had significantly 
greater levels of methylation with respect to NK for the discovery dataset as well as an 
independent dataset of 12 pairs (P = 3.85x10−17 and P = 9.26x10−10 respectively, 2-tailed t-
test, Figure 3a and b). Furthermore, βmean was consistently high across an independent cohort 
of fresh frozen WT (n = 86; Additional file 2: Table S4) encompassing the seven post-
chemotherapy WT histological subtypes classified into two risk groups, as defined by the 
International Society of Paediatric Oncology [20] (SIOP; Figure 3c). Within this cohort, a 
significant difference was seen between WT risk groups (P = 0.0024, 2-tailed T-test) with 
more elevated methylation levels observed in high risk WT (average βmean = 0.87 vs. 0.78). 
Based on methylation levels in the discovery dataset, a support vector machine (SVM; using 
R package e1071) correctly classified 100% and 98% samples within each replication set 
respectively indicating the discriminative potential of these DMRs as biomarkers. Clinical 
details for both of these cohorts can be found in Additional file 1: Table S1. 
Figure 3 Levels of methylation in serum cfDNA during WT treatment. Levels of %Mmean 
(for 14 CpGs within DMR-2) show significant differences between controls and pre-op 
samples (p = 0.010), controls and post-op samples (p = 0.017), pre-chemotherapy and pre-op 
(p = 0.028) and pre-chemotherapy and post-op (p = 0.047; all by 2-tailed T-test). Data shows 
increasing levels of methylated cfDNA associated with WT necrosis. Level of significance is 
shown by * (<0.05) or ** (<0.01) with horizontal lines indicating the respective comparison). 
DMRs 1–2 are located within the extended major histocompatibility complex (MHC) region 
[21]. Although the MHC is highly polymorphic [22], our matched study design controlled for 
any genetic heterogeneity, ensuring that the observed signal was not confounded by copy 
number or other DNA sequence variation. We validated methylation levels for these DMRs 
using bisulfite-sequencing (Additional file 2: Figure S3 and Table S5) and confirmed the 
absence of C➔T mutation. MHC cluster hypermethylation and reciprocal loss of gene 
expression is common across cancers as a mechanism to evade immunosurveillance and 
increase oncogenic potential [23–26]. To further explore the association between DMR 
methylation and tumourigenesis, we extracted DNA from three specimens of human 
embryonic kidney (EK, gestational age = 22, 22 and 23 weeks) and separately microdissected 
embryonic blastema (EB, n = 3; the predicted WT cell-of-origin). Bisulfite sequencing of 
DMRs 1 and 2 showed average β-values of 0.007 for EK and 0.12 for EB. Furthermore, 
analysis of methylation levels in 20 cases with matched WT precursor lesions termed 
nephrogenic rests (NR) showed intermediate methylation levels (Additional file 2: Figure 
S2). Put together, this data suggests that sequential increase in methylation levels is 
associated with transformation of embryonic precursor cells towards a malignant phenotype. 
As all DMRs were methylated in WT in comparison to NK, we predicted that levels of 
methylated DNA in the circulation may increase with tumour burden. When assessing levels 
of a methylated blood biomarker, varying proportions of leukocyte subpopulations can alter 
the overall methylation signal giving false yield [27]. Therefore, to assess the potential 
influence that blood populations may have on our dataset, we examined publically available 
methylation signatures that define normal peripheral blood subgroups [28] as well as 
methylation levels of normal whole blood (extracted using Marmal-aid [29]; n = 411). We 
found that DMRs 1–3 did not overlap with any blood-related methylation signature, and that 
normal blood methylation levels for DMRs 1–3 were extremely low (average βm = 0.12, 
Figure 3d). Therefore, we concluded that the WT-specific hypermethylated DMRs were not 
detected as a result of shifts in leukocyte populations in chemotherapy-treated tissue. Hence, 
we explored the potential of DMRs 1–3 as tumour-specific blood biomarkers, as they should 
be detectable above a low background and should not be confounded by shifts in leukocyte 
populations in the circulation. 
To test the potential efficacy of these biomarkers, we performed bisulfite-sequencing of 
DMR-2 on cfDNA isolated from serum samples taken from 10 children with WT at 
diagnosis, during pre-operative chemotherapy and following nephrectomy as well as four 
cancer-free age-matched control serum samples (Additional file 2: Table S6). The entire 
sequenced region (chr6:32,116,940-32,117,259) spanned 319 bp and included 44 CpGs, 
many of which showed either no variation or extreme variation in methylation between 
samples. Therefore, to identify CpGs that showed consistent methylation at one time-point 
and differential methylation between time-points, we grouped samples within each time-point 
and performed an ANOVA test. From this, we selected a subset of CpGs (n = 14) that 
showed differential methylation between at least one pair of groups, irrespective of 
directionality of methylation changes, avoiding those with very low variance. Aggregating 
the percentage of methylated cfDNA across these 14 CpGs (%Mmean) showed that control 
samples had the lowest levels of methylated cfDNA (13.4) and that children with WT had 
relatively higher levels taken at diagnosis before treatment starts (14.5). There was then a 
substantial and significant increase in the level of methylated cfDNA taken after the pre-
operative chemotherapy phase (19.9) that persisted into the immediate post-operative period 
(19.2; Figure 3). This proof-of-principle experiment establishes DMR-2 as a potential blood-
based biomarker for WT. 
Discussion 
This study has identified three differentially methylated regions (DMRs) with genome-wide 
significance in Wilms tumour (WT) that are present in nearly all WT (118 out of a total of 
120 WTs examined) and are not mediated by cell type composition. In comparison to 
previous mutational studies, our epigenetic biomarker is far more ubiquitous and even 
supersedes 11p15 epimutation (in ~70% WT) as the most common biomarker in WT. 
Therefore, our results suggest that analysis of an epigenetic mark in cell-free DNA could be 
more successful than analysis of tumour-specific somatic mutations which are much less 
common. Furthermore, our study revealed a significant difference in methylation levels 
between intermediate and high risk WT which could be of diagnostic use and suggest a use 
for novel therapeutic approaches to high risk WT. 
Although the NK samples do not contain blastema but WT samples do, our correction for cell 
type composition compensates for these effects allowing for identification of three true 
DMRs that are not mediated by cell mixture effects. Methylation analysis of DMRs 1–2 in 
embryonic kidney and embryonic blastema showed that these regions are not methylated in 
the presumed WT cell-of-origin. Analysis of nephrogenic rests showed that the precursor 
lesion had intermediate levels of methylation at the same regions which were then further 
methylated in the associated tumours (Additional file 2: Figure S2). We therefore concluded 
that increased methylation at these loci is associated with tumourigenic transformation and is 
not simply a manifestation of the embryonic origin of these tumours. Furthermore, as 84/86 
WTs were correctly classified by methylation status in our independent cohort, which 
included tumours stratified into all 7 histological subtypes, and consistent high levels of 
methylation were seen in the test set of tumours with detailed assessment of their variable 
cellular composition (Additional file 2: Figure S1), we can conclude that all cells constituting 
the tumour contributed to the observed gain of methylation. 
Our data suggests that WT release methylated DMR-2 cfDNA (M-cfDNA) following 
exposure to chemotherapy. Supporting this, a higher proportion of M-cfDNA (%Mmean of 
23.6 compared to 17.3) was observed in serum sampled after pre-operative chemotherapy in 
patients with the regressive subtype of WT, defined by >2/3 necrosis in the nephrectomy 
specimen, compared to patients with other WT subtypes that show less than 2/3 necrosis in 
response to chemotherapy [20]. In this small ‘proof of principle’ cases series, we noted that 
post-operative M-cfDNA levels remained high in the immediate post-operative period, 
sampled at day 4 up to 24 days post-surgery. This short term persistence may be due to the 
fact that serum cfDNA can retain interaction with nucleosome proteins which protects the 
DNA from degradation rendering it relatively stable [30]. This may also explain our ability to 
sequence such a long fragment (319 bp). A full post-surgery time course is required to assess 
this rate of degradation. Interestingly, one patient showed post-operative M-cfDNA levels 
1.3-fold greater than the group mean; a 22% increase post-surgery. We hypothesise that this 
post-surgery increase in M-cfDNA may be due to residual tumour within the patient and 
indeed, three months later, bone metastasis was detected. 
Conclusions 
In conclusion, we have defined the first epigenetic biomarker for the analysis of circulating 
cfDNA in Wilms tumour patients. We show that this may be useful to improve the accuracy 
of determining tumour response during pre-operative chemotherapy and predicting the 
histological risk group. This could allow appropriate modification of treatment prior to 
planned nephrectomy, particularly important for surgical planning in bilateral WT, where 
maximising tumour response to allow partial nephrectomy is the goal. Due to the low relapse 
rate in WT, a much larger, prospectively collected sample series of patients is required to 
demonstrate clinical utility as a prognostic biomarker for relapse-free survival. Based on 
these ‘proof of principle’ findings, a European multi-centre clinical trial with appropriate 
sampling is planned to rigorously test whether analysis of this epigenetic biomarker would 
improve the accuracy of prediction of relapse in all cases. 
Methods 
Sample selection 
Use of patient samples in this study was conducted with appropriate parental written consent 
and ethical approval granted by the NHS London Bridge Research Ethics Committee (ref: 
12/LO/0101) with experiments performed in compliance with the Helsinki Declaration. 
Patients were enrolled in the UK either into the International Society of Paediatric Oncology 
(SIOP) Wilms Tumour 2001 Clinical Trial and Study or the Improving Patient Outcomes for 
Renal Tumours of Childhood (IMPORT) study, with appropriate parental written consent. 
Blood serum samples from age-matched controls without cancer were taken from Great 
Ormond Street Hospital Department of Chemical Pathology with parental written consent. 
Marmal-aid v1.2.1 [31] was used to extract publically available methylation data annotated as 
disease = ‘Healthy’ and tissue = blood (n = 411). Embryonic kidney was obtained from fetal 
post-mortem examinations carried out at the Fetal Pathology Unit, University Hospital of 
Wales with written parental consent. 
DNA extraction 
As NR can only be identified by pathological review of haematoxylin and eosin (H&E) 
stained formalin-fixed paraffin embedded (FFPE) sections, 3 µm H&E sections from post-
nephrectomy FFPE blocks were studied by two independent paediatric pathologists who 
marked out regions of normal kidney (NK) nephrogenic rest (NR) and Wilms tumour (WT). 
A total of 22 matched trios (NK, NR and WT) and 12 matched pairs of NK and WT (90 
samples) were microdissected by cutting multiple 5 µm sections and removing the desired 
region with a scalpel. Embryonic blastema (EB) was also microdissected from 5 µm FFPE 
sections following a master H&E section as a guide. Tissue was taken from the whole section 
without microdissection to extract DNA from whole embryonic kidney (EK). Fresh frozen 
(FF) tissue (n = 86 samples) was taken from 83 patient nephrectomies that were classified 
according to centralised SIOP pathology review including stromal (n = 15), epithelial (n = 
10), blastemal (n = 11), mixed (n = 23), diffuse anaplastic (n = 14), focal anaplasia (n = 2) or 
regressive (n = 11) type. DNA was extracted from FFPE and FF tissue using the DNeasy 
Blood and Tissue Kit (QIAGEN), however manufacturer’s instructions were modified for 
FFPE DNA: samples were heated to 90 °C for 1 hour post-incubation at 56 °C and incubated 
at 70 °C for 10 minutes with buffer AL. For cfDNA analysis DNA was extracted from pre-
chemotherapy (n = 5), pre-operative (n = 8) or post-operative (n = 8) patient serum and age-
matched cancer-free control serum (n = 7) using the QIAamp Circulating Nucleic Acid kit 
(QIAGEN). 
Genome-wide methylation analysis 
DNA extracted from FFPE (n = 90) was first treated using the REPLIg FFPE kit (QIAGEN) 
[32]. Both FF (n = 86) and treated FFPE DNA was then bisulfite-converted using the EZ 
DNA Methylation Kit (Zymo Research) and interrogated using the Illumina 450 k platform. 
Two FFPE NR samples failed stringent quality control metrics and were excluded. For all 
analyses, open source software packages implemented in R [33] or Bioconductor [34] were 
used as indicated. Raw data was filtered to exclude samples with detection p-value <0.01 and 
normalised using subset within quantile normalisation (SWAN) using the Bioconductor R 
package ChAMP version 2.14 [18,35]. For initial MVP detection the normalised data matrix 
for 22 pairs (NK and WT) was included. Bayesian framework linear modelling using the 
Bioconductor R package Limma [36] version 3.20.4 [37] was performed to find sites of 
differential methylation that varied between NK and WT pairs and that were common across 
patients which avoids false positives from patient-specific SNPs or age effects. To this 
model, the TREAT function was applied to adjust p-values based on the ∆β-value (>0.1) [38] 
which were further adjusted to correct for multiple testing [39]. The DMR-lasso algorithm in 
the ChAMP package was then used to find differentially methylated regions (DMRs) [18] 
with settings adjusted to include only CpGs that reach genome-wide significance (p < 
5x10−8). To the same model, we applied the RefFreeEWAS algorithm [19] which uses single 
value decomposition to estimate the number of cell types contributing to overall histology. 
The algorithm then deconvoluted the β-values based on the estimated number of cell types (d 
= 3) and a design matrix specifying patient pairs and sample histology, and generated 
bootstrap-derived CpG-specific p-values and covariates that correspond to a ‘true’ 
methylation signal with no cell mixture effects. 
After confirming our three DMRs were not due to cell composition effects, the DMR values 
were compared to levels in a replication dataset of 12 pairs, the independent set of 86 FF WT 
and the matched NRs for 20 cases. Sample classification (by SVM) was performed using the 
22 pairs as a training set and 12 pairs and 86 WT as separate test sets using R CRAN package 
e1071 [40]. 
Assessment of DMR methylation by bisulfite-sequencing 
Of the three DMRs, we chose to validate methylation levels for DMRs 1–2 by sequencing 
both bisulfite-converted and normal DNA from 9 NK and WT pairs. We performed the same 
experiment to assess methylation levels in EK and EB. Bisulfite reads for DMR-1 showed 
poor coverage with only 6/18 validation samples giving sufficient reads (Additional file 2: 
Table S5). We therefore chose to focus on DMR-2 for detection in cfDNA from 28 serum 
samples. For cfDNA analysis, 5/21 patient (3 pre-op, 2 post-op) and 3/7 control samples 
failed to generate sufficient sequence reads for analysis. 
Primers were designed (Additional file 2: Table S7) using Primer 3 [41] and MethPrimer [42] 
and optimised using commercial DNA. DNA for bisulfite-sequencing was converted using 
the EZ DNA methylation kit (Zymo Research). Library preparation PCRs were performed 
using NEBNext (New England Biolabs) and KAPA HiFi Uracil + (KAPA Biosystems). 
Products were cleaned using magnetic beads (Beckman Coulter) and quantified using 
Picogreen reagents. Sample-specific tags were added prior to sequencing using the Illumina 
Mi-Seq. Raw bisulfite-converted paired-end reads were mapped to human genome build hg19 
with Bismark v0.9.0 [43] using Bowtie 2 [44] as the aligner. Methylated and unmethylated 
base counts were generated with the bismark_methylation_extractor utility and exported as 
BedGraph files for further analysis and display in IGV [45]. Aligned BAM files were sorted 
and indexed with SAMtools [46] for assessment of the regions of interest in IGV. The 
number of C reads divided by total reads per CpG site was then calculated to discern the % 
level of methylation per sample. 
To generate allele counts for the full sequence of DMR-2, we used the ANGSD package [47]. 
ANOVA was performed in R using Bioconductor package Limma to make all possible 
contrasts between groups. CpGs were selected for further analysis if the Limma Toptable 
moderated F score >1 indicating that any of the contrasts between groups were non-zero and 
if group variance for that CpG was >1. 
Data access 
450 k methylation data described in this study are available from GEO [48] with accession ID 
GSE59157. 
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